menu
    • menu
    [{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","upfrontCash":"$25.0 million","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"RNA-based Medicine","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Mina Therapeutics","amount2":1.25,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":1.25,"dosageForm":"","sponsorNew":"Mina Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Mina Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","upfrontCash":"$16.0 million","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"SLN-HAN-1","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Silence Therapeutics","amount2":1.3200000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":1.3200000000000001,"dosageForm":"","sponsorNew":"Silence Therapeutics \/ Hansoh Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Silence Therapeutics \/ Hansoh Pharmaceutical"},{"orgOrder":0,"company":"SRI International","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"SRI International","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"SRI International \/ Janssen Pharmaceutica","highestDevelopmentStatusID":"3","companyTruncated":"SRI International \/ Janssen Pharmaceutica"},{"orgOrder":0,"company":"AbSci","sponsor":"Merck & Co","pharmaFlowCategory":"D","upfrontCash":"$610.0 million","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Enzyme","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"AbSci","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"AbSci \/ Merck","highestDevelopmentStatusID":"2","companyTruncated":"AbSci \/ Merck"},{"orgOrder":0,"company":"BigHat Biosciences","sponsor":"Amgen Inc","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Antibody","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"BigHat Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"BigHat Biosciences \/ Amgen","highestDevelopmentStatusID":"3","companyTruncated":"BigHat Biosciences \/ Amgen"},{"orgOrder":0,"company":"Prellis Biologics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Antibody","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Prellis Biologics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Prellis Biologics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Prellis Biologics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Artisan Industries Inc.","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Cell and Gene therapy","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Cell Therapy","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Artisan Development Labs Inc.","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bioscience \/ Artisan Development Labs Inc."},{"orgOrder":0,"company":"Gandeeva Therapeutics","sponsor":"Lux Capital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Undisclosed","date":"January 2022","year":"2022","type":"Series A Financing","leadProduct":"Precision Medicine","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Gandeeva Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Gandeeva Therapeutics \/ Lux Capital","highestDevelopmentStatusID":"3","companyTruncated":"Gandeeva Therapeutics \/ Lux Capital"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Abcam plc","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"February 2022","year":"2022","type":"Collaboration","leadProduct":"VHH Antibody","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Abcam","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bioscience \/ Abcam"},{"orgOrder":0,"company":"Eighteen Fifty-Nine","sponsor":"Northpond Ventures","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"February 2022","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Eighteen Fifty-Nine","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Eighteen Fifty-Nine \/ Northpond Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Eighteen Fifty-Nine \/ Northpond Ventures"},{"orgOrder":0,"company":"i2o Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Macromolecules","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"i2o Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"i2o Therapeutics \/ Janssen","highestDevelopmentStatusID":"1","companyTruncated":"i2o Therapeutics \/ Janssen"},{"orgOrder":0,"company":"Excelra","sponsor":"X-Chem","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"February 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Excelra","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Excelra \/ X-Chem","highestDevelopmentStatusID":"2","companyTruncated":"Excelra \/ X-Chem"},{"orgOrder":0,"company":"WuXi AppTec","sponsor":"Orbit Discovery","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Peptide","date":"March 2022","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"WuXi AppTec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"WuXi AppTec \/ Orbit Discovery","highestDevelopmentStatusID":"3","companyTruncated":"WuXi AppTec \/ Orbit Discovery"},{"orgOrder":0,"company":"Specifica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Antibody","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Specifica","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Specifica \/ Not Applicable","highestDevelopmentStatusID":"3","companyTruncated":"Specifica \/ Not Applicable"},{"orgOrder":0,"company":"Prellis Biologics","sponsor":"Sanofi","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Antibody","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Prellis Biologics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Prellis Biologics \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"Prellis Biologics \/ Sanofi"},{"orgOrder":0,"company":"LifeMine Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","upfrontCash":"$70.0 million","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"LifeMine Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"LifeMine Therapeutics \/ GlaxoSmithKline","highestDevelopmentStatusID":"3","companyTruncated":"LifeMine Therapeutics \/ GlaxoSmithKline"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","upfrontCash":"$25.0 million","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Recombinant Human Hyaluronidase PH20 Enzyme","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Halozyme Therapeutics","amount2":0.19,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0.19,"dosageForm":"","sponsorNew":"Halozyme Therapeutics \/ Chugai","highestDevelopmentStatusID":"1","companyTruncated":"Halozyme Therapeutics \/ Chugai"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"BioNTech","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Vaccine","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"LNC-based mRNA Vaccine","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Matinas BioPharma \/ BioNTech","highestDevelopmentStatusID":"1","companyTruncated":"Matinas BioPharma \/ BioNTech"},{"orgOrder":0,"company":"VantAI","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Protein","graph1":"Technology","graph2":"Discovery Platform","graph3":"VantAI","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"VantAI \/ Boehringer Ingelheim","highestDevelopmentStatusID":"3","companyTruncated":"VantAI \/ Boehringer Ingelheim"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","upfrontCash":"$16.0 million","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"SLN-HAN-1","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Silence Therapeutics","amount2":1.3200000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":1.3200000000000001,"dosageForm":"","sponsorNew":"Silence Therapeutics \/ Hansoh Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Silence Therapeutics \/ Hansoh Pharmaceutical"},{"orgOrder":0,"company":"Apertura Gene Therapy","sponsor":"Deerfield Management Company","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Cell and Gene therapy","date":"April 2022","year":"2022","type":"Series A Financing","leadProduct":"AAV-based Gene Therapy","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Apertura Gene Therapy","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Apertura Gene Therapy \/ Deerfield Management Company","highestDevelopmentStatusID":"2","companyTruncated":"Apertura Gene Therapy \/ Deerfield Management Company"},{"orgOrder":0,"company":"Acuitas","sponsor":"GC Biopharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Vaccine","date":"April 2022","year":"2022","type":"Agreement","leadProduct":"mRNA Vaccine","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Acuitas","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Acuitas \/ GC Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"Acuitas \/ GC Biopharma"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"A*STAR's Bioprocessing Technology Institute","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Cell and Gene therapy","date":"April 2022","year":"2022","type":"Partnership","leadProduct":"AAV-based Gene Therapy","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Biologics \/ A*STAR's Bioprocessing Technology Institute","highestDevelopmentStatusID":"1","companyTruncated":"WuXi Biologics \/ A*STAR's Bioprocessing Technology Institute"},{"orgOrder":0,"company":"Empirico","sponsor":"AbCellera","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"May 2022","year":"2022","type":"Expanded Collaboration","leadProduct":"Antibody-based Therapy","moa":"GPCR","graph1":"Technology","graph2":"Discovery Platform","graph3":"Empirico","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Empirico \/ AbCellera","highestDevelopmentStatusID":"3","companyTruncated":"Empirico \/ AbCellera"},{"orgOrder":0,"company":"Illumina","sponsor":"Deerfield Management","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Undisclosed","date":"May 2022","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Illumina","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Extended-release Capsule","sponsorNew":"Illumina \/ Deerfield Management","highestDevelopmentStatusID":"3","companyTruncated":"Illumina \/ Deerfield Management"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Editing Oligonucleotides","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"ProQR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ProQR Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nimble Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Undisclosed","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Nimble Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Nimble Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Nimble Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Anagenex","sponsor":"Catalio","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"June 2022","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Anagenex","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Anagenex \/ Catalio","highestDevelopmentStatusID":"2","companyTruncated":"Anagenex \/ Catalio"},{"orgOrder":0,"company":"Evotec","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Janssen","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Janssen"},{"orgOrder":0,"company":"xFOREST Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"xFOREST Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"xFOREST Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"xFOREST Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Sanyou Biopharmaceuticals","sponsor":"Dragon Sail Pharmaceutical","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"June 2022","year":"2022","type":"Partnership","leadProduct":"Antibody","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Sanyou Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Sanyou Biopharmaceuticals \/ Dragon Sail Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Sanyou Biopharmaceuticals \/ Dragon Sail Pharmaceutical"},{"orgOrder":0,"company":"Cronos Group","sponsor":"Geocann","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"June 2022","year":"2022","type":"Partnership","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Technology","graph2":"Undisclosed","graph3":"Cronos Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cronos Group \/ Geocann","highestDevelopmentStatusID":"1","companyTruncated":"Cronos Group \/ Geocann"},{"orgOrder":0,"company":"Touchlight","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"July 2022","year":"2022","type":"Licensing Agreement","leadProduct":"mRNA-based Vaccine","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Touchlight","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Touchlight \/ Pfizer","highestDevelopmentStatusID":"1","companyTruncated":"Touchlight \/ Pfizer"},{"orgOrder":0,"company":"Ring Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Technology","country":"","productType":"Cell and Gene therapy","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Ring Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Ring Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Ring Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"LSA","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Cell and Gene therapy","date":"July 2022","year":"2022","type":"Licensing Agreement","leadProduct":"CAR-T Therapy","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Biomedica \/ LSA","highestDevelopmentStatusID":"1","companyTruncated":"Oxford Biomedica \/ LSA"},{"orgOrder":0,"company":"Kyowa Pharmaceutical Industry","sponsor":"Bora Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Undisclosed","date":"August 2021","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Kyowa Pharmaceutical Industry","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Kyowa Pharmaceutical Industry \/ Bora Pharmaceutical Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Kyowa Pharmaceutical Industry \/ Bora Pharmaceutical Laboratories"},{"orgOrder":0,"company":"Thorne HealthTech","sponsor":"AstraZeneca","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Undisclosed","date":"August 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Thorne HealthTech","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Thorne HealthTech \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Thorne HealthTech \/ AstraZeneca"},{"orgOrder":0,"company":"Starpharma","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"August 2022","year":"2022","type":"Agreement","leadProduct":"Antibody Drug Conjugate","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Starpharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Starpharma \/ MSD","highestDevelopmentStatusID":"1","companyTruncated":"Starpharma \/ MSD"},{"orgOrder":0,"company":"Prellis Biologics","sponsor":"Celesta Capital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"August 2022","year":"2022","type":"Series C Financing","leadProduct":"Antibody","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Prellis Biologics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Prellis Biologics \/ Celesta Capital","highestDevelopmentStatusID":"3","companyTruncated":"Prellis Biologics \/ Celesta Capital"},{"orgOrder":0,"company":"X-Chem","sponsor":"BioDuro","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"August 2022","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"X-Chem","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"X-Chem \/ BioDuro-Sundia","highestDevelopmentStatusID":"3","companyTruncated":"X-Chem \/ BioDuro-Sundia"},{"orgOrder":0,"company":"Zerion Pharma","sponsor":"Hovione","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"August 2022","year":"2022","type":"Expanded Collaboration","leadProduct":"Beta-lactoglobulin","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Zerion Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Zerion Pharma \/ Hovione","highestDevelopmentStatusID":"4","companyTruncated":"Zerion Pharma \/ Hovione"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Merck & Co","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"August 2022","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ Merck","highestDevelopmentStatusID":"2","companyTruncated":"Biocytogen \/ Merck"},{"orgOrder":0,"company":"ElevateBio","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Cell and Gene therapy","date":"August 2022","year":"2022","type":"Partnership","leadProduct":"iPSC-based Therapeutic","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"ElevateBio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"ElevateBio \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"1","companyTruncated":"ElevateBio \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"OmniAb","sponsor":"Avista Public Acquisition Corp. II","pharmaFlowCategory":"D","upfrontCash":"$130.0 million","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"March 2022","year":"2022","type":"Merger","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"OmniAb","amount2":0.40000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.40000000000000002,"dosageForm":"","sponsorNew":"OmniAb \/ Avista Public Acquisition Corp. II","highestDevelopmentStatusID":"3","companyTruncated":"OmniAb \/ Avista Public Acquisition Corp. II"},{"orgOrder":0,"company":"Synaffix","sponsor":"Emergence Therapeutics","pharmaFlowCategory":"D","upfrontCash":"$360.0 million","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"September 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Synaffix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Synaffix \/ Emergence","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ Emergence"},{"orgOrder":0,"company":"Orbital Therapeutics","sponsor":"Beam Therapeutics","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Technology","country":"","productType":"Vaccine","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"RNA-based Vaccine","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Orbital Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Orbital Therapeutics \/ Beam Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Orbital Therapeutics \/ Beam Therapeutics"},{"orgOrder":0,"company":"Forge Biologics","sponsor":"Drive Capital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Cell and Gene therapy","date":"September 2022","year":"2022","type":"Series C Financing","leadProduct":"AAV-based Gene Therapy","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Forge Biologics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Forge Biologics \/ Drive Capital","highestDevelopmentStatusID":"1","companyTruncated":"Forge Biologics \/ Drive Capital"},{"orgOrder":0,"company":"GigaGen","sponsor":"Department of Defense","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"September 2022","year":"2022","type":"Agreement","leadProduct":"Recombinant Human Polyclonal Antibody","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"GigaGen \/ Department of Defense","highestDevelopmentStatusID":"3","companyTruncated":"GigaGen \/ Department of Defense"},{"orgOrder":0,"company":"Cytoreason","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","upfrontCash":"$20.0 million","therapeuticArea":"Technology","country":"","productType":"Undisclosed","date":"September 2022","year":"2022","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Cytoreason","amount2":0.11,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.11,"dosageForm":"","sponsorNew":"Cytoreason \/ Pfizer","highestDevelopmentStatusID":"2","companyTruncated":"Cytoreason \/ Pfizer"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"OliPass","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"September 2022","year":"2022","type":"Partnership","leadProduct":"Antisense Oligonucleotide","moa":"mRNA","graph1":"Technology","graph2":"Preclinical","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Vanda Pharmaceuticals \/ OliPass","highestDevelopmentStatusID":"4","companyTruncated":"Vanda Pharmaceuticals \/ OliPass"},{"orgOrder":0,"company":"Alloy Therapeutics","sponsor":"8VC","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"October 2022","year":"2022","type":"Series D Financing","leadProduct":"In-vivo Human Antibody","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Alloy Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Alloy Therapeutics \/ 8VC","highestDevelopmentStatusID":"3","companyTruncated":"Alloy Therapeutics \/ 8VC"},{"orgOrder":0,"company":"Pantherna Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"October 2022","year":"2022","type":"Agreement","leadProduct":"mRNA-based Regenerative Medicine","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Pantherna Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Pantherna Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Pantherna Therapeutics \/ Astellas Pharma"},{"orgOrder":0,"company":"Circularis Biotechnologies","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"October 2022","year":"2022","type":"Acquisition","leadProduct":"Circular RNA-based Therapeutic","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Circularis Biotechnologies","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Circularis Biotechnologies \/ Ginkgo Bioworks","highestDevelopmentStatusID":"3","companyTruncated":"Circularis Biotechnologies \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Technology","country":"","productType":"Cell and Gene therapy","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Charles River Laboratories, Inc \/ Not Applicable","highestDevelopmentStatusID":"3","companyTruncated":"Charles River Laboratories, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Illumina","sponsor":"AstraZeneca","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Undisclosed","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Illumina","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Illumina \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Illumina \/ AstraZeneca"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Dualsystems Biotech","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"aTyr Pharma \/ Dualsystems Biotech","highestDevelopmentStatusID":"2","companyTruncated":"aTyr Pharma \/ Dualsystems Biotech"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Cell and Gene therapy","date":"October 2022","year":"2022","type":"Public Offering","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Prime Medicine","amount2":0.17999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Prime Medicine \/ J.P. Morgan","highestDevelopmentStatusID":"1","companyTruncated":"Prime Medicine \/ J.P. Morgan"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Cell and Gene therapy","date":"October 2022","year":"2022","type":"Public Offering","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Prime Medicine","amount2":0.17999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Prime Medicine \/ J.P. Morgan","highestDevelopmentStatusID":"1","companyTruncated":"Prime Medicine \/ J.P. Morgan"},{"orgOrder":0,"company":"VectorBuilder","sponsor":"Legend Capital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Cell and Gene therapy","date":"October 2022","year":"2022","type":"Series C Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"VectorBuilder","amount2":0.059999999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"VectorBuilder \/ Legend Capital","highestDevelopmentStatusID":"1","companyTruncated":"VectorBuilder \/ Legend Capital"},{"orgOrder":0,"company":"XtalPi","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"XtalPi","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"XtalPi \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"XtalPi \/ Janssen Pharmaceutical"},{"orgOrder":0,"company":"ProteoNic","sponsor":"GigaGen","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"November 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Recombinant Polyclonal Antibody","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"ProteoNic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"ProteoNic \/ GigaGen","highestDevelopmentStatusID":"1","companyTruncated":"ProteoNic \/ GigaGen"},{"orgOrder":0,"company":"OmniAb","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"November 2022","year":"2022","type":"Demerger","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"OmniAb","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"OmniAb \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"OmniAb \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"AbCellera","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"November 2022","year":"2022","type":"Partnership","leadProduct":"Antibody","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"WuXi Advanced Therapies","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Cell and Gene therapy","date":"August 2022","year":"2022","type":"Licensing Agreement","leadProduct":"AAV Vectors","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"WuXi Advanced Therapies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Advanced Therapies \/ Janssen","highestDevelopmentStatusID":"1","companyTruncated":"WuXi Advanced Therapies \/ Janssen"},{"orgOrder":0,"company":"Salipro Biotech","sponsor":"Sanofi","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Undisclosed","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Salipro Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Salipro Biotech \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Salipro Biotech \/ Sanofi"},{"orgOrder":0,"company":"Metagenomi","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"$80.0 million","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"RNA-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Metagenomi","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Metagenomi \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Metagenomi \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Touchlight","sponsor":"Voyager Therapeutics, Inc","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Undisclosed","date":"November 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"IND Enabling","graph3":"Touchlight","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Touchlight \/ Voyager Therapeutic","highestDevelopmentStatusID":"5","companyTruncated":"Touchlight \/ Voyager Therapeutic"},{"orgOrder":0,"company":"Beacon Discovery","sponsor":"Eurofins CDMO","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"February 2021","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Beacon Discovery","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Beacon Discovery \/ Eurofins","highestDevelopmentStatusID":"2","companyTruncated":"Beacon Discovery \/ Eurofins"},{"orgOrder":0,"company":"SonoThera","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Cell and Gene therapy","date":"December 2022","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"SonoThera","amount2":0.059999999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"SonoThera \/ ARCH Venture Partners","highestDevelopmentStatusID":"1","companyTruncated":"SonoThera \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Entactbio","sponsor":"4BIO Capital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Undisclosed","date":"December 2022","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Entactbio","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Entactbio \/ 4BIO Capital","highestDevelopmentStatusID":"2","companyTruncated":"Entactbio \/ 4BIO Capital"},{"orgOrder":0,"company":"Infinimmune","sponsor":"Playground Global","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"December 2022","year":"2022","type":"Financing","leadProduct":"Antibody","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Infinimmune","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.01,"dosageForm":"","sponsorNew":"Infinimmune \/ Playground Global","highestDevelopmentStatusID":"2","companyTruncated":"Infinimmune \/ Playground Global"},{"orgOrder":0,"company":"Nimble Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Peptide","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Nimble Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Nimble Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Nimble Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Parallel Bio","sponsor":"Refactor Capital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Undisclosed","date":"December 2022","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Parallel Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Parallel Bio \/ Refactor Capital","highestDevelopmentStatusID":"2","companyTruncated":"Parallel Bio \/ Refactor Capital"},{"orgOrder":0,"company":"Alteogen","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Undisclosed","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Alteogen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alteogen \/ Sandoz","highestDevelopmentStatusID":"3","companyTruncated":"Alteogen \/ Sandoz"},{"orgOrder":0,"company":"OriCiro Genomics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"January 2023","year":"2023","type":"Acquisition","leadProduct":"mRNA-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"OriCiro Genomics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"OriCiro Genomics \/ Moderna","highestDevelopmentStatusID":"2","companyTruncated":"OriCiro Genomics \/ Moderna"},{"orgOrder":0,"company":"Belharra Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"January 2023","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Belharra Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Belharra Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"1","companyTruncated":"Belharra Therapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"Synaffix","sponsor":"Amgen Inc","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate-based Therapy","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Synaffix","amount2":2,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":2,"dosageForm":"","sponsorNew":"Synaffix \/ Amgen Inc","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ Amgen Inc"},{"orgOrder":0,"company":"IntoCell","sponsor":"ADC Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"January 2023","year":"2023","type":"Agreement","leadProduct":"Antibody","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"IntoCell","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"IntoCell \/ ADC Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"IntoCell \/ ADC Therapeutics"},{"orgOrder":0,"company":"Nimble Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"D","upfrontCash":"$20.0 million","therapeuticArea":"Technology","country":"","productType":"Peptide","date":"January 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Nimble Therapeutics","amount2":1.1200000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":1.1200000000000001,"dosageForm":"","sponsorNew":"Nimble Therapeutics \/ Genentech","highestDevelopmentStatusID":"4","companyTruncated":"Nimble Therapeutics \/ Genentech"},{"orgOrder":0,"company":"Synaffix","sponsor":"Hummingbird Bioscience","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate-based Therapy","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Synaffix","amount2":0.14999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Synaffix \/ Hummingbird Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ Hummingbird Bioscience"},{"orgOrder":0,"company":"Harbor Discoveries","sponsor":"Deerfield Management","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Harbor Discoveries","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Harbor Discoveries \/ Deerfield Management","highestDevelopmentStatusID":"2","companyTruncated":"Harbor Discoveries \/ Deerfield Management"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Antibody","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Astellas Pharma","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Astellas Pharma"},{"orgOrder":0,"company":"AskBio","sponsor":"ReCode Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Cell and Gene therapy","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"AskBio \/ ReCode Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"AskBio \/ ReCode Therapeutics"},{"orgOrder":0,"company":"InstaDeep","sponsor":"BioNTech","pharmaFlowCategory":"D","upfrontCash":"$443.3 million","therapeuticArea":"Technology","country":"","productType":"Undisclosed","date":"January 2023","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"InstaDeep","amount2":0.68999999999999995,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.68999999999999995,"dosageForm":"","sponsorNew":"InstaDeep \/ BioNTech","highestDevelopmentStatusID":"3","companyTruncated":"InstaDeep \/ BioNTech"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"National Resilience","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Matinas BioPharma \/ National Resilience","highestDevelopmentStatusID":"1","companyTruncated":"Matinas BioPharma \/ National Resilience"},{"orgOrder":0,"company":"MicrofluidX","sponsor":"CCRM","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Cell and Gene therapy","date":"October 2022","year":"2022","type":"Partnership","leadProduct":"mRNA-based CART-cell Therapy","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"MicrofluidX","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"MicrofluidX \/ CCRM","highestDevelopmentStatusID":"2","companyTruncated":"MicrofluidX \/ CCRM"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Cristal Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Group \/ Cristal Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Lonza Group \/ Cristal Therapeutics"},{"orgOrder":0,"company":"Cryoport Systems Inc","sponsor":"Syneos Health","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Cell and Gene therapy","date":"January 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Cryoport Systems Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Cryoport Systems Inc \/ Syneos Health","highestDevelopmentStatusID":"3","companyTruncated":"Cryoport Systems Inc \/ Syneos Health"},{"orgOrder":0,"company":"Neochromosome","sponsor":"Sumitovant Biopharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Neochromosome","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Neochromosome \/ Sumitovant Biopharma","highestDevelopmentStatusID":"2","companyTruncated":"Neochromosome \/ Sumitovant Biopharma"},{"orgOrder":0,"company":"Lonza Group","sponsor":"McSAF","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Group \/ McSAF","highestDevelopmentStatusID":"3","companyTruncated":"Lonza Group \/ McSAF"},{"orgOrder":0,"company":"Atomic AI","sponsor":"Playground Global","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"January 2023","year":"2023","type":"Series A Financing","leadProduct":"RNA-based Medicine","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Atomic AI","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Atomic AI \/ Playground Global","highestDevelopmentStatusID":"3","companyTruncated":"Atomic AI \/ Playground Global"},{"orgOrder":0,"company":"X-Chem","sponsor":"Kymera Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"January 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"X-Chem","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"X-Chem \/ Kymera Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"X-Chem \/ Kymera Therapeutics"},{"orgOrder":0,"company":"Generate Biomedicines","sponsor":"Amgen Inc","pharmaFlowCategory":"D","upfrontCash":"$50.0 million","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Engineered Protein-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Generate Biomedicines","amount2":1.8999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":1.8999999999999999,"dosageForm":"","sponsorNew":"Generate Biomedicines \/ Amgen Inc","highestDevelopmentStatusID":"3","companyTruncated":"Generate Biomedicines \/ Amgen Inc"},{"orgOrder":0,"company":"Genesis Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","upfrontCash":"$20.0 million","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Genesis Therapeutics","amount2":0.67000000000000004,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.67000000000000004,"dosageForm":"","sponsorNew":"Genesis Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Genesis Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Amphista Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","upfrontCash":"$30.0 million","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Small molecule","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"Targeted Protein Degradation Therapy","moa":"Protein","graph1":"Technology","graph2":"Discovery Platform","graph3":"Amphista Therapeutics","amount2":1.28,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":1.28,"dosageForm":"Inhalation","sponsorNew":"Amphista Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Amphista Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Amphista Therapeutics","sponsor":"Merck Group","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"Targeted Protein Degradation Therapy","moa":"Protein","graph1":"Technology","graph2":"Discovery Platform","graph3":"Amphista Therapeutics","amount2":1,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":1,"dosageForm":"Inhalation","sponsorNew":"Amphista Therapeutics \/ Merck Group","highestDevelopmentStatusID":"3","companyTruncated":"Amphista Therapeutics \/ Merck Group"},{"orgOrder":0,"company":"Proxygen","sponsor":"Merck Group","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"AUSTRIA","productType":"Small molecule","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Molecular glue","graph1":"Technology","graph2":"Discovery","graph3":"Proxygen","amount2":0.55000000000000004,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.55000000000000004,"dosageForm":"","sponsorNew":"Proxygen \/ Merck Group","highestDevelopmentStatusID":"2","companyTruncated":"Proxygen \/ Merck Group"},{"orgOrder":0,"company":"Atomwise","sponsor":"Sanofi","pharmaFlowCategory":"D","upfrontCash":"$20.0 million","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","date":"August 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Atomwise","amount2":1.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":1.02,"dosageForm":"","sponsorNew":"Atomwise \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"Atomwise \/ Sanofi"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Eli Lilly","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"JAPAN","productType":"Peptide","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Peptide-drug Conjugate","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"PeptiDream","amount2":1.24,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":1.24,"dosageForm":"","sponsorNew":"PeptiDream \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"PeptiDream \/ Eli Lilly"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Sanofi","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"HONG KONG","productType":"Undisclosed","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Insilico Medicine","amount2":1.22,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":1.22,"dosageForm":"","sponsorNew":"Insilico Medicine \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"Insilico Medicine \/ Sanofi"},{"orgOrder":0,"company":"PeptiDream","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"JAPAN","productType":"Peptide","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Peptide-drug Conjugate","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"PeptiDream","amount2":2.1000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":2.1000000000000001,"dosageForm":"","sponsorNew":"PeptiDream \/ MSD","highestDevelopmentStatusID":"3","companyTruncated":"PeptiDream \/ MSD"},{"orgOrder":0,"company":"Ratio Therapeutics","sponsor":"Duquesne Capital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"February 2023","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Ratio Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.02,"dosageForm":"","sponsorNew":"Ratio Therapeutics \/ Duquesne Capital","highestDevelopmentStatusID":"3","companyTruncated":"Ratio Therapeutics \/ Duquesne Capital"},{"orgOrder":0,"company":"Synaffix","sponsor":"MacroGenics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"February 2022","year":"2022","type":"Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Synaffix","amount2":0.58999999999999997,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0.58999999999999997,"dosageForm":"","sponsorNew":"Synaffix \/ MacroGenics","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ MacroGenics"},{"orgOrder":0,"company":"Generian Pharmaceuticals","sponsor":"Mitobridge","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Generian Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Generian Pharmaceuticals \/ Mitobridge","highestDevelopmentStatusID":"3","companyTruncated":"Generian Pharmaceuticals \/ Mitobridge"},{"orgOrder":0,"company":"Bio Immunitas","sponsor":"GenScript ProBio","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Bio Immunitas","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Bio Immunitas \/ GenScript ProBio","highestDevelopmentStatusID":"3","companyTruncated":"Bio Immunitas \/ GenScript ProBio"},{"orgOrder":0,"company":"Adimab","sponsor":"Ablexis","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"February 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Adimab","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Adimab \/ Ablexis","highestDevelopmentStatusID":"3","companyTruncated":"Adimab \/ Ablexis"},{"orgOrder":0,"company":"Evotec","sponsor":"Related Sciences","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Undisclosed","date":"February 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Related Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Related Sciences"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Merck Group","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"April 2022","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ Merck","highestDevelopmentStatusID":"2","companyTruncated":"Biocytogen \/ Merck"},{"orgOrder":0,"company":"Schrodinger","sponsor":"Eli Lilly","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Schrodinger","amount2":0.42999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.42999999999999999,"dosageForm":"","sponsorNew":"Schrodinger \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Schrodinger \/ Eli Lilly"},{"orgOrder":0,"company":"Life Edit Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"mRNA-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Life Edit Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Life Edit Therapeutics \/ Moderna","highestDevelopmentStatusID":"3","companyTruncated":"Life Edit Therapeutics \/ Moderna"},{"orgOrder":0,"company":"Luxna Biotech","sponsor":"Summit Pharmaceuticals Europe Srl","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"February 2020","year":"2020","type":"Financing","leadProduct":"Oligonucleotide","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Luxna Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Luxna Biotech \/ Summit Pharmaceuticals Europe Srl","highestDevelopmentStatusID":"1","companyTruncated":"Luxna Biotech \/ Summit Pharmaceuticals Europe Srl"},{"orgOrder":0,"company":"TandemAI","sponsor":"Qiming Venture Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Undisclosed","date":"March 2023","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"TandemAI","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"TandemAI \/ Qiming Venture Partners","highestDevelopmentStatusID":"3","companyTruncated":"TandemAI \/ Qiming Venture Partners"},{"orgOrder":0,"company":"Chroma Medicine","sponsor":"Google Ventures","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"March 2023","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Chroma Medicine","amount2":0.14000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Chroma Medicine \/ Google Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Chroma Medicine \/ Google Ventures"},{"orgOrder":0,"company":"Touchlight","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Technology","country":"","productType":"Cell and Gene therapy","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"IND Enabling","graph3":"Touchlight","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Touchlight \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Touchlight \/ Not Applicable"},{"orgOrder":0,"company":"Charles River Laboratories International","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","date":"February 2023","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Charles River Laboratories International","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Charles River Laboratories International \/ Pioneering Medicines","highestDevelopmentStatusID":"2","companyTruncated":"Charles River Laboratories International \/ Pioneering Medicines"},{"orgOrder":0,"company":"Kytopen","sponsor":"Mirus Bio","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Cell and Gene therapy","date":"January 2023","year":"2023","type":"Partnership","leadProduct":"Human Cellular Medicine","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Kytopen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Kytopen \/ Mirus Bio","highestDevelopmentStatusID":"1","companyTruncated":"Kytopen \/ Mirus Bio"},{"orgOrder":0,"company":"Antiverse","sponsor":"InnoSpark","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"March 2023","year":"2023","type":"Financing","leadProduct":"Antibody","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Antiverse","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Antiverse \/ InnoSpark","highestDevelopmentStatusID":"3","companyTruncated":"Antiverse \/ InnoSpark"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ Janssen Biotech","highestDevelopmentStatusID":"2","companyTruncated":"Biocytogen \/ Janssen Biotech"},{"orgOrder":0,"company":"Ring Therapeutics","sponsor":"Alexandria Venture Investments","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"March 2023","year":"2023","type":"Series C Financing","leadProduct":"Anellovirus-based Therapy","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Ring Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Ring Therapeutics \/ Alexandria Venture Investments","highestDevelopmentStatusID":"4","companyTruncated":"Ring Therapeutics \/ Alexandria Venture Investments"},{"orgOrder":0,"company":"AbCheck","sponsor":"Czech Republic","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"March 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"AbCheck","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"AbCheck \/ Czech Republic","highestDevelopmentStatusID":"3","companyTruncated":"AbCheck \/ Czech Republic"},{"orgOrder":0,"company":"Seamless Therapeutics","sponsor":"Wellington Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"March 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Seamless Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.01,"dosageForm":"","sponsorNew":"Seamless Therapeutics \/ Wellington Partners","highestDevelopmentStatusID":"3","companyTruncated":"Seamless Therapeutics \/ Wellington Partners"},{"orgOrder":0,"company":"CHARM Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"CHARM Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"CHARM Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"CHARM Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Arzeda","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Arzeda","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Arzeda \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Arzeda \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Generation Bio","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","upfrontCash":"$40.0 million","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Genetic Medicine","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Generation Bio","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Generation Bio \/ Moderna","highestDevelopmentStatusID":"2","companyTruncated":"Generation Bio \/ Moderna"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Monoclonal Antibody","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Xeris Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Xeris Pharmaceuticals \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Proxygen","sponsor":"Merck & Co","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Proxygen","amount2":2.5499999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":2.5499999999999998,"dosageForm":"","sponsorNew":"Proxygen \/ Merck & Co. Inc.","highestDevelopmentStatusID":"2","companyTruncated":"Proxygen \/ Merck & Co. Inc."},{"orgOrder":0,"company":"Veneno Technologies","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Peptide","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Veneno Technologies","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Veneno Technologies \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Veneno Technologies \/ Astellas Pharma"},{"orgOrder":0,"company":"Eterna Therapeutics","sponsor":"Lincoln Park Capital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"mRNA-based Therapy","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Eterna Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0.01,"dosageForm":"","sponsorNew":"Eterna Therapeutics \/ Lincoln Park Capital","highestDevelopmentStatusID":"1","companyTruncated":"Eterna Therapeutics \/ Lincoln Park Capital"},{"orgOrder":0,"company":"Araris Biotech","sponsor":"Samsung Venture Investment Corporation","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"April 2023","year":"2023","type":"Financing","leadProduct":"Antibody Drug Conjugate","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Araris Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Araris Biotech \/ Samsung Venture Investment Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Araris Biotech \/ Samsung Venture Investment Corporation"},{"orgOrder":0,"company":"Center for iPS Cell Research and Application","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Cell and Gene therapy","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"iPS cell-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Center for iPS Cell Research and Application","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Center for iPS Cell Research and Application \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Center for iPS Cell Research and Application \/ Astellas Pharma"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Rubic One Health","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Vaccine","date":"April 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Dyadic International, Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Dyadic International, Inc \/ Rubic One Health","highestDevelopmentStatusID":"3","companyTruncated":"Dyadic International, Inc \/ Rubic One Health"},{"orgOrder":0,"company":"Veneno Technologies","sponsor":"Sumitomo Pharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Peptide","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Veneno Technologies","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Veneno Technologies \/ Sumitomo Dainippon Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Veneno Technologies \/ Sumitomo Dainippon Pharma"},{"orgOrder":0,"company":"3B Pharmaceuticals","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","upfrontCash":"$40.0 million","therapeuticArea":"Technology","country":"","productType":"Peptide","date":"April 2023","year":"2023","type":"Licensing Agreement","leadProduct":"FAP-2286","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"3B Pharmaceuticals","amount2":0.46999999999999997,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.46999999999999997,"dosageForm":"","sponsorNew":"3B Pharmaceuticals \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"3","companyTruncated":"3B Pharmaceuticals \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Orbital Therapeutics","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"April 2023","year":"2023","type":"Series A Financing","leadProduct":"RNA-based therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Orbital Therapeutics","amount2":0.27000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.27000000000000002,"dosageForm":"","sponsorNew":"Orbital Therapeutics \/ ARCH Venture Partners","highestDevelopmentStatusID":"3","companyTruncated":"Orbital Therapeutics \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Initial Therapeutics","sponsor":"Apple Tree Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"May 2023","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Initial Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Initial Therapeutics \/ Apple Tree Partners","highestDevelopmentStatusID":"3","companyTruncated":"Initial Therapeutics \/ Apple Tree Partners"},{"orgOrder":0,"company":"Amphista Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","upfrontCash":"$30.0 million","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Targeted Protein Degradation Therapy","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Amphista Therapeutics","amount2":1.28,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":1.28,"dosageForm":"","sponsorNew":"Amphista Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Amphista Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Cyclica","sponsor":"Recursion Pharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"May 2023","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Cyclica","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Cyclica \/ Recursion Pharma","highestDevelopmentStatusID":"3","companyTruncated":"Cyclica \/ Recursion Pharma"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Undisclosed","date":"May 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0.40999999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.40999999999999998,"dosageForm":"","sponsorNew":"Ginkgo Bioworks \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bioworks \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Just \u2013 Evotec Biologics","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Undisclosed","date":"May 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Just \u2013 Evotec Biologics","amount2":0.64000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0.64000000000000001,"dosageForm":"","sponsorNew":"Just \u2013 Evotec Biologics \/ Sandoz B2B","highestDevelopmentStatusID":"1","companyTruncated":"Just \u2013 Evotec Biologics \/ Sandoz B2B"},{"orgOrder":0,"company":"Salipro Biotech","sponsor":"DyNAbind","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Salipro Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Salipro Biotech \/ DyNAbind","highestDevelopmentStatusID":"2","companyTruncated":"Salipro Biotech \/ DyNAbind"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"BioNTech","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Vaccine","date":"May 2023","year":"2023","type":"Termination","leadProduct":"mRNA-based Vaccine","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Matinas BioPharma \/ BioNTech","highestDevelopmentStatusID":"4","companyTruncated":"Matinas BioPharma \/ BioNTech"},{"orgOrder":0,"company":"Thousand Oaks Biologics","sponsor":"GeneQuantum Healthcare","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"CHINA","productType":"Large molecule","date":"May 2023","year":"2023","type":"Partnership","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Thousand Oaks Biologics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Thousand Oaks Biologics \/ GeneQuantum Healthcare","highestDevelopmentStatusID":"2","companyTruncated":"Thousand Oaks Biologics \/ GeneQuantum Healthcare"},{"orgOrder":0,"company":"ClearPoint Neuro","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Cell and Gene therapy","date":"May 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Gene-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"ClearPoint Neuro","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"ClearPoint Neuro \/ UCB Pharma S.A","highestDevelopmentStatusID":"3","companyTruncated":"ClearPoint Neuro \/ UCB Pharma S.A"},{"orgOrder":0,"company":"ElevateBio","sponsor":"AyurMaya Capital Management Fund","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Undisclosed","date":"May 2023","year":"2023","type":"Series D Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"ElevateBio","amount2":0.40000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.40000000000000002,"dosageForm":"","sponsorNew":"ElevateBio \/ AyurMaya Capital Management Fund","highestDevelopmentStatusID":"3","companyTruncated":"ElevateBio \/ AyurMaya Capital Management Fund"},{"orgOrder":0,"company":"AstriVax","sponsor":"VLAIO","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Vaccine","date":"May 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"AstriVax","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"AstriVax \/ VLAIO","highestDevelopmentStatusID":"3","companyTruncated":"AstriVax \/ VLAIO"},{"orgOrder":0,"company":"XtalPi","sponsor":"Eli Lilly","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"XtalPi","amount2":0.25,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.25,"dosageForm":"","sponsorNew":"XtalPi \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"XtalPi \/ Eli Lilly"},{"orgOrder":0,"company":"aVaxziPen","sponsor":"CEPI","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Vaccine","date":"June 2023","year":"2023","type":"Partnership","leadProduct":"Protein-based Vaccine","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"aVaxziPen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"aVaxziPen \/ CEPI","highestDevelopmentStatusID":"3","companyTruncated":"aVaxziPen \/ CEPI"},{"orgOrder":0,"company":"Merdury Pharmaceutical","sponsor":"BIOKEY","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Undisclosed","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Undislcosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Merdury Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Merdury Pharmaceutical \/ BioKey","highestDevelopmentStatusID":"3","companyTruncated":"Merdury Pharmaceutical \/ BioKey"},{"orgOrder":0,"company":"Iktos","sponsor":"Curreio","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Iktos","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Iktos \/ Curreio","highestDevelopmentStatusID":"2","companyTruncated":"Iktos \/ Curreio"},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"AbCellera","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"GPCR Antibody","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Confo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Confo Therapeutics \/ AbCellera","highestDevelopmentStatusID":"2","companyTruncated":"Confo Therapeutics \/ AbCellera"},{"orgOrder":0,"company":"Acuitas","sponsor":"Bayer AG","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Cell and Gene therapy","date":"June 2023","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Acuitas","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Acuitas \/ Bayer AG","highestDevelopmentStatusID":"1","companyTruncated":"Acuitas \/ Bayer AG"},{"orgOrder":0,"company":"Elsie Biotechnologies","sponsor":"GSK","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"July 2023","year":"2023","type":"Collaboration","leadProduct":"Oligonucleotide Drug","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Elsie Biotechnologies","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Elsie Biotechnologies \/ GSK","highestDevelopmentStatusID":"3","companyTruncated":"Elsie Biotechnologies \/ GSK"},{"orgOrder":0,"company":"Zhejiang Doer Biologics","sponsor":"BioNTech","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Undisclosed","date":"July 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Zhejiang Doer Biologics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Zhejiang Doer Biologics \/ BioNTech","highestDevelopmentStatusID":"2","companyTruncated":"Zhejiang Doer Biologics \/ BioNTech"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","upfrontCash":"$16.0 million","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"July 2023","year":"2023","type":"Collaboration","leadProduct":"siRNA","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Silence Therapeutics","amount2":1.3200000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":1.3200000000000001,"dosageForm":"","sponsorNew":"Silence Therapeutics \/ Hansoh Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Silence Therapeutics \/ Hansoh Pharma"},{"orgOrder":0,"company":"Pioneering Medicines","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","upfrontCash":"$100.0 million","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","date":"July 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Pioneering Medicines","amount2":0.80000000000000004,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.80000000000000004,"dosageForm":"","sponsorNew":"Pioneering Medicines \/ Pfizer Inc","highestDevelopmentStatusID":"2","companyTruncated":"Pioneering Medicines \/ Pfizer Inc"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Chroma Medicine","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"July 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Epigenetic Medicine","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Sangamo Therapeutics \/ Chroma Medicine","highestDevelopmentStatusID":"3","companyTruncated":"Sangamo Therapeutics \/ Chroma Medicine"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","upfrontCash":"$21.2 million","therapeuticArea":"Technology","country":"","productType":"Peptide","date":"July 2023","year":"2023","type":"Collaboration","leadProduct":"Protein Degrader Drug","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"PeptiDream","amount2":0.75,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.75,"dosageForm":"","sponsorNew":"PeptiDream \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"PeptiDream \/ Astellas Pharma"},{"orgOrder":0,"company":"InstaDeep","sponsor":"BioNTech","pharmaFlowCategory":"D","upfrontCash":"$548.6 million","therapeuticArea":"Technology","country":"","productType":"Undisclosed","date":"July 2023","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"InstaDeep","amount2":0.55000000000000004,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.68999999999999995,"dosageForm":"","sponsorNew":"InstaDeep \/ BioNTech","highestDevelopmentStatusID":"3","companyTruncated":"InstaDeep \/ BioNTech"},{"orgOrder":0,"company":"CAS","sponsor":"Molecule.one","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"August 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"CAS","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"CAS \/ Molecule.one","highestDevelopmentStatusID":"2","companyTruncated":"CAS \/ Molecule.one"},{"orgOrder":0,"company":"Genesis Therapeutics","sponsor":"Andreessen Horowitz","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"August 2023","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Genesis Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.20000000000000001,"dosageForm":"","sponsorNew":"Genesis Therapeutics \/ Andreessen Horowitz","highestDevelopmentStatusID":"3","companyTruncated":"Genesis Therapeutics \/ Andreessen Horowitz"},{"orgOrder":0,"company":"Superluminal Medicines","sponsor":"RA Capital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"August 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Superluminal Medicines","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Superluminal Medicines \/ RA Capital","highestDevelopmentStatusID":"2","companyTruncated":"Superluminal Medicines \/ RA Capital"},{"orgOrder":0,"company":"Tentarix Biotherapeutics","sponsor":"Amplitude Ventures","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Undisclosed","date":"September 2023","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Tentarix Biotherapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Tentarix Biotherapeutics \/ Amplitude Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Tentarix Biotherapeutics \/ Amplitude Ventures"},{"orgOrder":0,"company":"Septerna","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"$47.5 million","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"September 2023","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Septerna","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Septerna \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Septerna \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"BeiGene","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"September 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ BeiGene","highestDevelopmentStatusID":"3","companyTruncated":"Nona Biosciences \/ BeiGene"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Genentech","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Peptide","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"Peptide-radioisotope Drug Conjugate","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"PeptiDream","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"PeptiDream \/ Genentech","highestDevelopmentStatusID":"2","companyTruncated":"PeptiDream \/ Genentech"},{"orgOrder":0,"company":"BioLoomics","sponsor":"Innovation Endeavors","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"September 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"BioLoomics","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.01,"dosageForm":"","sponsorNew":"BioLoomics \/ Innovation Endeavors","highestDevelopmentStatusID":"2","companyTruncated":"BioLoomics \/ Innovation Endeavors"},{"orgOrder":0,"company":"AbCellera","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"September 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"AbCellera \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Partillion Bioscience","sponsor":"Alloy Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"September 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Partillion Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Partillion Bioscience \/ Alloy Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Partillion Bioscience \/ Alloy Therapeutics"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0.33000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.33000000000000002,"dosageForm":"","sponsorNew":"Ginkgo Bioworks \/ Pfizer Inc","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bioworks \/ Pfizer Inc"},{"orgOrder":0,"company":"Medicinova","sponsor":"Sanofi","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Cell and Gene therapy","date":"October 2023","year":"2023","type":"Agreement","leadProduct":"AAV Gene Therapy","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Medicinova","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0.01,"dosageForm":"","sponsorNew":"Medicinova \/ Sanofi Genzyme","highestDevelopmentStatusID":"1","companyTruncated":"Medicinova \/ Sanofi Genzyme"},{"orgOrder":0,"company":"Salipro Biotech","sponsor":"Icosagen","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Salipro Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Salipro Biotech \/ Icosagen","highestDevelopmentStatusID":"2","companyTruncated":"Salipro Biotech \/ Icosagen"},{"orgOrder":0,"company":"EpimAb Biotherapeutics","sponsor":"Almirall","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Bispecific Antibody","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"EpimAb Biotherapeutics","amount2":0.20999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.20999999999999999,"dosageForm":"","sponsorNew":"EpimAb Biotherapeutics \/ Almirall","highestDevelopmentStatusID":"2","companyTruncated":"EpimAb Biotherapeutics \/ Almirall"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Genentech","pharmaFlowCategory":"D","upfrontCash":"$26.0 million","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Sosei Heptares","amount2":1.03,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":1.03,"dosageForm":"","sponsorNew":"Sosei Heptares \/ Genentech","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Heptares \/ Genentech"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"Nona Biosciences","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Bioconjugate","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"GeneQuantum Healthcare","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"GeneQuantum Healthcare \/ Nona Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"GeneQuantum Healthcare \/ Nona Biosciences"},{"orgOrder":0,"company":"Cannasoul","sponsor":"Synaptogenix","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"November 2023","year":"2023","type":"Partnership","leadProduct":"Cannabinoid-based Therapeutic","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Cannasoul","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Cannasoul \/ Synaptogenix","highestDevelopmentStatusID":"1","companyTruncated":"Cannasoul \/ Synaptogenix"},{"orgOrder":0,"company":"Serina Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"November 2023","year":"2023","type":"Licensing Agreement","leadProduct":"RNA-based Therapeutic","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Serina Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Serina Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"3","companyTruncated":"Serina Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Araris Biotech","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Araris Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Araris Biotech \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Araris Biotech \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Prism Biolab","sponsor":"Eli Lilly","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Prism Biolab","amount2":0.66000000000000003,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.66000000000000003,"dosageForm":"","sponsorNew":"Prism Biolab \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Prism Biolab \/ Eli Lilly"},{"orgOrder":0,"company":"Shape Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Shape Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Shape Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"4","companyTruncated":"Shape Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Lycia Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Lycia Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Nona Biosciences \/ Lycia Therapeutics"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"The Benchmark Company LLC","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"ImmunoPrecise","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoPrecise \/ The Benchmark Company LLC","highestDevelopmentStatusID":"3","companyTruncated":"ImmunoPrecise \/ The Benchmark Company LLC"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"The Benchmark Company","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"ImmunoPrecise","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoPrecise \/ The Benchmark Company","highestDevelopmentStatusID":"3","companyTruncated":"ImmunoPrecise \/ The Benchmark Company"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Nona Biosciences","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Evive Biotech \/ Nona Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Evive Biotech \/ Nona Biosciences"},{"orgOrder":0,"company":"X-Chem","sponsor":"Relay Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"X-Chem","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"X-Chem \/ Relay Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"X-Chem \/ Relay Therapeutics"},{"orgOrder":0,"company":"Aqemia","sponsor":"Sanofi","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Aqemia","amount2":0.14000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Aqemia \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Aqemia \/ Sanofi"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"The Benchmark Company","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"ImmunoPrecise","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoPrecise \/ The Benchmark Company","highestDevelopmentStatusID":"3","companyTruncated":"ImmunoPrecise \/ The Benchmark Company"},{"orgOrder":0,"company":"Depixus","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Depixus","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Depixus \/ Daiichi Sankyo","highestDevelopmentStatusID":"2","companyTruncated":"Depixus \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Anagenex","sponsor":"Nimbus Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Anagenex","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Anagenex \/ Nimbus Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Anagenex \/ Nimbus Therapeutics"},{"orgOrder":0,"company":"Genentech","sponsor":"NVIDIA","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Undisclosed","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Genentech \/ NVIDIA","highestDevelopmentStatusID":"3","companyTruncated":"Genentech \/ NVIDIA"},{"orgOrder":0,"company":"Isomorphic Labs","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","upfrontCash":"$37.5 million","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Isomorphic Labs","amount2":1.24,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":1.24,"dosageForm":"","sponsorNew":"Isomorphic Labs \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Isomorphic Labs \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Moonwalk Biosciences","sponsor":"Alpha Wave Ventures","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Undisclosed","date":"January 2024","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Moonwalk Biosciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Moonwalk Biosciences \/ Alpha Wave Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Moonwalk Biosciences \/ Alpha Wave Ventures"},{"orgOrder":0,"company":"AbCheck","sponsor":"Ampersand Biomedicines","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"January 2024","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"AbCheck","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"AbCheck \/ Ampersand Biomedicines","highestDevelopmentStatusID":"3","companyTruncated":"AbCheck \/ Ampersand Biomedicines"},{"orgOrder":0,"company":"Elsie Biotechnologies","sponsor":"GSK","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"February 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Elsie Biotechnologies","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Elsie Biotechnologies \/ GSK","highestDevelopmentStatusID":"3","companyTruncated":"Elsie Biotechnologies \/ GSK"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ Gilead Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Biocytogen \/ Gilead Sciences"},{"orgOrder":0,"company":"InveniAI","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Undisclosed","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"InveniAI","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"InveniAI \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"InveniAI \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"VantAI","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"VantAI","amount2":0.67000000000000004,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.67000000000000004,"dosageForm":"","sponsorNew":"VantAI \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"VantAI \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Cell and Gene therapy","date":"December 2023","year":"2023","type":"Termination","leadProduct":"AAV-mediated Gene Therapy","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"JCR Pharmaceuticals \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"JCR Pharmaceuticals \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"EVQLV","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"EVQLV","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"EVQLV \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"EVQLV \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Orbis Medicines","sponsor":"Novo Holding","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Undisclosed","date":"February 2024","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Orbis Medicines","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Orbis Medicines \/ Novo Holding","highestDevelopmentStatusID":"3","companyTruncated":"Orbis Medicines \/ Novo Holding"},{"orgOrder":0,"company":"Leash Biosciences","sponsor":"Springtide Ventures","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"April 2024","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Leash Biosciences","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.01,"dosageForm":"","sponsorNew":"Leash Biosciences \/ Springtide Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Leash Biosciences \/ Springtide Ventures"},{"orgOrder":0,"company":"Invenra","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"April 2024","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Invenra","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Invenra \/ Astellas Pharma","highestDevelopmentStatusID":"3","companyTruncated":"Invenra \/ Astellas Pharma"},{"orgOrder":0,"company":"MedinCell","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","upfrontCash":"$35.0 million","therapeuticArea":"Technology","country":"","productType":"Undisclosed","date":"April 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"MedinCell","amount2":1.9399999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":1.9399999999999999,"dosageForm":"Injection","sponsorNew":"MedinCell \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"MedinCell \/ AbbVie Inc"},{"orgOrder":0,"company":"Vilya","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"June 2024","year":"2024","type":"Series A Financing","leadProduct":"Macrocycle-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Vilya","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Vilya \/ ARCH Venture Partners","highestDevelopmentStatusID":"3","companyTruncated":"Vilya \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Menten AI","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Peptide","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Peptide-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Menten AI","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Menten AI \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Menten AI \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"ExpressionEdits","sponsor":"Octopus Ventures","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Large molecule","date":"May 2024","year":"2024","type":"Financing","leadProduct":"Protein-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"ExpressionEdits","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.01,"dosageForm":"","sponsorNew":"ExpressionEdits \/ Octopus Ventures","highestDevelopmentStatusID":"3","companyTruncated":"ExpressionEdits \/ Octopus Ventures"},{"orgOrder":0,"company":"Enveda Bioscience","sponsor":"Premji Invest","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Enveda Bioscience","amount2":0.12,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0.12,"dosageForm":"","sponsorNew":"Enveda Bioscience \/ Premji Invest","highestDevelopmentStatusID":"4","companyTruncated":"Enveda Bioscience \/ Premji Invest"},{"orgOrder":0,"company":"Immunocan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Technology","country":"CHINA","productType":"Large molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Alpaca-derived Nanobody Therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Immunocan","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Immunocan \/ Not Applicable","highestDevelopmentStatusID":"3","companyTruncated":"Immunocan \/ Not Applicable"},{"orgOrder":0,"company":"Alloy Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"May 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Antibody-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Alloy Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Alloy Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Alloy Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Nabla Bio","sponsor":"Radical Ventures","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"May 2024","year":"2024","type":"Series A Financing","leadProduct":"Antibody-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Nabla Bio","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Nabla Bio \/ Radical Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Nabla Bio \/ Radical Ventures"},{"orgOrder":0,"company":"Secarna Pharma","sponsor":"Orbit Discovery","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Antisense Oligonucleotide-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Secarna Pharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Secarna Pharma \/ Orbit Discovery","highestDevelopmentStatusID":"3","companyTruncated":"Secarna Pharma \/ Orbit Discovery"},{"orgOrder":0,"company":"Elsie Biotechnologies","sponsor":"GSK","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"June 2024","year":"2024","type":"Acquisition","leadProduct":"Oligonucleotide-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Elsie Biotechnologies","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Elsie Biotechnologies \/ GSK","highestDevelopmentStatusID":"3","companyTruncated":"Elsie Biotechnologies \/ GSK"},{"orgOrder":0,"company":"RevolKa","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"May 2024","year":"2024","type":"Agreement","leadProduct":"RK007","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"RevolKa","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"RevolKa \/ Daiichi Sankyo","highestDevelopmentStatusID":"1","companyTruncated":"RevolKa \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Isomorphic Labs","sponsor":"Eli Lilly","pharmaFlowCategory":"D","upfrontCash":"$45.0 million","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Isomorphic Labs","amount2":1.75,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":1.75,"dosageForm":"","sponsorNew":"Isomorphic Labs \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Isomorphic Labs \/ Eli Lilly"},{"orgOrder":0,"company":"Totus Medicines","sponsor":"Eli Lilly","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Totus Medicines","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Totus Medicines \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Totus Medicines \/ Eli Lilly"},{"orgOrder":0,"company":"NEOsphere Biotechnologies","sponsor":"Kymera Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"GERMANY","productType":"Small molecule","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"NEOsphere Biotechnologies","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"NEOsphere Biotechnologies \/ Kymera Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"NEOsphere Biotechnologies \/ Kymera Therapeutics"},{"orgOrder":0,"company":"Enveda Bioscience","sponsor":"Microsoft","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Undisclosed","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Enveda Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Enveda Bioscience \/ Microsoft","highestDevelopmentStatusID":"4","companyTruncated":"Enveda Bioscience \/ Microsoft"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Oxford Nanopore Technologies","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Undisclosed","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Oxford Nanopore Technologies","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Oxford Nanopore Technologies"},{"orgOrder":0,"company":"Eisai","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","upfrontCash":"$650.0 million","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Termination","leadProduct":"Farletuzumab Ecteribulin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eisai","amount2":3.1000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eisai \/ Bristol Myers Squibb","highestDevelopmentStatusID":"14","companyTruncated":"Eisai \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Agreement","leadProduct":"Olverembatinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ascentage Pharma","amount2":1.3,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ascentage Pharma \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"14","companyTruncated":"Ascentage Pharma \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","upfrontCash":"$625.0 million","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Belrestotug","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Iteos Therapeutics","amount2":2.0800000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Iteos Therapeutics \/ GSK","highestDevelopmentStatusID":"14","companyTruncated":"Iteos Therapeutics \/ GSK"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Public Offering","leadProduct":"IDE397","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ideaya Biosciences","amount2":0.26000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"14","companyTruncated":"Ideaya Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"Yellow Jersey Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","upfrontCash":"$1,250.0 million","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Large molecule","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"NM26","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Yellow Jersey Therapeutics","amount2":1.25,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Yellow Jersey Therapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":"14","companyTruncated":"Yellow Jersey Therapeutics \/ Johnson & Johnson"},{"orgOrder":0,"company":"Foreseen Biotechnology","sponsor":"Ipsen","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"FS001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Foreseen Biotechnology","amount2":1.03,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Foreseen Biotechnology \/ Ipsen","highestDevelopmentStatusID":"14","companyTruncated":"Foreseen Biotechnology \/ Ipsen"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Public Offering","leadProduct":"IDE397","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ideaya Biosciences","amount2":0.29999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"14","companyTruncated":"Ideaya Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"EyeBio","sponsor":"Merck & Co","pharmaFlowCategory":"D","upfrontCash":"$1,300.0 million","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"EYE103","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"EyeBio","amount2":3,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"EyeBio \/ Merck & Co","highestDevelopmentStatusID":"14","companyTruncated":"EyeBio \/ Merck & Co"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","upfrontCash":"$800.0 million","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"Eneboparatide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Amolyt Pharma","amount2":1.05,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Amolyt Pharma \/ AstraZeneca","highestDevelopmentStatusID":"14","companyTruncated":"Amolyt Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Nerio Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Nerio Therapeutics","amount2":1.3,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Nerio Therapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"14","companyTruncated":"Nerio Therapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Ironshore Pharmaceuticals","sponsor":"Collegium Pharmaceutical","pharmaFlowCategory":"D","upfrontCash":"$525.0 million","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"Methylphenidate Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ironshore Pharmaceuticals","amount2":0.55000000000000004,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ironshore Pharmaceuticals \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"14","companyTruncated":"Ironshore Pharmaceuticals \/ Collegium Pharmaceutical"},{"orgOrder":0,"company":"OPKO Health","sponsor":"HealthCare Royalty","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","date":"July 2024","year":"2024","type":"Agreement","leadProduct":"Somatrogon","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"OPKO Health","amount2":0.25,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"OPKO Health \/ HealthCare Royalty","highestDevelopmentStatusID":"14","companyTruncated":"OPKO Health \/ HealthCare Royalty"},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"SK Biopharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"225Ac-FL-091","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Full-Life Technologies","amount2":0.56999999999999995,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Full-Life Technologies \/ SK Biopharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"Full-Life Technologies \/ SK Biopharmaceuticals"},{"orgOrder":0,"company":"Cardurion Pharmaceutical","sponsor":"Ascenta Capital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Series B Financing","leadProduct":"Tovinontrine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cardurion Pharmaceutical","amount2":0.26000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cardurion Pharmaceutical \/ Ascenta Capital","highestDevelopmentStatusID":"14","companyTruncated":"Cardurion Pharmaceutical \/ Ascenta Capital"},{"orgOrder":0,"company":"Valinor Pharma","sponsor":"Grunenthal","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"Naloxegol Oxalate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Valinor Pharma","amount2":0.25,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Valinor Pharma \/ Grunenthal","highestDevelopmentStatusID":"14","companyTruncated":"Valinor Pharma \/ Grunenthal"},{"orgOrder":0,"company":"Frontier Medicine","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Frontier Medicine","amount2":1,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Frontier Medicine \/ AbbVie Inc","highestDevelopmentStatusID":"14","companyTruncated":"Frontier Medicine \/ AbbVie Inc"},{"orgOrder":0,"company":"Scynexis","sponsor":"GSK","pharmaFlowCategory":"D","upfrontCash":"$90.0 million","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Ibrexafungerp Citrate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Scynexis","amount2":0.58999999999999997,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Scynexis \/ GSK","highestDevelopmentStatusID":"14","companyTruncated":"Scynexis \/ GSK"},{"orgOrder":0,"company":"Pinetree Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","upfrontCash":"$45.0 million","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Pinetree Therapeutics","amount2":0.5,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Pinetree Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"14","companyTruncated":"Pinetree Therapeutics \/ AstraZeneca"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Ipsen","pharmaFlowCategory":"D","upfrontCash":"$111.0 million","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Tovorafenib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Day One Biopharmaceuticals","amount2":0.46000000000000002,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Day One Biopharmaceuticals \/ Ipsen","highestDevelopmentStatusID":"14","companyTruncated":"Day One Biopharmaceuticals \/ Ipsen"},{"orgOrder":0,"company":"Compugen","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","upfrontCash":"$60.0 million","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"COM503","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Compugen","amount2":0.84999999999999998,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Compugen \/ Gilead Sciences","highestDevelopmentStatusID":"14","companyTruncated":"Compugen \/ Gilead Sciences"},{"orgOrder":0,"company":"Bharat Serums & Vaccines ltd","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"Carboprost Tromethamine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bharat Serums & Vaccines ltd","amount2":1.6399999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bharat Serums & Vaccines ltd \/ Mankind Pharma","highestDevelopmentStatusID":"14","companyTruncated":"Bharat Serums & Vaccines ltd \/ Mankind Pharma"},{"orgOrder":0,"company":"Zelira Therapeutics","sponsor":"Forman Investment Trust","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Financing","leadProduct":"Tetrahydrocannabinol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Zelira Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Zelira Therapeutics \/ Forman Investment Trust","highestDevelopmentStatusID":"14","companyTruncated":"Zelira Therapeutics \/ Forman Investment Trust"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"NMD670","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"NMD PHARMA \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"NMD PHARMA \/ Not Applicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Bexatamig","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"14","companyTruncated":"Innate Pharma \/ Sanofi"},{"orgOrder":0,"company":"Abionyx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"CER-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Abionyx Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Abionyx Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Abionyx Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Risvodetinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Inhibikase Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Merck & Co \/ Not Applicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Bucillamine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Revive Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"INB-100","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"IN8bio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"IN8bio \/ Not Applicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Olverembatinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ascentage Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Allogeneic Medicinal Signaling Cell Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Longeveron \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Longeveron \/ Not Applicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Large molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Akero Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Crofelemer","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Jaguar Health \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Jaguar Health \/ Not Applicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"KB-GDT-01","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kiromic BioPharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Kiromic BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"Apex Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Apex Labs","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Apex Labs \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Apex Labs \/ Not Applicable"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"LSD","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"MindBio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"MindBio Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Large molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Efgartigimod Alfa","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Argenx \/ Not Applicable"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Starton Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Starton Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Adagrasib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Cadisegliatin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"vTv Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"AstraZeneca \/ Not Applicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"TGR-63","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"IGC Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Vogenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Mizagliflozin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Vogenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Vogenx \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Vogenx \/ Not Applicable"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Private Placement","leadProduct":"KT-2000","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Rakovina Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"14","companyTruncated":"Rakovina Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioSenic","sponsor":"ABO Securities","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Agreement","leadProduct":"Arsenic Trioxide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioSenic \/ ABO Securities","highestDevelopmentStatusID":"14","companyTruncated":"BioSenic \/ ABO Securities"},{"orgOrder":0,"company":"ALK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Birch Pollen Extract","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ALK \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ALK \/ Not Applicable"},{"orgOrder":0,"company":"SFA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Calcium","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"SFA Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"SFA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"SFA Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"SpliSense","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"SPL84","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"SpliSense","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"SpliSense \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"SpliSense \/ Not Applicable"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Liposomal Tacrolimus","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lipella Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Lipella Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Maralixibat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Mirum Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"SN BioScience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"7-Ethyl-10-Hydroxycamptothecin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"SN BioScience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"SN BioScience \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"SN BioScience \/ Not Applicable"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Sleep","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Serdexmethylphenidate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Zevra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Zevra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"BMF-219","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Biomea Fusion \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Biomea Fusion \/ Not Applicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Large molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Pepinemab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Vaccinex \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Vaccinex \/ Not Applicable"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Abelacimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Anthos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Anthos Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"KB-GDT-01","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kiromic BioPharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Kiromic BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"Calico Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Fosigotifator","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Calico Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Calico Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Calico Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Sarepta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Guselkumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Johnson & Johnson \/ Not Applicable"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"CG Oncology \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"CG Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"ABI-4334","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Assembly Biosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Assembly Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nephrology","country":"","productType":"Peptide","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"LSALT Peptide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Arch Biopartners \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Ribitol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"NMD670","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"NMD PHARMA \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"NMD PHARMA \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Mim8","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Sotagliflozin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Lexicon pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Sleep","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Solriamfetol Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Axsome Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Reproxalap","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Aldeyra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Aficamten","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Cytokinetics \/ Not Applicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Ganaxolone","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Marinus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Marinus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Deramiocel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Capricor Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Allyx Therapeutics","sponsor":"Yale University","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"BMS-984923","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Allyx Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Allyx Therapeutics \/ Yale University","highestDevelopmentStatusID":"14","companyTruncated":"Allyx Therapeutics \/ Yale University"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Tafenoquine Succinate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"60 Degrees Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"60 Degrees Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Nutriband","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Fentanyl","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Nutriband \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Nutriband \/ Not Applicable"},{"orgOrder":0,"company":"4Moving Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Liraglutide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"4Moving Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"4Moving Biotech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"4Moving Biotech \/ Not Applicable"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Sonelokimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"MoonLake Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"MoonLake Immunotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"ABI-5366","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Assembly Biosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Assembly Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Imunon \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Imunon \/ Not Applicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Vilobelimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"InflaRx \/ Not Applicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Cosibelimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Checkpoint Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Checkpoint Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Trilaciclib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"G1 Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"G1 Therapeutics, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"ENTR-601-44","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Entrada Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Entrada Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Entrada Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Large molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"SRK-439","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Scholar Rock \/ Not Applicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"RGLS8429","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Regulus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Regulus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"WTX-330","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Werewolf Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Werewolf Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Quince Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Bryostatin-1","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Synaptogenix \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Synaptogenix \/ Not Applicable"},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Rinvecalinase Alfa","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"DiaMedica Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"DiaMedica Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"DiaMedica Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Amphotericin B","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Matinas BioPharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Matinas BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"MRT-2359","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Monte Rosa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Monte Rosa Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Deramiocel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Capricor Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"PharmAbcine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"PMC-403","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"PharmAbcine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"PharmAbcine \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"PharmAbcine \/ Not Applicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Crinecerfont","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Neurocrine Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"KB-GDT-01","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kiromic BioPharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Kiromic BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"VBI-1901","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"VBI Vaccines \/ Not Applicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Merck & Co \/ Not Applicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Nomlabofusp","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Larimar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Larimar Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"BMF-219","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Biomea Fusion \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Biomea Fusion \/ Not Applicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Bria-OTS","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Lantheus Holding","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2024","year":"2024","type":"Private Placement","leadProduct":"[68Ga]-Trivehexin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Radiopharm Theranostics","amount2":0.02,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Radiopharm Theranostics \/ Lantheus Holding","highestDevelopmentStatusID":"14","companyTruncated":"Radiopharm Theranostics \/ Lantheus Holding"},{"orgOrder":0,"company":"BioSenic","sponsor":"Phebra","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Arsenic Trioxide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioSenic \/ Phebra","highestDevelopmentStatusID":"14","companyTruncated":"BioSenic \/ Phebra"},{"orgOrder":0,"company":"Codexis","sponsor":"Crosswalk Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"AAV Gene Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Codexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Codexis \/ Crosswalk Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"Codexis \/ Crosswalk Therapeutics"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"California Institute for Regenerative Medicines","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Funding","leadProduct":"Cytarabine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Senti Biosciences","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Senti Biosciences \/ California Institute for Regenerative Medicines","highestDevelopmentStatusID":"14","companyTruncated":"Senti Biosciences \/ California Institute for Regenerative Medicines"},{"orgOrder":0,"company":"Radionetics Oncology","sponsor":"Eli Lilly","pharmaFlowCategory":"D","upfrontCash":"$140.0 million","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Radionetics Oncology","amount2":1,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Radionetics Oncology \/ Eli Lilly","highestDevelopmentStatusID":"14","companyTruncated":"Radionetics Oncology \/ Eli Lilly"},{"orgOrder":0,"company":"CureVac","sponsor":"Biogen","pharmaFlowCategory":"D","upfrontCash":"$429.2 million","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"GSK4382276A","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"CureVac","amount2":1.5600000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"CureVac \/ Biogen","highestDevelopmentStatusID":"14","companyTruncated":"CureVac \/ Biogen"},{"orgOrder":0,"company":"ThirtyFiveBio","sponsor":"Innovate UK","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ThirtyFiveBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ThirtyFiveBio \/ Innovate UK","highestDevelopmentStatusID":"14","companyTruncated":"ThirtyFiveBio \/ Innovate UK"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"July 2024","year":"2024","type":"Funding","leadProduct":"mRNA-1010","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Moderna Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ BARDA","highestDevelopmentStatusID":"14","companyTruncated":"Moderna Therapeutics \/ BARDA"},{"orgOrder":0,"company":"Glycotope","sponsor":"PentixaPharm","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"GT-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Glycotope","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Glycotope \/ Pentixapharm","highestDevelopmentStatusID":"14","companyTruncated":"Glycotope \/ Pentixapharm"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"InfectoPharm Drugs and Consilium","pharmaFlowCategory":"D","upfrontCash":"$0.9 million","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"October 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cosmo Pharmaceuticals \/ InfectoPharm Drugs and Consilium","highestDevelopmentStatusID":"14","companyTruncated":"Cosmo Pharmaceuticals \/ InfectoPharm Drugs and Consilium"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Hyundai Pharm","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"June 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cosmo Pharmaceuticals \/ Hyundai Pharm","highestDevelopmentStatusID":"14","companyTruncated":"Cosmo Pharmaceuticals \/ Hyundai Pharm"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"$0.7 million","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cosmo Pharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"Cosmo Pharmaceuticals \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"October 2021","year":"2021","type":"Acquisition","leadProduct":"Clascoterone","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cassiopea","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cassiopea \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"Cassiopea \/ Cosmo Pharmaceuticals"},{"orgOrder":0,"company":"The Medicines Patent Pool","sponsor":"Aurobindo Pharma Limited","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Cabotegravir","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"The Medicines Patent Pool","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"The Medicines Patent Pool \/ Aurobindo Pharma Limited","highestDevelopmentStatusID":"14","companyTruncated":"The Medicines Patent Pool \/ Aurobindo Pharma Limited"},{"orgOrder":0,"company":"Kanvas Biosciences","sponsor":"DCVC","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Funding","leadProduct":"KAN-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kanvas Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kanvas Biosciences \/ DCVC","highestDevelopmentStatusID":"14","companyTruncated":"Kanvas Biosciences \/ DCVC"},{"orgOrder":0,"company":"Beacon Therapeutics","sponsor":"TCGX","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Series B Financing","leadProduct":"Laruparetigene Zovaparvovec","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Beacon Therapeutics","amount2":0.17000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Beacon Therapeutics \/ TCGX","highestDevelopmentStatusID":"14","companyTruncated":"Beacon Therapeutics \/ TCGX"},{"orgOrder":0,"company":"Celltrion","sponsor":"Hasten Biopharmaceutic","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Acquisition","leadProduct":"Azilsartan","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Celltrion \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"14","companyTruncated":"Celltrion \/ Hasten Biopharmaceutic"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Pertuzumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"14","companyTruncated":"Zydus Lifesciences \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"McGill University","sponsor":"Brain Canada","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Sleep","country":"","productType":"Undisclosed","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"McGill University","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"McGill University \/ Brain Canada","highestDevelopmentStatusID":"14","companyTruncated":"McGill University \/ Brain Canada"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Afrigen Biologics and Vaccines","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Vaccine","date":"July 2024","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Merck & Co \/ Afrigen Biologics and Vaccines","highestDevelopmentStatusID":"14","companyTruncated":"Merck & Co \/ Afrigen Biologics and Vaccines"},{"orgOrder":0,"company":"Genexine","sponsor":"EPD Biotherapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Merger","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Genexine \/ EPD Biotherapeutics","highestDevelopmentStatusID":"14","companyTruncated":"Genexine \/ EPD Biotherapeutics"},{"orgOrder":0,"company":"SmartCella","sponsor":"Fj\u00e4rde AP-fonden","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Financing","leadProduct":"PROC-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"SmartCella","amount2":0.050000000000000003,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"SmartCella \/ Fj\u00e4rde AP-fonden","highestDevelopmentStatusID":"14","companyTruncated":"SmartCella \/ Fj\u00e4rde AP-fonden"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"IASO Bio","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Equecabtagene Autoleucel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Innovent Biologics \/ IASO Bio","highestDevelopmentStatusID":"14","companyTruncated":"Innovent Biologics \/ IASO Bio"},{"orgOrder":0,"company":"Myricx Bio","sponsor":"Novo Holdings","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Series A Financing","leadProduct":"MYX2468","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Myricx Bio","amount2":0.11,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Myricx Bio \/ Novo Holdings","highestDevelopmentStatusID":"14","companyTruncated":"Myricx Bio \/ Novo Holdings"},{"orgOrder":0,"company":"Synsight","sponsor":"Iktos","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Synsight","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Synsight \/ Iktos","highestDevelopmentStatusID":"14","companyTruncated":"Synsight \/ Iktos"},{"orgOrder":0,"company":"RS BioTherapeutics","sponsor":"University of Colorado School of Medicine","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"RSBT-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"RS BioTherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"RS BioTherapeutics \/ University of Colorado School of Medicine","highestDevelopmentStatusID":"14","companyTruncated":"RS BioTherapeutics \/ University of Colorado School of Medicine"},{"orgOrder":0,"company":"Trevena","sponsor":"R-Bridge Healthcare Fund","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Financing","leadProduct":"Oliceridine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Trevena","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Trevena \/ R-Bridge Healthcare Fund","highestDevelopmentStatusID":"14","companyTruncated":"Trevena \/ R-Bridge Healthcare Fund"},{"orgOrder":0,"company":"CellProthera","sponsor":"BioCardia","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"ProtheraCytes","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"CellProthera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"CellProthera \/ BioCardia","highestDevelopmentStatusID":"14","companyTruncated":"CellProthera \/ BioCardia"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"TuHURA Biosciences","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Agreement","leadProduct":"KVA12123","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kintara Therapeutics","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kintara Therapeutics \/ TuHURA Biosciences","highestDevelopmentStatusID":"14","companyTruncated":"Kintara Therapeutics \/ TuHURA Biosciences"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Quemliclustat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arcus Biosciences \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"14","companyTruncated":"Arcus Biosciences \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"$100.0 million","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"Dinutuximab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Apeiron Biologics","amount2":0.13,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Apeiron Biologics \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"Apeiron Biologics \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Bionxt Solutions","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Agreement","leadProduct":"Cladribine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Undisclosed \/ BioNxt Solutions","highestDevelopmentStatusID":"14","companyTruncated":"Undisclosed \/ BioNxt Solutions"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Mitsubishi Tanabe Pharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"July 2024","year":"2024","type":"Agreement","leadProduct":"Covid-19 Vaccine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Mitsubishi Tanabe Pharma","highestDevelopmentStatusID":"14","companyTruncated":"Moderna Therapeutics \/ Mitsubishi Tanabe Pharma"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"TSX Venture Exchange","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Private Placement","leadProduct":"TLD-1433","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Theralase Technologies \/ TSX Venture Exchange","highestDevelopmentStatusID":"14","companyTruncated":"Theralase Technologies \/ TSX Venture Exchange"},{"orgOrder":0,"company":"SciRhom","sponsor":"Andera Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Series A Financing","leadProduct":"SR-878","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"SciRhom","amount2":0.070000000000000007,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"SciRhom \/ Andera Partners","highestDevelopmentStatusID":"14","companyTruncated":"SciRhom \/ Andera Partners"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","upfrontCash":"$12.0 million","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Termination","leadProduct":"Rifamycin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"RedHill Biopharma","amount2":0.040000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"RedHill Biopharma \/ RedHill Biopharma","highestDevelopmentStatusID":"14","companyTruncated":"RedHill Biopharma \/ RedHill Biopharma"},{"orgOrder":0,"company":"Endomimetics","sponsor":"Innovate Alabama","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Peptide","date":"July 2024","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Endomimetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Endomimetics \/ Innovate Alabama","highestDevelopmentStatusID":"14","companyTruncated":"Endomimetics \/ Innovate Alabama"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Docetaxel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Prelude Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Prelude Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"14","companyTruncated":"Prelude Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Crossject","sponsor":"Bpifrance","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Financing","leadProduct":"Midazolam","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Crossject","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Crossject \/ Bpifrance","highestDevelopmentStatusID":"14","companyTruncated":"Crossject \/ Bpifrance"},{"orgOrder":0,"company":"HepaRegeniX","sponsor":"Vesalius Biocapital IV","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Series C Financing","leadProduct":"HRX-215","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"HepaRegeniX","amount2":0.02,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"HepaRegeniX \/ Vesalius Biocapital IV","highestDevelopmentStatusID":"14","companyTruncated":"HepaRegeniX \/ Vesalius Biocapital IV"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Merz Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"Etilevodopa","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Acorda Therapeutics","amount2":0.19,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Acorda Therapeutics \/ Merz Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"Acorda Therapeutics \/ Merz Therapeutics"},{"orgOrder":0,"company":"Sanofi","sponsor":"Cosette Pharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Sleep","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"Zolpidem Tartrate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sanofi \/ Cosette Pharma","highestDevelopmentStatusID":"14","companyTruncated":"Sanofi \/ Cosette Pharma"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Amylyx Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"Avexitide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eiger BioPharmaceuticals","amount2":0.040000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eiger BioPharmaceuticals \/ Amylyx Pharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"Eiger BioPharmaceuticals \/ Amylyx Pharmaceuticals"},{"orgOrder":0,"company":"Ensol BioSciences","sponsor":"Spine BioPharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Peptide","date":"July 2024","year":"2024","type":"Agreement","leadProduct":"SB-01","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ensol BioSciences","amount2":0.16,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ensol BioSciences \/ Spine BioPharma","highestDevelopmentStatusID":"14","companyTruncated":"Ensol BioSciences \/ Spine BioPharma"},{"orgOrder":0,"company":"Link Immunotherapeutics","sponsor":"Context Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"CT-95","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Link Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Link Immunotherapeutics \/ Context Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"Link Immunotherapeutics \/ Context Therapeutics"},{"orgOrder":0,"company":"Evotec","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Evotec \/ Pfizer Inc","highestDevelopmentStatusID":"14","companyTruncated":"Evotec \/ Pfizer Inc"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Beacon Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Agreement","leadProduct":"AAV204","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Beacon Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"Abeona Therapeutics \/ Beacon Therapeutics"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Financing","leadProduct":"Golimumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"14","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Pan Cancer T","sponsor":"InnovationQuarter","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Financing","leadProduct":"PCT-1","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Pan Cancer T","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Pan Cancer T \/ InnovationQuarter","highestDevelopmentStatusID":"14","companyTruncated":"Pan Cancer T \/ InnovationQuarter"},{"orgOrder":0,"company":"Onco360","sponsor":"Geron","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Partnership","leadProduct":"Imetelstat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Onco360","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Onco360 \/ Geron","highestDevelopmentStatusID":"14","companyTruncated":"Onco360 \/ Geron"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"GenFleet Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"VS-7375","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Verastem Oncology \/ GenFleet Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"Verastem Oncology \/ GenFleet Therapeutics"},{"orgOrder":0,"company":"Tiba Biotech","sponsor":"BARDA","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Tiba Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Tiba Biotech \/ BARDA","highestDevelopmentStatusID":"14","companyTruncated":"Tiba Biotech \/ BARDA"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Evofem Biosciences","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Divestment","leadProduct":"Secnidazole","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Lupin Ltd","amount2":0.080000000000000002,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lupin Ltd \/ Evofem Biosciences","highestDevelopmentStatusID":"14","companyTruncated":"Lupin Ltd \/ Evofem Biosciences"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Akos Biosciences","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"EV102","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Enveric Biosciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Enveric Biosciences \/ Akos Biosciences","highestDevelopmentStatusID":"14","companyTruncated":"Enveric Biosciences \/ Akos Biosciences"},{"orgOrder":0,"company":"MediWound","sponsor":"Molnlycke Health Care","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Podiatry","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Private Placement","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"MediWound","amount2":0.029999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"MediWound \/ Molnlycke Health Care","highestDevelopmentStatusID":"14","companyTruncated":"MediWound \/ Molnlycke Health Care"},{"orgOrder":0,"company":"Trethera","sponsor":"Small Business Innovation Research","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Funding","leadProduct":"TRE-515","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Trethera \/ Small Business Innovation Research","highestDevelopmentStatusID":"14","companyTruncated":"Trethera \/ Small Business Innovation Research"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Podiatry","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Funding","leadProduct":"R327","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Recce Pharmaceuticals \/ U.S. Department of Defense","highestDevelopmentStatusID":"14","companyTruncated":"Recce Pharmaceuticals \/ U.S. Department of Defense"},{"orgOrder":0,"company":"MediWound","sponsor":"EIC","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Podiatry","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Funding","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"MediWound","amount2":0.02,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"MediWound \/ EIC","highestDevelopmentStatusID":"14","companyTruncated":"MediWound \/ EIC"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"SPC-14","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Silo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Silo Pharma \/ Undisclosed","highestDevelopmentStatusID":"14","companyTruncated":"Silo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Willett Advisors","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Series C Financing","leadProduct":"STX-478","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Scorpion Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Scorpion Therapeutics \/ Willett Advisors","highestDevelopmentStatusID":"14","companyTruncated":"Scorpion Therapeutics \/ Willett Advisors"},{"orgOrder":0,"company":"Soleo Health","sponsor":"GC Biopharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Partnership","leadProduct":"Immune Globulin Intravenous, Human","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Soleo Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Soleo Health \/ GC Biopharma","highestDevelopmentStatusID":"14","companyTruncated":"Soleo Health \/ GC Biopharma"},{"orgOrder":0,"company":"Genomics plc","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Undisclosed","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Genomics plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Genomics plc \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"Genomics plc \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Renalys Pharma","sponsor":"Catalys Pacific","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Series A Financing","leadProduct":"Sparsentan","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Renalys Pharma","amount2":0.040000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Renalys Pharma \/ Catalys Pacific","highestDevelopmentStatusID":"14","companyTruncated":"Renalys Pharma \/ Catalys Pacific"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Sionna Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Galicaftor","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AbbVie Inc \/ Sionna Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"AbbVie Inc \/ Sionna Therapeutics"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Vonoprazan Fumarate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Takeda Pharmaceutical \/ Mankind Pharma","highestDevelopmentStatusID":"14","companyTruncated":"Takeda Pharmaceutical \/ Mankind Pharma"},{"orgOrder":0,"company":"CatalYm","sponsor":"Canaan Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Series D Financing","leadProduct":"Nivolumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"CatalYm","amount2":0.14999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"CatalYm \/ Canaan Partners","highestDevelopmentStatusID":"14","companyTruncated":"CatalYm \/ Canaan Partners"},{"orgOrder":0,"company":"Asceneuron","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Series C Financing","leadProduct":"ASN51","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Asceneuron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Asceneuron \/ EQT Life Sciences","highestDevelopmentStatusID":"14","companyTruncated":"Asceneuron \/ EQT Life Sciences"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Bayer AG","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"ORIC-944","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ORIC Pharmaceuticals \/ Bayer AG","highestDevelopmentStatusID":"14","companyTruncated":"ORIC Pharmaceuticals \/ Bayer AG"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","upfrontCash":"$26.5 million","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Baricitinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aclaris Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aclaris Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"14","companyTruncated":"Aclaris Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"TCG","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Series A Financing","leadProduct":"Aldafermin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"NGM Biopharmaceuticals","amount2":0.12,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"NGM Biopharmaceuticals \/ TCG","highestDevelopmentStatusID":"14","companyTruncated":"NGM Biopharmaceuticals \/ TCG"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"ACEA Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Agreement","leadProduct":"Lidocaine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Scilex Pharmaceuticals \/ ACEA Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"Scilex Pharmaceuticals \/ ACEA Therapeutics"},{"orgOrder":0,"company":"SciSparc","sponsor":"Undisclosed","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"SciSparc","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"SciSparc \/ Undisclosed","highestDevelopmentStatusID":"14","companyTruncated":"SciSparc \/ Undisclosed"},{"orgOrder":0,"company":"Ancilia Bioscience","sponsor":"Safar Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Financing","leadProduct":"Bacteria-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ancilia Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ancilia Bioscience \/ Safar Partners","highestDevelopmentStatusID":"14","companyTruncated":"Ancilia Bioscience \/ Safar Partners"},{"orgOrder":0,"company":"Sanyou Biopharmaceuticals","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sanyou Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sanyou Biopharmaceuticals \/ Hangzhou Zhongmei Huadong Pharmaceutical","highestDevelopmentStatusID":"14","companyTruncated":"Sanyou Biopharmaceuticals \/ Hangzhou Zhongmei Huadong Pharmaceutical"},{"orgOrder":0,"company":"Draupnir Bio","sponsor":"MP Healthcare","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Draupnir Bio","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Draupnir Bio \/ MP Healthcare","highestDevelopmentStatusID":"14","companyTruncated":"Draupnir Bio \/ MP Healthcare"},{"orgOrder":0,"company":"Nika Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"July 2024","year":"2024","type":"Agreement","leadProduct":"ITV-1 - ImmunH","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Nika Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Nika Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"14","companyTruncated":"Nika Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Longeveron","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Public Offering","leadProduct":"Allogeneic Medicinal Signaling Cell Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Longeveron","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Longeveron \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"14","companyTruncated":"Longeveron \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Haystack Oncology","sponsor":"Lisata Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Peptide","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Certepetide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Haystack Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Haystack Oncology \/ Lisata Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"Haystack Oncology \/ Lisata Therapeutics"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Samsara BioCapital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Financing","leadProduct":"Lanifibranor","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Inventiva Pharma","amount2":0.02,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Inventiva Pharma \/ Samsara BioCapital","highestDevelopmentStatusID":"14","companyTruncated":"Inventiva Pharma \/ Samsara BioCapital"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Meitheal Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"Fosfomycin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Nabriva Therapeutics \/ Meitheal Pharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"Nabriva Therapeutics \/ Meitheal Pharmaceuticals"},{"orgOrder":0,"company":"GT Apeiron","sponsor":"Exscientia","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"GTAEXS617","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"GT Apeiron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"GT Apeiron \/ Exscientia","highestDevelopmentStatusID":"14","companyTruncated":"GT Apeiron \/ Exscientia"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"July 2024","year":"2024","type":"Funding","leadProduct":"mRNA-1018","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Moderna Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ BARDA","highestDevelopmentStatusID":"14","companyTruncated":"Moderna Therapeutics \/ BARDA"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Resyca BV Partner","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Partnership","leadProduct":"SPC-15","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Silo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Silo Pharma \/ Resyca BV Partner","highestDevelopmentStatusID":"14","companyTruncated":"Silo Pharma \/ Resyca BV Partner"},{"orgOrder":0,"company":"Rona Therapeutics","sponsor":"LongRiver Investments","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Series A Financing","leadProduct":"RN0191","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Rona Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Rona Therapeutics \/ LongRiver Investments","highestDevelopmentStatusID":"14","companyTruncated":"Rona Therapeutics \/ LongRiver Investments"},{"orgOrder":0,"company":"Andelyn Biosciences","sponsor":"UMass Chan Medical School","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Andelyn Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Andelyn Biosciences \/ UMass Chan Medical School","highestDevelopmentStatusID":"14","companyTruncated":"Andelyn Biosciences \/ UMass Chan Medical School"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Public Offering","leadProduct":"AB-101","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Artiva Biotherapeutics","amount2":0.17000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Artiva Biotherapeutics \/ Jefferies","highestDevelopmentStatusID":"14","companyTruncated":"Artiva Biotherapeutics \/ Jefferies"},{"orgOrder":0,"company":"GRO Biosciences","sponsor":"Atlas Venture","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Rheumatology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"GRO Biosciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"GRO Biosciences \/ Atlas Venture","highestDevelopmentStatusID":"14","companyTruncated":"GRO Biosciences \/ Atlas Venture"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Zydus Lifesciences","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Vonoprazan Fumarate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Takeda Pharmaceutical \/ Zydus Lifesciences","highestDevelopmentStatusID":"14","companyTruncated":"Takeda Pharmaceutical \/ Zydus Lifesciences"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Vonoprazan Fumarate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Takeda Pharmaceutical \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"14","companyTruncated":"Takeda Pharmaceutical \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Public Offering","leadProduct":"Sirolimus","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Biodexa Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Biodexa Pharmaceuticals \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"14","companyTruncated":"Biodexa Pharmaceuticals \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Yale University","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Agreement","leadProduct":"Tafenoquine Succinate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"60 Degrees Pharmaceuticals \/ Yale University","highestDevelopmentStatusID":"14","companyTruncated":"60 Degrees Pharmaceuticals \/ Yale University"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Public Offering","leadProduct":"TTX-MC138","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ ThinkEquity","highestDevelopmentStatusID":"14","companyTruncated":"TransCode Therapeutics \/ ThinkEquity"},{"orgOrder":0,"company":"Pharma Two B","sponsor":"Hepion Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Merger","leadProduct":"Pramipexole Dihydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Pharma Two B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Pharma Two B \/ Hepion Pharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"Pharma Two B \/ Hepion Pharmaceuticals"},{"orgOrder":0,"company":"Valneva","sponsor":"CEPI","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"July 2024","year":"2024","type":"Funding","leadProduct":"Chikungunya Vaccine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Valneva","amount2":0.040000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Valneva \/ CEPI","highestDevelopmentStatusID":"14","companyTruncated":"Valneva \/ CEPI"},{"orgOrder":0,"company":"Cell BioEngine","sponsor":"SOSV","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Funding","leadProduct":"CBE-101","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cell BioEngine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cell BioEngine \/ SOSV","highestDevelopmentStatusID":"14","companyTruncated":"Cell BioEngine \/ SOSV"},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Pharmacology\/Toxicology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Funding","leadProduct":"Selonabant","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Anebulo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Anebulo Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"14","companyTruncated":"Anebulo Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Lario Therapeutics","sponsor":"Michael J. Fox Foundation","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","date":"July 2024","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Lario Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lario Therapeutics \/ Michael J. Fox Foundation","highestDevelopmentStatusID":"14","companyTruncated":"Lario Therapeutics \/ Michael J. Fox Foundation"},{"orgOrder":0,"company":"Apollo Therapeutics","sponsor":"University of Oxford","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Apollo Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Apollo Therapeutics \/ University of Oxford","highestDevelopmentStatusID":"14","companyTruncated":"Apollo Therapeutics \/ University of Oxford"},{"orgOrder":0,"company":"Biophytis","sponsor":"Undisclosed","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Partnership","leadProduct":"20-Hydroxyecdysone","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Biophytis \/ Undisclosed","highestDevelopmentStatusID":"14","companyTruncated":"Biophytis \/ Undisclosed"},{"orgOrder":0,"company":"Eisai","sponsor":"Sato Pharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Fosravuconazole","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eisai \/ Sato Pharma","highestDevelopmentStatusID":"14","companyTruncated":"Eisai \/ Sato Pharma"},{"orgOrder":0,"company":"Eyenovia","sponsor":"SENJU PHARMACEUTICAL CO LTD","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Fonadelpar","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eyenovia \/ SENJU PHARMACEUTICAL CO LTD","highestDevelopmentStatusID":"14","companyTruncated":"Eyenovia \/ SENJU PHARMACEUTICAL CO LTD"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Public Offering","leadProduct":"Avutometinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Verastem Oncology","amount2":0.059999999999999998,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Verastem Oncology \/ Guggenheim Securities","highestDevelopmentStatusID":"14","companyTruncated":"Verastem Oncology \/ Guggenheim Securities"},{"orgOrder":0,"company":"Third Arc Bio","sponsor":"Vida Ventures","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","date":"July 2024","year":"2024","type":"Series A Financing","leadProduct":"ADC-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Third Arc Bio","amount2":0.17000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Third Arc Bio \/ Vida Ventures","highestDevelopmentStatusID":"14","companyTruncated":"Third Arc Bio \/ Vida Ventures"},{"orgOrder":0,"company":"Abiologics","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Financing","leadProduct":"Synteins-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Abiologics","amount2":0.050000000000000003,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Abiologics \/ Flagship Pioneering","highestDevelopmentStatusID":"14","companyTruncated":"Abiologics \/ Flagship Pioneering"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Public Offering","leadProduct":"TTX-MC138","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ ThinkEquity","highestDevelopmentStatusID":"14","companyTruncated":"TransCode Therapeutics \/ ThinkEquity"},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"EIC","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Funding","leadProduct":"Padeliporfin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ImPact Biotech","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ImPact Biotech \/ EIC","highestDevelopmentStatusID":"14","companyTruncated":"ImPact Biotech \/ EIC"},{"orgOrder":0,"company":"Beacon Biosignals","sponsor":"Skye Bioscience","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Nimacimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Beacon Biosignals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Beacon Biosignals \/ Skye Bioscience","highestDevelopmentStatusID":"14","companyTruncated":"Beacon Biosignals \/ Skye Bioscience"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Canaan Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Series C Financing","leadProduct":"ABX-002","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Autobahn Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Autobahn Therapeutics \/ Canaan Partners","highestDevelopmentStatusID":"14","companyTruncated":"Autobahn Therapeutics \/ Canaan Partners"},{"orgOrder":0,"company":"Fortress Biotech","sponsor":"NIAID","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"May 2024","year":"2024","type":"Funding","leadProduct":"CMV Vaccine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Fortress Biotech","amount2":0.02,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Fortress Biotech \/ NIAID","highestDevelopmentStatusID":"14","companyTruncated":"Fortress Biotech \/ NIAID"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"DIMERx","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Licensing Agreement","leadProduct":"AMX-201","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Massachusetts General Hospital \/ DIMERx","highestDevelopmentStatusID":"14","companyTruncated":"Massachusetts General Hospital \/ DIMERx"},{"orgOrder":0,"company":"Evergreen Theragnostics","sponsor":"Medical University of Innsbruck","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"177Lu-EVG-321","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Evergreen Theragnostics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Evergreen Theragnostics \/ Medical University of Innsbruck","highestDevelopmentStatusID":"14","companyTruncated":"Evergreen Theragnostics \/ Medical University of Innsbruck"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Cleveland Clinic","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"TFF Pharmaceuticals \/ Cleveland Clinic","highestDevelopmentStatusID":"14","companyTruncated":"TFF Pharmaceuticals \/ Cleveland Clinic"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"University College London","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"225Ac-rhPSMA-10.1","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Blue Earth Therapeutics \/ University College London","highestDevelopmentStatusID":"14","companyTruncated":"Blue Earth Therapeutics \/ University College London"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"KYE Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Vamorolone","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Catalyst Pharmaceuticals \/ Kye Pharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"Catalyst Pharmaceuticals \/ Kye Pharmaceuticals"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Beacon Biosignals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Nimacimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Skye Bioscience \/ Beacon Biosignals","highestDevelopmentStatusID":"14","companyTruncated":"Skye Bioscience \/ Beacon Biosignals"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Series C Financing","leadProduct":"ABX-002","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Autobahn Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Autobahn Therapeutics \/ ARCH Venture Partners","highestDevelopmentStatusID":"14","companyTruncated":"Autobahn Therapeutics \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Nexcella","sponsor":"CIRM","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Funding","leadProduct":"NXC-201","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Nexcella","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Nexcella \/ CIRM","highestDevelopmentStatusID":"14","companyTruncated":"Nexcella \/ CIRM"},{"orgOrder":0,"company":"ChemomAb","sponsor":"HBM Healthcare Investments","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Private Placement","leadProduct":"CM-101","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ChemomAb","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ChemomAb \/ HBM Healthcare Investments","highestDevelopmentStatusID":"14","companyTruncated":"ChemomAb \/ HBM Healthcare Investments"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"MagnaPharm","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Tretinoin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sol-Gel Technologies \/ MagnaPharm","highestDevelopmentStatusID":"14","companyTruncated":"Sol-Gel Technologies \/ MagnaPharm"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Aditxt","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"ATI-1701","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Appili Therapeutics \/ Aditxt","highestDevelopmentStatusID":"14","companyTruncated":"Appili Therapeutics \/ Aditxt"},{"orgOrder":0,"company":"Marvel Biosciences","sponsor":"iBraiN Institute","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Istradefylline","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Marvel Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Marvel Biosciences \/ iBraiN Institute","highestDevelopmentStatusID":"14","companyTruncated":"Marvel Biosciences \/ iBraiN Institute"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"University of Texas MD Anderson","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Ivonescimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Summit Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Summit Therapeutics \/ University of Texas MD Anderson","highestDevelopmentStatusID":"14","companyTruncated":"Summit Therapeutics \/ University of Texas MD Anderson"},{"orgOrder":0,"company":"Immunis","sponsor":"Springbok","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Musculoskeletal","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Partnership","leadProduct":"IMM01-STEM","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Immunis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Immunis \/ Springbok","highestDevelopmentStatusID":"14","companyTruncated":"Immunis \/ Springbok"},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Driehaus Capital Management","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Confo Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Confo Therapeutics \/ Driehaus Capital Management","highestDevelopmentStatusID":"14","companyTruncated":"Confo Therapeutics \/ Driehaus Capital Management"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Wellcome Trust","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Funding","leadProduct":"ALTO-100","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alto Neuroscience","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alto Neuroscience \/ Wellcome Trust","highestDevelopmentStatusID":"14","companyTruncated":"Alto Neuroscience \/ Wellcome Trust"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Private Placement","leadProduct":"KT-2000","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Rakovina Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"14","companyTruncated":"Rakovina Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Great Point Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Private Placement","leadProduct":"PMN310","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ProMIS Neurosciences","amount2":0.12,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ProMIS Neurosciences \/ Great Point Partners","highestDevelopmentStatusID":"14","companyTruncated":"ProMIS Neurosciences \/ Great Point Partners"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"ThinkEquity","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"CEL-SCI","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"CEL-SCI \/ ThinkEquity","highestDevelopmentStatusID":"14","companyTruncated":"CEL-SCI \/ ThinkEquity"},{"orgOrder":0,"company":"ReviR Therapeutics","sponsor":"Lapam Capital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ReviR Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ReviR Therapeutics \/ Lapam Capital","highestDevelopmentStatusID":"14","companyTruncated":"ReviR Therapeutics \/ Lapam Capital"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Genomma Lab","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"Ibuprofen","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Undisclosed \/ Genomma Lab","highestDevelopmentStatusID":"14","companyTruncated":"Undisclosed \/ Genomma Lab"},{"orgOrder":0,"company":"PANTHERx Rare Pharmacy","sponsor":"ITF Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Partnership","leadProduct":"Givinostat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"PANTHERx Rare Pharmacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"PANTHERx Rare Pharmacy \/ ITF Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"PANTHERx Rare Pharmacy \/ ITF Therapeutics"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Columbia University","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Apamistamab-I-131","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Actinium pharmaceuticals \/ Columbia University","highestDevelopmentStatusID":"14","companyTruncated":"Actinium pharmaceuticals \/ Columbia University"},{"orgOrder":0,"company":"PK MED","sponsor":"Bpifrance","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Financing","leadProduct":"PKM-02","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"PK MED","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"PK MED \/ Bpifrance","highestDevelopmentStatusID":"14","companyTruncated":"PK MED \/ Bpifrance"},{"orgOrder":0,"company":"Versatope Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"July 2024","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Versatope Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Versatope Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"14","companyTruncated":"Versatope Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Merdury Pharmaceutical","sponsor":"Health2Sync","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Semaglutide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Merdury Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Merdury Pharmaceutical \/ Health2Sync","highestDevelopmentStatusID":"14","companyTruncated":"Merdury Pharmaceutical \/ Health2Sync"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"WeComput","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","date":"July 2024","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Innovent Biologics \/ WeComput","highestDevelopmentStatusID":"14","companyTruncated":"Innovent Biologics \/ WeComput"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Silicon Valley Bank","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Financing","leadProduct":"Cytisine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Achieve Life Sciences \/ Silicon Valley Bank","highestDevelopmentStatusID":"14","companyTruncated":"Achieve Life Sciences \/ Silicon Valley Bank"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Kowa Pharmaceuticals America","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Agreement","leadProduct":"Roflumilast","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arcutis Biotherapeutics \/ Kowa Pharmaceuticals America","highestDevelopmentStatusID":"14","companyTruncated":"Arcutis Biotherapeutics \/ Kowa Pharmaceuticals America"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","upfrontCash":"$150.0 million","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Carboplatin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"MacroGenics","amount2":0.91000000000000003,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"MacroGenics \/ Incyte Corporation","highestDevelopmentStatusID":"14","companyTruncated":"MacroGenics \/ Incyte Corporation"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"KabaFusion","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Partnership","leadProduct":"Immune Globulin Intravenous, Human","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"GC Biopharma \/ KabaFusion","highestDevelopmentStatusID":"14","companyTruncated":"GC Biopharma \/ KabaFusion"},{"orgOrder":0,"company":"Eyenovia","sponsor":"SGN Nanopharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Cyclosporine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eyenovia \/ SGN Nanopharma","highestDevelopmentStatusID":"14","companyTruncated":"Eyenovia \/ SGN Nanopharma"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Fairmount","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Private Placement","leadProduct":"Tovorafenib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Day One Biopharmaceuticals","amount2":0.17999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Day One Biopharmaceuticals \/ Fairmount","highestDevelopmentStatusID":"14","companyTruncated":"Day One Biopharmaceuticals \/ Fairmount"},{"orgOrder":0,"company":"CastleVax","sponsor":"BARDA","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"July 2024","year":"2024","type":"Funding","leadProduct":"CVAX-01","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"CastleVax","amount2":0.029999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"CastleVax \/ BARDA","highestDevelopmentStatusID":"14","companyTruncated":"CastleVax \/ BARDA"},{"orgOrder":0,"company":"Immuneel Therapeutics","sponsor":"taiba Healthcare Group","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Financing","leadProduct":"Varnimcabtagene Autoleucel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Immuneel Therapeutics","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Immuneel Therapeutics \/ taiba Healthcare Group","highestDevelopmentStatusID":"14","companyTruncated":"Immuneel Therapeutics \/ taiba Healthcare Group"},{"orgOrder":0,"company":"LTZ Therapeutics","sponsor":"Lapam Capital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Series A Financing","leadProduct":"LTZ-301","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"LTZ Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"LTZ Therapeutics \/ Lapam Capital","highestDevelopmentStatusID":"14","companyTruncated":"LTZ Therapeutics \/ Lapam Capital"},{"orgOrder":0,"company":"Leveragen","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Leveragen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Leveragen \/ Moderna Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"Leveragen \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"FOXG1 Research Foundation","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"AAV-based Gene Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Charles River Laboratories, Inc \/ FOXG1 Research Foundation","highestDevelopmentStatusID":"14","companyTruncated":"Charles River Laboratories, Inc \/ FOXG1 Research Foundation"},{"orgOrder":0,"company":"Pinetree Therapeutics","sponsor":"STIC Investments","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Pinetree Therapeutics","amount2":0.02,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Pinetree Therapeutics \/ STIC Investments","highestDevelopmentStatusID":"14","companyTruncated":"Pinetree Therapeutics \/ STIC Investments"},{"orgOrder":0,"company":"Cortice Biosciences","sponsor":"CNS Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Abeotaxane","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cortice Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cortice Biosciences \/ CNS Pharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"Cortice Biosciences \/ CNS Pharmaceuticals"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"MThera Pharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"NB-01","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"NeuroBo Pharmaceuticals \/ MThera Pharma","highestDevelopmentStatusID":"14","companyTruncated":"NeuroBo Pharmaceuticals \/ MThera Pharma"},{"orgOrder":0,"company":"CORTx","sponsor":"MRFF","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Large molecule","date":"July 2024","year":"2024","type":"Funding","leadProduct":"mRNA-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"CORTx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"CORTx \/ MRFF","highestDevelopmentStatusID":"14","companyTruncated":"CORTx \/ MRFF"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"GSK","pharmaFlowCategory":"D","upfrontCash":"$150.0 million","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Vaccine","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Flagship Pioneering","amount2":7.2000000000000002,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Flagship Pioneering \/ GSK","highestDevelopmentStatusID":"14","companyTruncated":"Flagship Pioneering \/ GSK"},{"orgOrder":0,"company":"AbCellera","sponsor":"Eli Lilly","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Expanded Collaboration","leadProduct":"ADC-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AbCellera \/ Eli Lilly","highestDevelopmentStatusID":"14","companyTruncated":"AbCellera \/ Eli Lilly"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Brookline Capital Market","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"July 2024","year":"2024","type":"Public Offering","leadProduct":"OST31-164","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"OS Therapies","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"OS Therapies \/ Brookline Capital Market","highestDevelopmentStatusID":"14","companyTruncated":"OS Therapies \/ Brookline Capital Market"},{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","upfrontCash":"$800.0 million","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Acquisition","leadProduct":"JNT-517","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Jnana Therapeutics","amount2":1.1299999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Jnana Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"14","companyTruncated":"Jnana Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Sagesse Bio","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Partnership","leadProduct":"Lixadesiran","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sirnaomics \/ Sagesse Bio","highestDevelopmentStatusID":"14","companyTruncated":"Sirnaomics \/ Sagesse Bio"},{"orgOrder":0,"company":"Medicilon","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Medicilon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Medicilon \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"14","companyTruncated":"Medicilon \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"KVK.Tech","sponsor":"Medix","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Partnership","leadProduct":"Phentermine Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"KVK.Tech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"KVK.Tech \/ Medix","highestDevelopmentStatusID":"14","companyTruncated":"KVK.Tech \/ Medix"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Ideaya Biosciences","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Biocytogen","amount2":0.40999999999999998,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Biocytogen \/ IDEAYA Biosciences","highestDevelopmentStatusID":"14","companyTruncated":"Biocytogen \/ IDEAYA Biosciences"},{"orgOrder":0,"company":"Avicenna Pharmaceutical","sponsor":"Molecure","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Avicenna Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Avicenna Pharmaceutical \/ Molecure","highestDevelopmentStatusID":"14","companyTruncated":"Avicenna Pharmaceutical \/ Molecure"},{"orgOrder":0,"company":"PolyPid","sponsor":"Citizens JMP","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Private Placement","leadProduct":"Doxycycline Hyclate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"PolyPid","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"PolyPid \/ Citizens JMP","highestDevelopmentStatusID":"14","companyTruncated":"PolyPid \/ Citizens JMP"},{"orgOrder":0,"company":"Outpace Bio","sponsor":"RA Capital Management","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Series B Financing","leadProduct":"OPB-101","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Outpace Bio","amount2":0.20000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Outpace Bio \/ RA Capital Management","highestDevelopmentStatusID":"14","companyTruncated":"Outpace Bio \/ RA Capital Management"},{"orgOrder":0,"company":"Passage Bio","sponsor":"GEMMA Biotherapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Licensing Agreement","leadProduct":"PBGM01","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Passage Bio","amount2":0.13,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Passage Bio \/ GEMMA Biotherapeutics","highestDevelopmentStatusID":"14","companyTruncated":"Passage Bio \/ GEMMA Biotherapeutics"},{"orgOrder":0,"company":"ImmuneOnco","sponsor":"Instil Bio","pharmaFlowCategory":"D","upfrontCash":"$50.0 million","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Licensing Agreement","leadProduct":"SYN-2510","moa":"PD-L1\/VEGF","graph1":"Technology","graph2":"Phase I\/II","graph3":"ImmuneOnco","amount2":2.0499999999999998,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ImmuneOnco \/ Instil Bio","highestDevelopmentStatusID":"14","companyTruncated":"ImmuneOnco \/ Instil Bio"},{"orgOrder":0,"company":"Sanofi","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Licensing Agreement","leadProduct":"AMX-818","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sanofi \/ Vir Biotechnology","highestDevelopmentStatusID":"14","companyTruncated":"Sanofi \/ Vir Biotechnology"},{"orgOrder":0,"company":"Healx","sponsor":"R42 Group","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Series C Financing","leadProduct":"HLX-1502","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Healx","amount2":0.050000000000000003,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Healx \/ R42 Group","highestDevelopmentStatusID":"14","companyTruncated":"Healx \/ R42 Group"},{"orgOrder":0,"company":"BridGene Biosciences","sponsor":"Galapagos","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BridGene Biosciences","amount2":0.16,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BridGene Biosciences \/ Galapagos","highestDevelopmentStatusID":"14","companyTruncated":"BridGene Biosciences \/ Galapagos"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","upfrontCash":"$8,700.0 million","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Acquisition","leadProduct":"Tavapadon","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cerevel Therapeutics","amount2":8.6999999999999993,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cerevel Therapeutics \/ Abbvie Inc","highestDevelopmentStatusID":"14","companyTruncated":"Cerevel Therapeutics \/ Abbvie Inc"},{"orgOrder":0,"company":"Jade Biosciences","sponsor":"Fairmount","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Jade Biosciences","amount2":0.080000000000000002,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Jade Biosciences \/ Fairmount","highestDevelopmentStatusID":"14","companyTruncated":"Jade Biosciences \/ Fairmount"},{"orgOrder":0,"company":"LimmaTech Biologics","sponsor":"Valneva","pharmaFlowCategory":"D","upfrontCash":"$10.8 million","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"August 2024","year":"2024","type":"Partnership","leadProduct":"S4V","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"LimmaTech Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"LimmaTech Biologics \/ Valneva","highestDevelopmentStatusID":"14","companyTruncated":"LimmaTech Biologics \/ Valneva"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Collaboration","leadProduct":"Vortioxetine Hydrobromide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"H. Lundbeck AS \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"14","companyTruncated":"H. Lundbeck AS \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"BioSyngen","sponsor":"A STAR","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioSyngen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioSyngen \/ A STAR","highestDevelopmentStatusID":"14","companyTruncated":"BioSyngen \/ A STAR"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"Apotex Inc","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Clobetasol Propionate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Formosa Pharmaceuticals \/ Apotex Inc","highestDevelopmentStatusID":"14","companyTruncated":"Formosa Pharmaceuticals \/ Apotex Inc"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"SWK Funding LLC","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Financing","leadProduct":"Hypochlorous Acid","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Relief Therapeutics","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Relief Therapeutics \/ SWK Funding LLC","highestDevelopmentStatusID":"14","companyTruncated":"Relief Therapeutics \/ SWK Funding LLC"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"California Institute for Regenerative Medicines","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Funding","leadProduct":"SENTI-202","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Senti Biosciences","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Senti Biosciences \/ California Institute for Regenerative Medicines","highestDevelopmentStatusID":"14","companyTruncated":"Senti Biosciences \/ California Institute for Regenerative Medicines"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Series C Financing","leadProduct":"MBX 2109","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"MBX Biosciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"MBX Biosciences \/ Deep Track Capital","highestDevelopmentStatusID":"14","companyTruncated":"MBX Biosciences \/ Deep Track Capital"},{"orgOrder":0,"company":"SK Pharmteco","sponsor":"Rznomics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"SK Pharmteco","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"SK Pharmteco \/ Rznomics","highestDevelopmentStatusID":"14","companyTruncated":"SK Pharmteco \/ Rznomics"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"CVC Capital Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Acquisition","leadProduct":"Methoxsalen","moa":"DNA synthesis Inhibitor","graph1":"Technology","graph2":"Phase I\/II","graph3":"Mallinckrodt Pharmaceuticals","amount2":0.93000000000000005,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Mallinckrodt Pharmaceuticals \/ CVC Capital Partners","highestDevelopmentStatusID":"14","companyTruncated":"Mallinckrodt Pharmaceuticals \/ CVC Capital Partners"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","upfrontCash":"$905.0 million","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Agreement","leadProduct":"Vorasidenib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Agios Pharmaceuticals","amount2":0.91000000000000003,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Agios Pharmaceuticals \/ Royalty Pharma","highestDevelopmentStatusID":"14","companyTruncated":"Agios Pharmaceuticals \/ Royalty Pharma"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"BVF Partners LP","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Private Placement","leadProduct":"Levosimendan","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Tenax Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Tenax Therapeutics \/ BVF Partners LP","highestDevelopmentStatusID":"14","companyTruncated":"Tenax Therapeutics \/ BVF Partners LP"},{"orgOrder":0,"company":"Seed Therapeutics","sponsor":"Eisai","pharmaFlowCategory":"D","upfrontCash":"$1,500.0 million","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","date":"August 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Seed Therapeutics","amount2":1.5,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Seed Therapeutics \/ Eisai","highestDevelopmentStatusID":"14","companyTruncated":"Seed Therapeutics \/ Eisai"},{"orgOrder":0,"company":"Release Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Release Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Release Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"14","companyTruncated":"Release Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"D","upfrontCash":"$50.0 million","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Licensing Agreement","leadProduct":"ST-501","moa":"Tau protein production Reducer","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sangamo Therapeutics","amount2":1.8999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sangamo Therapeutics \/ Genentech","highestDevelopmentStatusID":"14","companyTruncated":"Sangamo Therapeutics \/ Genentech"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","upfrontCash":"$170.0 million","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Agreement","leadProduct":"Atezolizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Merck & Co \/ Daiichi Sankyo","highestDevelopmentStatusID":"14","companyTruncated":"Merck & Co \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Eli Lilly","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Financing","leadProduct":"AX-158","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Artax Biopharma","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Artax Biopharma \/ Eli Lilly","highestDevelopmentStatusID":"14","companyTruncated":"Artax Biopharma \/ Eli Lilly"},{"orgOrder":0,"company":"NeuroTherapia","sponsor":"Cleveland Clinic","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Series B Financing","leadProduct":"NTRX-07","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"NeuroTherapia","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"NeuroTherapia \/ Cleveland Clinic","highestDevelopmentStatusID":"14","companyTruncated":"NeuroTherapia \/ Cleveland Clinic"},{"orgOrder":0,"company":"WuXi AppTec","sponsor":"Silo Pharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Peptide","date":"August 2024","year":"2024","type":"Partnership","leadProduct":"SPU-16","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"WuXi AppTec","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"WuXi AppTec \/ Silo Pharma","highestDevelopmentStatusID":"14","companyTruncated":"WuXi AppTec \/ Silo Pharma"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Pharmacosmos AS","pharmaFlowCategory":"D","upfrontCash":"$405.0 million","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Acquisition","leadProduct":"Trilaciclib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"G1 Therapeutics, Inc","amount2":0.40999999999999998,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"G1 Therapeutics, Inc \/ Pharmacosmos AS","highestDevelopmentStatusID":"14","companyTruncated":"G1 Therapeutics, Inc \/ Pharmacosmos AS"},{"orgOrder":0,"company":"IDRx","sponsor":"RA Capital Management","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Series B Financing","leadProduct":"IDRX-42","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"IDRx","amount2":0.12,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"IDRx \/ RA Capital Management","highestDevelopmentStatusID":"14","companyTruncated":"IDRx \/ RA Capital Management"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"NewBridge Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Agreement","leadProduct":"Burosumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kyowa Kirin \/ NewBridge Pharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"Kyowa Kirin \/ NewBridge Pharmaceuticals"},{"orgOrder":0,"company":"Precigen","sponsor":"Stifel","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"August 2024","year":"2024","type":"Public Offering","leadProduct":"PRGN-2012","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Precigen","amount2":0.029999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Precigen \/ Stifel","highestDevelopmentStatusID":"14","companyTruncated":"Precigen \/ Stifel"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Eli Lilly","pharmaFlowCategory":"D","upfrontCash":"$3,200.0 million","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"MORF-057","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Morphic Therapeutic","amount2":3.2000000000000002,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Morphic Therapeutic \/ Eli Lilly","highestDevelopmentStatusID":"14","companyTruncated":"Morphic Therapeutic \/ Eli Lilly"},{"orgOrder":0,"company":"Exscientia","sponsor":"Recursion Pharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Merger","leadProduct":"GTAEXS617","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Exscientia \/ Recursion Pharma","highestDevelopmentStatusID":"14","companyTruncated":"Exscientia \/ Recursion Pharma"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Public Offering","leadProduct":"Namodenoson","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Can-Fite BioPharma","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Can-Fite BioPharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"14","companyTruncated":"Can-Fite BioPharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Cantor","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Public Offering","leadProduct":"Arimoclomol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Zevra Therapeutics \/ Cantor","highestDevelopmentStatusID":"14","companyTruncated":"Zevra Therapeutics \/ Cantor"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Conduit Pharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Licensing Agreement","leadProduct":"AZD1656","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AstraZeneca \/ Conduit Pharma","highestDevelopmentStatusID":"14","companyTruncated":"AstraZeneca \/ Conduit Pharma"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Medigene","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Collaboration","leadProduct":"Gene-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"WuXi Biologics \/ Medigene","highestDevelopmentStatusID":"14","companyTruncated":"WuXi Biologics \/ Medigene"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"BARDA","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"August 2024","year":"2024","type":"Funding","leadProduct":"Live Nonreplicating Smallpox and Monkeypox Vaccine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bavarian Nordic","amount2":0.16,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bavarian Nordic \/ BARDA","highestDevelopmentStatusID":"14","companyTruncated":"Bavarian Nordic \/ BARDA"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Sixth Street","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Financing","leadProduct":"Plozasiran","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arrowhead Pharmaceuticals \/ Sixth Street","highestDevelopmentStatusID":"14","companyTruncated":"Arrowhead Pharmaceuticals \/ Sixth Street"},{"orgOrder":0,"company":"Humanetics","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Funding","leadProduct":"Genistein","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Humanetics \/ U.S. Department of Defense","highestDevelopmentStatusID":"14","companyTruncated":"Humanetics \/ U.S. Department of Defense"},{"orgOrder":0,"company":"NEC Corporation","sponsor":"AGC Biologics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"August 2024","year":"2024","type":"Collaboration","leadProduct":"NECVAX-NEO1","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"NEC Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"NEC Corporation \/ AGC Biologics","highestDevelopmentStatusID":"14","companyTruncated":"NEC Corporation \/ AGC Biologics"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","upfrontCash":"$50.0 million","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Collaboration","leadProduct":"BMS-986419","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Evotec","amount2":4,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"14","companyTruncated":"Evotec \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"BioNTech","sponsor":"Genmab","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Termination","leadProduct":"Acasunlimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioNTech \/ Genmab","highestDevelopmentStatusID":"14","companyTruncated":"BioNTech \/ Genmab"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Devart Middle East","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Agreement","leadProduct":"Lidocaine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Scilex Pharmaceuticals \/ Devart Middle East","highestDevelopmentStatusID":"14","companyTruncated":"Scilex Pharmaceuticals \/ Devart Middle East"},{"orgOrder":0,"company":"Curon Biopharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","upfrontCash":"$700.0 million","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Acquisition","leadProduct":"CN201","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Curon Biopharmaceutical","amount2":1.3,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Curon Biopharmaceutical \/ Merck & Co","highestDevelopmentStatusID":"14","companyTruncated":"Curon Biopharmaceutical \/ Merck & Co"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Partnership","leadProduct":"Lithium Salicylate Proline","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alzamend Neuro \/ Massachusetts General Hospital","highestDevelopmentStatusID":"14","companyTruncated":"Alzamend Neuro \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"Abbott Laboratories","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Collaboration","leadProduct":"Tecarfarin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cadrenal Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cadrenal Therapeutics \/ Abbott Laboratories","highestDevelopmentStatusID":"14","companyTruncated":"Cadrenal Therapeutics \/ Abbott Laboratories"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Leerink Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Public Offering","leadProduct":"Lysergide D-tartrate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Mind Medicine \/ Leerink Partners","highestDevelopmentStatusID":"14","companyTruncated":"Mind Medicine \/ Leerink Partners"},{"orgOrder":0,"company":"Development Center for Biotechnology","sponsor":"HoneyBear Biosciences","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Large molecule","date":"May 2023","year":"2023","type":"Licensing Agreement","leadProduct":"ADC-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Development Center for Biotechnology","amount2":0.02,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Development Center for Biotechnology \/ HoneyBear Biosciences","highestDevelopmentStatusID":"14","companyTruncated":"Development Center for Biotechnology \/ HoneyBear Biosciences"},{"orgOrder":0,"company":"NovaBay Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Omega-3","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"NovaBay Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"NovaBay Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"NovaBay Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"INI-2004","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Inimmune","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Inimmune \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Inimmune \/ Not Applicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Tradipitant","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Vanda Pharmaceuticals \/ Eli Lilly","highestDevelopmentStatusID":"14","companyTruncated":"Vanda Pharmaceuticals \/ Eli Lilly"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Large molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"RAG-17","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ractigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ractigen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Azeliragon","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cantex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Cantex Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sonnet BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Sonnet BioTherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"ALG-055009","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Aligos Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Decoy20","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Indaptus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Indaptus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"LAE001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Laekna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Laekna Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Large molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Lecanemab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Eisai \/ Not Applicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Avutometinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Verastem Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"ATRN-119","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aprea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Aprea Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Bevacizumab Gamma","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Outlook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Crofelemer","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Jaguar Health \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Jaguar Health \/ Not Applicable"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Sleep","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Mazindol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"NLS Pharmaceutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"NLS Pharmaceutics \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"TTX-MC138","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"TransCode Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Cytisine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Achieve Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"SPG302","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Spinogenix \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Spinogenix \/ Not Applicable"},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Bemdaneprocel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BlueRock Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BlueRock Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BlueRock Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"SPG302","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Spinogenix \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Spinogenix \/ Not Applicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Intra-Cellular Therapies \/ Not Applicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"TFF Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Ayrtons Saunders","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Nicotine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ayrtons Saunders","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ayrtons Saunders \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ayrtons Saunders \/ Not Applicable"},{"orgOrder":0,"company":"Xeno Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"XEN-101","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Xeno Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Xeno Biosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Xeno Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"GenVivo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"GVO-1102","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"GenVivo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"GenVivo \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"GenVivo \/ Not Applicable"},{"orgOrder":0,"company":"Bioxodes","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Ir-CPI","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bioxodes","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bioxodes \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Bioxodes \/ Not Applicable"},{"orgOrder":0,"company":"Resolution Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Cell and Gene therapy","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"RTX001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Resolution Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Resolution Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Resolution Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Syncromune","sponsor":"Williams Cancer Foundation","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"SV-102","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Syncromune","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Syncromune \/ Williams Cancer Foundation","highestDevelopmentStatusID":"14","companyTruncated":"Syncromune \/ Williams Cancer Foundation"},{"orgOrder":0,"company":"Humacyte","sponsor":"FGK Clinical Research","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Acellular Tissue Engineered Vessel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Humacyte \/ FGK Clinical Research","highestDevelopmentStatusID":"14","companyTruncated":"Humacyte \/ FGK Clinical Research"},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Graviton Bioscience","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"GV101","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ovid Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ovid Therapeutics \/ Graviton Bioscience","highestDevelopmentStatusID":"14","companyTruncated":"Ovid Therapeutics \/ Graviton Bioscience"},{"orgOrder":0,"company":"Signet","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"sigx1094","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Signet","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Signet \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Signet \/ Not Applicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"ARCT-810","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arcturus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Arcturus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"KaliVir Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"KaliVir Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"KaliVir Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"KaliVir Immunotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Circle Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Peptide","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"CID-078","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Circle Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Circle Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Circle Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Foundation Medicine \/ Janssen Biotech","highestDevelopmentStatusID":"14","companyTruncated":"Foundation Medicine \/ Janssen Biotech"},{"orgOrder":0,"company":"AviadoBio","sponsor":"The Ohio State University Wexner Medical Center","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"AAV-PGRN","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AviadoBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AviadoBio \/ The Ohio State University Wexner Medical Center","highestDevelopmentStatusID":"14","companyTruncated":"AviadoBio \/ The Ohio State University Wexner Medical Center"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"NeuraLight","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"NeuroSense Therapeutics \/ NeuraLight","highestDevelopmentStatusID":"14","companyTruncated":"NeuroSense Therapeutics \/ NeuraLight"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Donanemab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Integrative Research Laboratories","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Pirepemat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"IRLAB \/ Integrative Research Laboratories","highestDevelopmentStatusID":"14","companyTruncated":"IRLAB \/ Integrative Research Laboratories"},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"225Ac-FL-020","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Full-Life Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Full-Life Technologies \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Full-Life Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"TYRA-300","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Tyra Biosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Tyra Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"American Regent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Disodium Hydrogen Phosphate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"American Regent \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"American Regent \/ Not Applicable"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Heron Therapeutics \/ Mayo Clinic","highestDevelopmentStatusID":"14","companyTruncated":"Heron Therapeutics \/ Mayo Clinic"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Legend Biotech","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Legend Biotech","highestDevelopmentStatusID":"14","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Legend Biotech"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Dupilumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"14","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Gyre Therapeutics","sponsor":"Nanjing Healthnice Pharmaceutical Technology","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Avatrombopag Maleate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Gyre Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Gyre Therapeutics \/ Nanjing Healthnice Pharmaceutical Technology","highestDevelopmentStatusID":"14","companyTruncated":"Gyre Therapeutics \/ Nanjing Healthnice Pharmaceutical Technology"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Suffield Research Centre","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Bucillamine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Revive Therapeutics \/ Suffield Research Centre","highestDevelopmentStatusID":"14","companyTruncated":"Revive Therapeutics \/ Suffield Research Centre"},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Denosumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Alvotech \/ Not Applicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"INZ-701","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Inozyme Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Inozyme Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"TFS Trial Form Support","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Buntanetap","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Annovis Bio \/ TFS Trial Form Support","highestDevelopmentStatusID":"14","companyTruncated":"Annovis Bio \/ TFS Trial Form Support"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Naproxen","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ANI Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ANI Pharmaceuticals Inc \/ Not Applicable"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Descartes-08","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cartesian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Cartesian Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Descartes-08","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cartesian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Cartesian Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"ubenimex","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Delta-Fly Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Delta-Fly Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Delta-Fly Pharma \/ Not Applicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"MaaT033","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"MaaT Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Vanzacaftor","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Vertex Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Fresenius SE & Co. KGaA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Fresenius SE & Co. KGaA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Fresenius SE & Co. KGaA \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Fresenius SE & Co. KGaA \/ Not Applicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Medipal Holdings Corporation","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"JR-446","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"JCR Pharmaceuticals \/ Medipal Holdings Corporation","highestDevelopmentStatusID":"14","companyTruncated":"JCR Pharmaceuticals \/ Medipal Holdings Corporation"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"SAT-3247","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Satellos Bioscience \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Satellos Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"LG Chem","sponsor":"Yifan Pharmaceutical","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"LG Chem \/ Yifan Pharmaceutical","highestDevelopmentStatusID":"14","companyTruncated":"LG Chem \/ Yifan Pharmaceutical"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Gubra","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"BI 3034701","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Boehringer Ingelheim GmbH \/ Gubra","highestDevelopmentStatusID":"14","companyTruncated":"Boehringer Ingelheim GmbH \/ Gubra"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Tazemetostat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"OSE Immunotherapeutics SA","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"BI 770371","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Boehringer Ingelheim GmbH \/ OSE Immunotherapeutics SA","highestDevelopmentStatusID":"14","companyTruncated":"Boehringer Ingelheim GmbH \/ OSE Immunotherapeutics SA"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Montelukast Sodium","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"IntelGenx \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"IntelGenx \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Faricimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Ivosidenib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Alembic Pharmaceuticals Limited \/ Not Applicable"},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"225Ac-FL-020","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Full-Life Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Full-Life Technologies \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Full-Life Technologies \/ Not Applicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"AstraZeneca \/ Not Applicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Budesonide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Viatris \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Viatris \/ Not Applicable"},{"orgOrder":0,"company":"Zhejiang Doer Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"DR10624","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Zhejiang Doer Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Zhejiang Doer Biologics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Zhejiang Doer Biologics \/ Not Applicable"},{"orgOrder":0,"company":"GSK","sponsor":"Medicines for Malaria Venture","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Tafenoquine Succinate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"GSK \/ Medicines for Malaria Venture","highestDevelopmentStatusID":"14","companyTruncated":"GSK \/ Medicines for Malaria Venture"},{"orgOrder":0,"company":"Oxolife","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Sodium Tungstate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Oxolife","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Oxolife \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Oxolife \/ Not Applicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"STP122G","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Sirnaomics \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Selinexor","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Zhiyi Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"SK10","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Zhiyi Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Zhiyi Biotech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Zhiyi Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Beijing Biostar Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Beijing Biostar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Beijing Biostar Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Beijing Biostar Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"HilleVax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Vaccine","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"HIL-214","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"HilleVax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"HilleVax \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"HilleVax \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Bedaquiline","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Interius BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"INT2104","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Interius BioTherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Interius BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Interius BioTherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"KT-474","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kymera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Kymera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"RMC-6236","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Revolution Medicines \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Revolution Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"NXC-201","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Immix Biopharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Immix Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Sellas Life Sciences Group \/ Not Applicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Outlook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Merus","sponsor":"Merck & Co","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Merus \/ Merck & Co","highestDevelopmentStatusID":"14","companyTruncated":"Merus \/ Merck & Co"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"NewAmsterdam Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"NewAmsterdam Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Edding Pharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Edding Pharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Edding Pharm \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Edding Pharm \/ Not Applicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"FLT201","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Spur Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Spur Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Maralixibat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Mirum Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"ADI-270","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Adicet Bio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Adicet Bio \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Sleep","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"E2086","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Eisai \/ Not Applicable"},{"orgOrder":0,"company":"Woolsey Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Fasudil","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Woolsey Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Woolsey Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Woolsey Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Zegocractin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"CalciMedica \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"CalciMedica \/ Not Applicable"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Bempikibart","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Q32 Bio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Q32 Bio \/ Not Applicable"},{"orgOrder":0,"company":"Belhaven Biopharma","sponsor":"Lovelace Biomedical","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Belhaven Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Belhaven Biopharma \/ Lovelace Biomedical","highestDevelopmentStatusID":"14","companyTruncated":"Belhaven Biopharma \/ Lovelace Biomedical"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"IRX4204","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"IO Biotech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"IO Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Arcutis Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"CURIUM US LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Dotatate Lutenium Lu-177","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"CURIUM US LLC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"CURIUM US LLC \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"CURIUM US LLC \/ Not Applicable"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Zevra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Zevra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Abiprubart","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kiniksa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Kiniksa Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"PPD","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Prabotulinumtoxin A","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AEON Biopharma \/ PPD","highestDevelopmentStatusID":"14","companyTruncated":"AEON Biopharma \/ PPD"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Rivoceranib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Elevar Therapeutics \/ Jiangsu Hengrui Pharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"Elevar Therapeutics \/ Jiangsu Hengrui Pharmaceuticals"},{"orgOrder":0,"company":"Celon Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"CPL500036","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Celon Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Celon Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Celon Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Fosgonimeton","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Athira Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Athira Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"MNPR-101-Zr","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Monopar Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"GT-02287","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Gain Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Gain Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"AVTX-009","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Avalo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Avalo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Tafenoquine Succinate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"60 Degrees Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"60 Degrees Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Abata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"ABA-101","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Abata Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Abata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Abata Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Pint Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Berotralstat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Pint Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Pint Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Pint Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Fosaprepitant","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Amneal Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Xspray Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Nilotinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Xspray Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Xspray Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Xspray Pharma \/ Not Applicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"TGR-63","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"IGC Pharma \/ Not Applicable"},{"orgOrder":0,"company":"EnPlusOne Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Inclisiran","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"EnPlusOne Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"EnPlusOne Biosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"EnPlusOne Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Jaguar Gene Therapy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"JAG201","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Jaguar Gene Therapy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Jaguar Gene Therapy \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Jaguar Gene Therapy \/ Not Applicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"AMT-130","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Uniqure \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Uniqure \/ Not Applicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Lupin Ltd \/ Not Applicable"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"United Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"United Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Lecanemab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Eisai \/ Not Applicable"},{"orgOrder":0,"company":"AusperBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"AHB-137","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AusperBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AusperBio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"AusperBio \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Annamycin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Rgenta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"RGT-61159","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Rgenta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Rgenta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Rgenta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Pharmass\u00eatX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Green Tea Extract","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Pharmass\u00eatX","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Pharmass\u00eatX \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Pharmass\u00eatX \/ Not Applicable"},{"orgOrder":0,"company":"Skyhawk Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"SKY-0515","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Skyhawk Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Skyhawk Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Skyhawk Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Peptide","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Certepetide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Lisata Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tr1X Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"TRX103","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Tr1X Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Tr1X Bio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Tr1X Bio \/ Not Applicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Allogeneic Medicinal Signaling Cell Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Longeveron \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Longeveron \/ Not Applicable"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"OK-101","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"OKYO Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"OKYO Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Paxalisib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kazia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Kazia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"20-Hydroxyecdysone","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Biophytis \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Biophytis \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Insulin Icodec","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Rivoceranib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Elevar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Elevar Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Exenatide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Vivani Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Vivani Medical \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Vivani Medical \/ Not Applicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"SAT-3247","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Satellos Bioscience \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Satellos Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Danuglipron","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Eftilagimod Alfa","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Immutep \/ Not Applicable"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Peptide","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"OK-101","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"OKYO Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"OKYO Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Namodenoson","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Can-Fite BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Sirolimus","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Biodexa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Biodexa Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Lecanemab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioArctic AB \/ Eisai","highestDevelopmentStatusID":"14","companyTruncated":"BioArctic AB \/ Eisai"},{"orgOrder":0,"company":"Olatec Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Dapansutrile","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Olatec Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Olatec Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Olatec Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"YolTech Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"YOLT-201","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"YolTech Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"YolTech Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"YolTech Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"AP\u2010PA02","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Armata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Armata Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Akebia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"OK-101","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"OKYO Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"OKYO Pharma \/ Not Applicable"},{"orgOrder":0,"company":"AskBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"AB-1005","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AskBio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"AskBio \/ Not Applicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Selexipag","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Alembic Pharmaceuticals Limited \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Sacubitril Sodium","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Clascoterone","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cosmo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Cosmo Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Clascoterone","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cosmo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Cosmo Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Clascoterone","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Nipocalimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Namodenoson","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Can-Fite BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"INO-3107","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Cosibelimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Checkpoint Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Checkpoint Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Azafaros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Nizubaglustat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Azafaros","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Azafaros \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Azafaros \/ Not Applicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Argenx","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Zai Lab \/ argenx","highestDevelopmentStatusID":"14","companyTruncated":"Zai Lab \/ argenx"},{"orgOrder":0,"company":"Arrivo BioVentures","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"RABI-767","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arrivo BioVentures","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arrivo BioVentures \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Arrivo BioVentures \/ Not Applicable"},{"orgOrder":0,"company":"Diakonos Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Dendritic Cell Vaccine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Diakonos Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Diakonos Oncology \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Diakonos Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"R-Azasetron Besylate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Sensorion \/ Not Applicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Hydrocortisone","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Eton Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Sabin Vaccine Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"cAD3-Sudan Ebolavirus Vaccine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sabin Vaccine Institute","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sabin Vaccine Institute \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Sabin Vaccine Institute \/ Not Applicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"ART26.12","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Artelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Artelo Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Bexotegrast","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Pliant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Pliant Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ANI Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ANI Pharmaceuticals Inc \/ Not Applicable"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"LX2006","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lexeo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Lexeo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cytonics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"CYT-108","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cytonics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cytonics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Cytonics \/ Not Applicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"9MW2821","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Mabwell \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Mabwell \/ Not Applicable"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Enzomenib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sumitomo Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Sumitomo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Tiopronin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Endo Pharm \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Endo Pharm \/ Not Applicable"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"NanoAb-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Scinai Immunotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Camurus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Octreotide Acetate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Camurus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Camurus \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Camurus \/ Not Applicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"IRX4204","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"IO Biotech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"IO Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Sellas Life Sciences Group \/ Not Applicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Clearmind Medicine \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Clearmind Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Flag Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"FLAG-003","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Flag Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Flag Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Flag Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Tolimidone","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Biodexa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Biodexa Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Barzolvolimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Celldex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Celldex Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Algernon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Sotagliflozin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Lexicon pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Peptide","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Certepetide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Lisata Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NexThera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"NT-101","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"NexThera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"NexThera \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"NexThera \/ Not Applicable"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"ALTO-100","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alto Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Alto Neuroscience \/ Not Applicable"},{"orgOrder":0,"company":"Orexo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Orexo \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Orexo \/ Not Applicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"7MW3711","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Mabwell \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Mabwell \/ Not Applicable"},{"orgOrder":0,"company":"Evommune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"EVO756","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Evommune \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Evommune \/ Not Applicable"},{"orgOrder":0,"company":"BioSyngen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"BRG01","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioSyngen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioSyngen \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BioSyngen \/ Not Applicable"},{"orgOrder":0,"company":"DiscGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Rebonuputemcel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"DiscGenics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"DiscGenics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"DiscGenics \/ Not Applicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Topiramate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Glenmark Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"GTX-102","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ultragenyx Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ultragenyx Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"VLA15","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"14","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"IMP761","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Immutep \/ Not Applicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Allogeneic Medicinal Signaling Cell Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Longeveron \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Longeveron \/ Not Applicable"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"ATH434","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alterity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Alterity Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"4D-150","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"4D Molecular Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"4D Molecular Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Darolutamide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"CT-996","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Genentech \/ Not Applicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Vaccine","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Colecalciferol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Diamyd Medical AB \/ Not Applicable"},{"orgOrder":0,"company":"Renalys Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Sparsentan","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Renalys Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Renalys Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Renalys Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BioTheryX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"BTX-9341","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioTheryX","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioTheryX \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BioTheryX \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Rilpivirine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Tabelecleucel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Atara Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bionomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"BNC210","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bionomics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bionomics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Bionomics \/ Not Applicable"},{"orgOrder":0,"company":"Abliva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"KL1333","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Abliva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Abliva \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Abliva \/ Not Applicable"},{"orgOrder":0,"company":"Alkeus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Gildeuretinol Acetate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alkeus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alkeus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Alkeus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Vonoprazan Fumarate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Phathom Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Phathom Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"CDI-988","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Cocrystal Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Biora Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Varoglutamstat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Vivoryon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Vivoryon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Vivoryon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioSenic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Arsenic Trioxide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioSenic \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BioSenic \/ Not Applicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Vimseltinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Deciphera Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Fremanezumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Teva Pharmaceutical Industries \/ Not Applicable"},{"orgOrder":0,"company":"Shionogi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Zatolmilast","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Shionogi \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Shionogi \/ Not Applicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"KB-GDT-01","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kiromic BioPharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Kiromic BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Tenacia Biotechnology","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Ganaxolone","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Marinus Pharmaceuticals \/ Tenacia Biotechnology","highestDevelopmentStatusID":"14","companyTruncated":"Marinus Pharmaceuticals \/ Tenacia Biotechnology"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Balstilimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Tivozanib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aveo Oncology \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Aveo Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Omadacycline","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Paratek Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Paratek Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Efzofitimod","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"aTyr Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Eculizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Samsung Bioepis \/ Not Applicable"},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Alvotech","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"STADA Arzneimittel","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"STADA Arzneimittel \/ Alvotech","highestDevelopmentStatusID":"14","companyTruncated":"STADA Arzneimittel \/ Alvotech"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"ZW191","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Zymeworks \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Zymeworks \/ Not Applicable"},{"orgOrder":0,"company":"Certa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"FT011","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Certa Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Certa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Certa Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"ADX71149","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Addex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Addex Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"R-Azasetron Besylate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Sensorion \/ Not Applicable"},{"orgOrder":0,"company":"Avenacy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Palonosetron","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Avenacy \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Avenacy \/ Not Applicable"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Emapticap pegol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"TME Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"TME Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Mazdutide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Innovent Biologics \/ Eli lilly","highestDevelopmentStatusID":"14","companyTruncated":"Innovent Biologics \/ Eli lilly"},{"orgOrder":0,"company":"Cytoki Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"CK-0045","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cytoki Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cytoki Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Cytoki Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Esketamine Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Zentiva","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Raltegravir Potassium","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lupin Ltd \/ Zentiva","highestDevelopmentStatusID":"14","companyTruncated":"Lupin Ltd \/ Zentiva"},{"orgOrder":0,"company":"SIFI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Polyhexanide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"SIFI \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"SIFI \/ Not Applicable"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"NVL-330","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Nuvalent \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Nuvalent \/ Not Applicable"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"KB-0742","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kronos Bio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Kronos Bio \/ Not Applicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Valacyclovir","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Virios Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Ondansetron","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Adial Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Adial Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Arcutis Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioAtla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Ozuriftamab Vedotin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioAtla","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioAtla \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BioAtla \/ Not Applicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Enlivex Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"LB54640","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Rhythm Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"SPG601","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Spinogenix \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Spinogenix \/ Not Applicable"},{"orgOrder":0,"company":"Reunion Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"RE104","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Reunion Neuroscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Reunion Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Reunion Neuroscience \/ Not Applicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"ICP-332","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"InnoCare Pharma \/ Not Applicable"},{"orgOrder":0,"company":"AffyImmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"AIC100","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AffyImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AffyImmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"AffyImmune Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"SpyBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"SPYVLP01","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"SpyBiotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"SpyBiotech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"SpyBiotech \/ Not Applicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Clesrovimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Merck & Co \/ Not Applicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Valiltramiprosate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alzheon \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Alzheon \/ Not Applicable"},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"ETD001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Enterprise Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Enterprise Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Enterprise Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Rilpivirine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Brii Biosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Brii Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"ConSynance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"CSTI-500","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ConSynance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ConSynance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ConSynance Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Foralumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Tiziana Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Merus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Petosemtamab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Merus \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Merus \/ Not Applicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Nkarta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"OST31-154","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"OS Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"OS Therapies \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"OS Therapies \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Giroctocogene Fitelparovec","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Cellectis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"UCART22","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cellectis \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Cellectis \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Peptide","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"INZ-701","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Inozyme Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Inozyme Pharma \/ Not Applicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Furosemide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"scPharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Aquestive Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Cosibelimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Checkpoint Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Checkpoint Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"BCDA-02","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BioCardia \/ Not Applicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Nicox SA \/ Not Applicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Sandoz B2B \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Fidanacogene elaparvovec","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Maralixibat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Mirum Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"VRDN-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Viridian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Viridian Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Omalizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kashiv BioSciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Kashiv BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"EB-003","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Enveric Biosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Enveric Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"A.forall","sponsor":"Sagent Pharmaceuticals","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"A.forall","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"A.forall \/ Sagent Pharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"A.forall \/ Sagent Pharmaceuticals"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Deuruxolitinib phosphate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Not Applicable"},{"orgOrder":0,"company":"Menarini","sponsor":"NewAmsterdam Pharma","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Menarini \/ NewAmsterdam Pharma","highestDevelopmentStatusID":"14","companyTruncated":"Menarini \/ NewAmsterdam Pharma"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"PMN310","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ProMIS Neurosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ProMIS Neurosciences \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Amivantamab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Macitentan","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Johnson & Johnson \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Elafibranor","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Modified Vaccinia Ankara","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Bavarian Nordic \/ Not Applicable"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"CEL-SCI \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"CEL-SCI \/ Not Applicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Merck & Co \/ Pfizer Inc","highestDevelopmentStatusID":"14","companyTruncated":"Merck & Co \/ Pfizer Inc"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Risankizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"AbbVie Inc \/ Not Applicable"},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Budesonide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"STADA Arzneimittel","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"STADA Arzneimittel \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"STADA Arzneimittel \/ Not Applicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Sugemalimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"CStone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"CStone Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Lecanemab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioArctic AB \/ Eisai","highestDevelopmentStatusID":"14","companyTruncated":"BioArctic AB \/ Eisai"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Setanaxib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Calliditas Therapeutics AB \/ Not Applicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Paliperidone Palmitate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Luye Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Luye Pharma \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Faricimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Arctic Vision","sponsor":"Clearside Biomedical","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Triamcinolone Acetonide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arctic Vision","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arctic Vision \/ Clearside Biomedical","highestDevelopmentStatusID":"14","companyTruncated":"Arctic Vision \/ Clearside Biomedical"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Barzolvolimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Celldex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Celldex Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"PALI-2108","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"VTX958","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ventyx Biosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ventyx Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Alumis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"ESK-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alumis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alumis \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Alumis \/ Not Applicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Arcutis Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"CT1812","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cognition Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Cognition Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Sabirnetug","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Acumen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Acumen Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Tegoprubart","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eledon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Eledon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Attralus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"AT-02","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Attralus \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Attralus \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"RelabotulinumtoxinA","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Galantamine Benzoate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alpha Cognition \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Alpha Cognition \/ Not Applicable"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Azelaprag","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioAge Labs \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BioAge Labs \/ Not Applicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"AstraZeneca \/ Not Applicable"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"BBT-877","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bridge Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Bridge Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"NRx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"DWN12088","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Daewoong Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Daewoong Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Peptide","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Elamipretide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Stealth Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Stealth Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Revumenib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Syndax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Syndax Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"COM503","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Compugen \/ Gilead Sciences","highestDevelopmentStatusID":"14","companyTruncated":"Compugen \/ Gilead Sciences"},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Ivonescimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Akeso \/ Not Applicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"FibroGen \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"FibroGen \/ Not Applicable"},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"TX000045","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Tectonic Therapeutic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Tectonic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Tectonic Therapeutic \/ Not Applicable"},{"orgOrder":0,"company":"ADvantage Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ADvantage Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ADvantage Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ADvantage Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Marius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Marius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Georgiamune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"GIM-531","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Georgiamune","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Georgiamune \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Georgiamune \/ Not Applicable"},{"orgOrder":0,"company":"Yamo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Racemetirosine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Yamo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Yamo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Yamo Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"180 Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"180 Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Eniluracil","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Processa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Processa Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"NTLA-3001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Intellia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Intellia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Axitinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ocular Therapeutix \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ocular Therapeutix \/ Not Applicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"PGN-EDO51","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"PepGen \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"PepGen \/ Not Applicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Suzetrigine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Vertex Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"CIN-110","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"CinRx Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"CinRx Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"CinRx Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aspargo Laboratories \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Aspargo Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ZYUS Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ZYUS Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ZYUS Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Arachis Hypogaea Allergen Powder-dnfp","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Stallergenes Greer \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Stallergenes Greer \/ Not Applicable"},{"orgOrder":0,"company":"ZYMEDI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"BC-NKA-20008","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ZYMEDI","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ZYMEDI \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ZYMEDI \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Daratumumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Johnson & Johnson \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Lecanemab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eisai \/ BioArctic AB","highestDevelopmentStatusID":"14","companyTruncated":"Eisai \/ BioArctic AB"},{"orgOrder":0,"company":"Connext","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"CNT201","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Connext","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Connext \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Connext \/ Not Applicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Emtricitabine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Lupin Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Immuneering Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Sleep","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Avadel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Avadel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Evorpacept","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ALX Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Pepinemab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Vaccinex \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Vaccinex \/ Not Applicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"VCN-01","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Theriva Biologics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Theriva Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Cytisine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Achieve Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Omadacycline","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Paratek Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Paratek Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Ebselen","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sound Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sound Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Sound Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Mazdutide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Innovent Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Trastuzumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Prestige BioPharma Pte Ltd \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Prestige BioPharma Pte Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Tabelecleucel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Pierre Fabre \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Pierre Fabre \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Mesoblast \/ Not Applicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Immune Globulin, Human","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Grifols International \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Grifols International \/ Not Applicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Simufilam","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Cassava Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Imunon \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Imunon \/ Not Applicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Peptide","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Rhythm Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Cellectis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Alemtuzumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cellectis \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Cellectis \/ Not Applicable"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Rivoceranib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Elevar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Elevar Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Soquelitinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Corvus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Corvus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Ixoberogene Soroparvovec","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Adverum Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"SPG302","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Spinogenix \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Spinogenix \/ Not Applicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"PDS0101","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"PDS Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Mitapivat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Agios Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Afamitresgene Autoleucel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Adaptimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Adaptimmune Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Dostarlimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Elinzanetant","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"KB-GDT-01","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kiromic BioPharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Kiromic BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Ifinatamab Deruxtecan","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Daiichi Sankyo \/ Not Applicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"NeuroSense Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Annamycin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"RGX-202","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Regenxbio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Regenxbio \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Peptide","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Zevra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Zevra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Alectinib Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Chugai Pharmaceutical \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"14","companyTruncated":"Chugai Pharmaceutical \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Nelarabine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Alembic Pharmaceuticals Limited \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"ANX007","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Annexon Biosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Annexon Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Ersodetug","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Rezolute \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Rezolute \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Anacaulase-bcdb","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"OCU400","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ocugen \/ Not Applicable"},{"orgOrder":0,"company":"Concentric Analgesics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Vocacapsaicin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Concentric Analgesics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Concentric Analgesics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Concentric Analgesics \/ Not Applicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Sunobinop","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Imbrium Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Imbrium Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Imbrium Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Salubris Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"JK06","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Salubris Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Salubris Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Salubris Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Akeso \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Selinexor","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BioMarin Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Meta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"META-001-PH","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Meta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Meta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Meta Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Apamistamab-I-131","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Actinium pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Finerenone","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Sellas Life Sciences Group \/ Not Applicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"TFF Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Clene Nanomedicine \/ Not Applicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"CTX-009","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Compass Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Compass Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Itolizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Equillium \/ Not Applicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Silmitasertib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Senhwa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Senhwa Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"3S Bio Inc","pharmaFlowCategory":"D","upfrontCash":"$6.5 million","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"July 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cosmo Pharmaceuticals","amount2":0.059999999999999998,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cosmo Pharmaceuticals \/ 3S Bio Inc","highestDevelopmentStatusID":"14","companyTruncated":"Cosmo Pharmaceuticals \/ 3S Bio Inc"},{"orgOrder":0,"company":"Bloomage Biotechnology Corp., Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Ectoine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bloomage Biotechnology Corp., Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bloomage Biotechnology Corp., Ltd \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Bloomage Biotechnology Corp., Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Bloomage Biotechnology Corp., Ltd","sponsor":"Lumenis","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Sodium Hyaluronate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bloomage Biotechnology Corp., Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bloomage Biotechnology Corp., Ltd \/ Lumenis","highestDevelopmentStatusID":"14","companyTruncated":"Bloomage Biotechnology Corp., Ltd \/ Lumenis"},{"orgOrder":0,"company":"Bloomage Biotechnology Corp., Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Zinc Hyaluronate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bloomage Biotechnology Corp., Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bloomage Biotechnology Corp., Ltd \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Bloomage Biotechnology Corp., Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Bloomage Biotechnology Corp., Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bloomage Biotechnology Corp., Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bloomage Biotechnology Corp., Ltd \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Bloomage Biotechnology Corp., Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Testosterone Enanthate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ever Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ever Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ever Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Eribulin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ever Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ever Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ever Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ever Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ever Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ever Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Trabectedin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ever Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ever Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ever Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Bortezomib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ever Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ever Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ever Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ever Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ever Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ever Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Pemetrexed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ever Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ever Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ever Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabazitaxel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ever Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ever Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ever Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Nestl\u00e9 Health Science","pharmaFlowCategory":"D","upfrontCash":"$250.0 million","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Agreement","leadProduct":"Fecal Microbiota Spores, Live","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Seres Therapeutics","amount2":0.53000000000000003,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Seres Therapeutics \/ Nestl\u00e9 Health Science","highestDevelopmentStatusID":"14","companyTruncated":"Seres Therapeutics \/ Nestl\u00e9 Health Science"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Gilead","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Seladelpar Lysine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Johnson & Johnson","amount2":0.32000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ Gilead","highestDevelopmentStatusID":"14","companyTruncated":"Johnson & Johnson \/ Gilead"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Leerink Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Public Offering","leadProduct":"Delpacibart Etedesiran","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Avidity Biosciences","amount2":0.25,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Avidity Biosciences \/ Leerink Partners","highestDevelopmentStatusID":"14","companyTruncated":"Avidity Biosciences \/ Leerink Partners"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Eli Lilly","pharmaFlowCategory":"D","upfrontCash":"$3,200.0 million","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Acquisition","leadProduct":"MORF-057","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Morphic Therapeutic","amount2":3.2000000000000002,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Morphic Therapeutic \/ Eli Lilly","highestDevelopmentStatusID":"14","companyTruncated":"Morphic Therapeutic \/ Eli Lilly"},{"orgOrder":0,"company":"Multitude Therapeutics","sponsor":"Adcendo","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Licensing Agreement","leadProduct":"ADCE-T02","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Multitude Therapeutics","amount2":1,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Multitude Therapeutics \/ Adcendo","highestDevelopmentStatusID":"14","companyTruncated":"Multitude Therapeutics \/ Adcendo"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Public Offering","leadProduct":"KT-474","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kymera Therapeutics","amount2":0.23000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kymera Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"14","companyTruncated":"Kymera Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Leerink Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Public Offering","leadProduct":"Delpacibart Etedesiran","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Avidity Biosciences","amount2":0.34999999999999998,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Avidity Biosciences \/ Leerink Partners","highestDevelopmentStatusID":"14","companyTruncated":"Avidity Biosciences \/ Leerink Partners"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Public Offering","leadProduct":"KT-474","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kymera Therapeutics","amount2":0.26000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kymera Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"14","companyTruncated":"Kymera Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"GondolaBio","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Demerger","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"GondolaBio","amount2":0.29999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"GondolaBio \/ BridgeBio Pharma","highestDevelopmentStatusID":"14","companyTruncated":"GondolaBio \/ BridgeBio Pharma"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"CBC Group","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Divestment","leadProduct":"Levetiracetam","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"UCB Pharma S.A","amount2":0.68000000000000005,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"UCB Pharma S.A \/ CBC Group","highestDevelopmentStatusID":"14","companyTruncated":"UCB Pharma S.A \/ CBC Group"},{"orgOrder":0,"company":"Lindy Biosciences","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","upfrontCash":"$20.0 million","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Lindy Biosciences","amount2":0.94999999999999996,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lindy Biosciences \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"14","companyTruncated":"Lindy Biosciences \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Genovate","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Cilostazol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Genovate","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Genovate \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Genovate \/ Not Applicable"},{"orgOrder":0,"company":"Epsilogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"MOv18 IgE","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Epsilogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Epsilogen \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Epsilogen \/ Not Applicable"},{"orgOrder":0,"company":"Ionctura","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Roginolisib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ionctura \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ionctura \/ Not Applicable"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Virpax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Virpax Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"STP125G","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Sirnaomics \/ Not Applicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Fremanezumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Teva Pharmaceutical Industries \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Chiglitazar Sodium","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Podiatry","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Edetate Calcium Disodium","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kane Biotech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Kane Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Psyence Biomed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Psyence Biomed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Psyence Biomed \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Psyence Biomed \/ Not Applicable"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Peptide","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"IRL201104","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Revolo Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Revolo Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Halberd Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Undisclosed","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Tri-Ax","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Halberd Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Halberd Corporation \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Halberd Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Notable Labs","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Volasertib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Notable Labs","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Notable Labs \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"14","companyTruncated":"Notable Labs \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Tilray","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Tilray","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Tilray \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Tilray \/ Not Applicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Lusvertikimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"OSE Immunotherapeutics SA \/ Not Applicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Sanofi","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Duvakitug","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Teva Pharmaceutical Industries \/ Sanofi","highestDevelopmentStatusID":"14","companyTruncated":"Teva Pharmaceutical Industries \/ Sanofi"},{"orgOrder":0,"company":"Eclipse Bioinnovations","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"RNA-based Vaccine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eclipse Bioinnovations","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eclipse Bioinnovations \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Eclipse Bioinnovations \/ Not Applicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"BIIB124","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"14","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Istaroxime","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Windtree Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Windtree Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ChemomAb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"CM-101","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ChemomAb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ChemomAb \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ChemomAb \/ Not Applicable"},{"orgOrder":0,"company":"AC Immune","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Vaccine","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"JNJ-2056","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AC Immune \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"14","companyTruncated":"AC Immune \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"OCU410","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ocugen \/ Not Applicable"},{"orgOrder":0,"company":"Kaerus Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"KER-0193","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kaerus Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kaerus Bioscience \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Kaerus Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Delgocitinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Leo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Cadisegliatin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"vTv Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"INO-3107","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Italfarmaco S.p.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Givinostat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Italfarmaco S.p.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Italfarmaco S.p.A \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Italfarmaco S.p.A \/ Not Applicable"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"RAG-18","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ractigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ractigen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bio-Thera Solutions \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Bio-Thera Solutions \/ Not Applicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"IASO-782","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"IASO Bio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"IASO Bio \/ Not Applicable"},{"orgOrder":0,"company":"Ariceum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"123I-ATT001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ariceum Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ariceum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ariceum Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"OCU410","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ocugen \/ Not Applicable"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Liposomal Tacrolimus","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lipella Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Lipella Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Spesolimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Boehringer Ingelheim GmbH \/ Not Applicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Potassium Phosphate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Amneal Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Avutometinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Verastem Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Novaliq","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Novaliq","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Novaliq \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Novaliq \/ Not Applicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BerGenBio ASA \/ Not Applicable"},{"orgOrder":0,"company":"Acticor Biotech SAS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Glenzocimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Acticor Biotech SAS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Acticor Biotech SAS \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Acticor Biotech SAS \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Trastuzumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"GigaGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"GIGA-2339","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"GigaGen \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"GigaGen \/ Not Applicable"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"UB-VV111","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Umoja Biopharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Umoja Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Human Acellular Vessel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Humacyte \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Humacyte \/ Not Applicable"},{"orgOrder":0,"company":"Citryll","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"CIT-013","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Citryll","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Citryll \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Citryll \/ Not Applicable"},{"orgOrder":0,"company":"Kexing Biopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kexing Biopharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kexing Biopharm \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Kexing Biopharm \/ Not Applicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"BNT111","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioNTech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BioNTech \/ Not Applicable"},{"orgOrder":0,"company":"Neurim Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Sleep","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Melatonin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Neurim Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Neurim Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Neurim Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Sanegene Bio","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"IBI3016","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Innovent Biologics \/ Sanegene Bio","highestDevelopmentStatusID":"14","companyTruncated":"Innovent Biologics \/ Sanegene Bio"},{"orgOrder":0,"company":"Ribomic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Umedaptanib Pegol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ribomic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ribomic \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ribomic \/ Not Applicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"George Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Telmisartan","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"George Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"George Medicines \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"George Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Entos Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Covigenix VAX-002","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Entos Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Entos Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Entos Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Servier","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Vorasidenib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Servier \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Servier \/ Not Applicable"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"EO-3021","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Elevation Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Elevation Oncology \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Elevation Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Apadamtase Alfa","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Takeda Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Angiex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"AGX101","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Angiex","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Angiex \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Angiex \/ Not Applicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Axitinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ocular Therapeutix \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ocular Therapeutix \/ Not Applicable"},{"orgOrder":0,"company":"Purdue Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Nalmefene Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Purdue Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Purdue Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Purdue Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Carbidopa","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Amneal Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Invenra","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Invenra","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Invenra \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Invenra \/ Not Applicable"},{"orgOrder":0,"company":"Purdue Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Nalmefene Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Purdue Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Purdue Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Purdue Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"PALI-2108","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Peptide","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"14","companyTruncated":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Epetraborole","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AN2 Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AN2 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"AN2 Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Reproxalap","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Aldeyra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"SAT-3247","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Satellos Bioscience \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Satellos Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Valbenazine Tosylate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ARS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ARS Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"KB-GDT-01","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kiromic BioPharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Kiromic BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ARS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ARS Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"AOC 1044","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Avidity Biosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Avidity Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"CAN10","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cantargia AB \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Cantargia AB \/ Not Applicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Palopegteriparatide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ascendis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Conduit Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"AZD1656","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Conduit Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Conduit Pharma \/ AstraZeneca","highestDevelopmentStatusID":"14","companyTruncated":"Conduit Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Furosemide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"scPharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Liposomal Tacrolimus","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lipella Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Lipella Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Aflibercept","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Sandoz B2B \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Tafenoquine Succinate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"60 Degrees Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"60 Degrees Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"WVE-N531","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Wave Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Wave Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Leronlimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"CytoDyn \/ Not Applicable"},{"orgOrder":0,"company":"Avalyn Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Nintedanib Esylate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Avalyn Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Avalyn Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Avalyn Pharma \/ Not Applicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"MBX 2109","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"MBX Biosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"MBX Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Eclipse Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eclipse Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eclipse Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Eclipse Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Tamibarotene","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Syros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Syros Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Lisaftoclax","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ascentage Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BioSyngen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"BRG01","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioSyngen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioSyngen \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BioSyngen \/ Not Applicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"9MW2821","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Mabwell \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Mabwell \/ Not Applicable"},{"orgOrder":0,"company":"Visen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Palopegteriparatide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Visen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Visen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Visen Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Actinogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Xanamem","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Actinogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Actinogen \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Actinogen \/ Not Applicable"},{"orgOrder":0,"company":"Noema Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Basimglurant","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Noema Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Noema Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Noema Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Vebreltinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Apollomics Inc \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Apollomics Inc \/ Not Applicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ATAI Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ATAI Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"PanTher Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"PanTher Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"PanTher Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"PanTher Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"LNK01004","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lynk Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Lynk Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Rivus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"HU6","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Rivus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Rivus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Rivus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"ARO-INHBE","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Arrowhead Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Amezalpat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Tempest Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Tempest Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"AMT-191","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Uniqure \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Uniqure \/ Not Applicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"TTX-MC138","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"TransCode Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"CV6 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"5-Fluorouracil","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"CV6 Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"CV6 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"CV6 Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Ropidoxuridine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Shuttle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Shuttle Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Turnstone Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"TIDAL-01","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Turnstone Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Turnstone Biologics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Turnstone Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Pepinemab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Vaccinex \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Vaccinex \/ Not Applicable"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"RenovoRx \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"RenovoRx \/ Not Applicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"IMP761","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Immutep \/ Not Applicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"MNPR-101-Zr","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Monopar Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Peptide","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Ruxotemitide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Verrica Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Verrica Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"ATSN-201","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Atsena Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Atsena Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Atsena Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Nanatinostat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Viracta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Viracta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"DermBiont","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"SM-020","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"DermBiont","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"DermBiont \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"DermBiont \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Syndax Pharmaceuticals","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Axatilimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Incyte Corporation \/ Syndax Pharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"Incyte Corporation \/ Syndax Pharmaceuticals"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"KB-GDT-01","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kiromic BioPharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Kiromic BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Mitomycin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"UroGen Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Genprex \/ Not Applicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Ivonescimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Akeso \/ Not Applicable"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Midomafetamine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lykos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Lykos Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Modified Vaccinia Ankara","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Bavarian Nordic \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Anacaulase-bcdb","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"AstraZeneca \/ Not Applicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Vimseltinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Deciphera Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aptar Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aptar Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aptar Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Aptar Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Tafasitamab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"PT217","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Phanes Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Phanes Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Epcoritamab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"14","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"ImmuneSensor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"IMSB301","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ImmuneSensor Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ImmuneSensor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ImmuneSensor Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sairiyo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Cepharanthine Dihydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sairiyo Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sairiyo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Sairiyo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"MRT-6160","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Monte Rosa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Monte Rosa Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"APG990","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Apogee Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Apogee Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"SAT-3247","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Satellos Bioscience \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Satellos Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"MOMA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"MOMA-313","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"MOMA Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"MOMA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"MOMA Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Trastuzumab Deruxtecan","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"14","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Trastuzumab Deruxtecan","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"14","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Enfortumab Vedotin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Astellas Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"14","companyTruncated":"Astellas Pharma \/ Pfizer Inc"},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"KVA12123","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Kineta \/ Not Applicable"},{"orgOrder":0,"company":"GlycoNex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Denosumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"GlycoNex","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"GlycoNex \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"GlycoNex \/ Not Applicable"},{"orgOrder":0,"company":"Latigo Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"LTG-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Latigo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Latigo Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Latigo Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"NV-387","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"NanoViricides \/ Not Applicable"},{"orgOrder":0,"company":"Azitra","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"ATR-12","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Azitra","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Azitra \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Azitra \/ Not Applicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"AstraZeneca \/ Not Applicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"ONP-002","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Oragenics \/ Not Applicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Sotagliflozin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Lexicon pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"BioStem Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Podiatry","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Amniotic Tissue Allograft","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioStem Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioStem Technologies \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BioStem Technologies \/ Not Applicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"BCDA-02","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BioCardia \/ Not Applicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Cebranopadol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Tris Pharma Inc \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Tris Pharma Inc \/ Not Applicable"},{"orgOrder":0,"company":"D&D Pharmatech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Peptide","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"DD01","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"D&D Pharmatech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"D&D Pharmatech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"D&D Pharmatech \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Amoxicillin Trihydrate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"RedHill Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"BNT162b2","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"14","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Luveltamab Tazevibulin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sutro Biopharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Sutro Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Nimacimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Skye Bioscience \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Skye Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Abata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"ABA-101","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Abata Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Abata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Abata Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"iOmx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"OMX-0407","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"iOmx Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"iOmx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"iOmx Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Azitra","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"ATR-04","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Azitra","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Azitra \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Azitra \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"BAY3283142","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"YolTech Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"YOLT-203","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"YolTech Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"YolTech Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"YolTech Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Sleep","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"ALKS 2680","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Alkermes Plc \/ Not Applicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Bremelanotide Acetate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Palatin Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"RAG-18","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ractigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ractigen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"64Cu-SAR-bisPSMA","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Clarity Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Jazz Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Renexxion","sponsor":"Dr. Falk Pharma","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Naronapride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Renexxion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Renexxion \/ Dr. Falk Pharma","highestDevelopmentStatusID":"14","companyTruncated":"Renexxion \/ Dr. Falk Pharma"},{"orgOrder":0,"company":"SciSparc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"SciSparc \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"SciSparc \/ Not Applicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Leronlimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"CytoDyn \/ Not Applicable"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Erdafitinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Janssen-Cilag \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Janssen-Cilag \/ Not Applicable"},{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Lenvatinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AiViva Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AiViva Biopharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"AiViva Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"GLPG5101","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Galapagos \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Galapagos \/ Not Applicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"9MW2821","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Mabwell \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Mabwell \/ Not Applicable"},{"orgOrder":0,"company":"CanariaBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"CanariaBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"CanariaBio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"CanariaBio \/ Not Applicable"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Fulzerasib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"GenFleet Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"GenFleet Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Lupin Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"SIFI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Polyhexanide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"SIFI \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"SIFI \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Crovalimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ARS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ARS Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"LB-100","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lixte Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Lixte Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Peptide","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Rhythm Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"OCU400","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ocugen \/ Not Applicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Regeneron Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Sotatercept","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Merck & Co \/ Not Applicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"BGB-16673","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BeiGene \/ Not Applicable"},{"orgOrder":0,"company":"Opna Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Opna Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Opna Bio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Opna Bio \/ Not Applicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"9MW2821","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Mabwell \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Mabwell \/ Not Applicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Ketamine Analog","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Mira Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Mira Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"177Lu-SN201","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Spago Nanomedical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Spago Nanomedical \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Spago Nanomedical \/ Not Applicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Betamethasone Valerate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Alembic Pharmaceuticals Limited \/ Not Applicable"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Axitinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Clearside Biomedical \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Clearside Biomedical \/ Not Applicable"},{"orgOrder":0,"company":"Invivyd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Pemivibart","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Invivyd \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Invivyd \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Amivantamab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Johnson & Johnson \/ Not Applicable"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"INNA-051","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ENA Respiratory","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ENA Respiratory \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ENA Respiratory \/ Not Applicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Modified Vaccinia Ankara-Bavarian Nordic","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Bavarian Nordic \/ Not Applicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Bomedemstat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Merck & Co \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Fezolinetant","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"JW Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Relmacabtagene Autoleucel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"JW Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"JW Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"JW Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Find Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"FTX-101","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Find Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Find Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Find Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"GenScript Biotech Corporation","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Legend Biotech \/ GenScript Biotech Corporation","highestDevelopmentStatusID":"14","companyTruncated":"Legend Biotech \/ GenScript Biotech Corporation"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Yunovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"ID110521156","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Yunovia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Yunovia \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Yunovia \/ Not Applicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Brimonidine Tartrate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Lupin Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Cilastatin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Arch Biopartners \/ Not Applicable"},{"orgOrder":0,"company":"Octapharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Fibrinogen","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Octapharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Octapharma \/ Not Applicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Isavuconazonium Sulfate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Basilea Pharmaceutica \/ Not Applicable"},{"orgOrder":0,"company":"Jeune Aesthetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"KB301","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Jeune Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Jeune Aesthetics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Jeune Aesthetics \/ Not Applicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"AAV5-hRORA","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ocugen \/ Not Applicable"},{"orgOrder":0,"company":"Azitra","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"ATR-12","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Azitra","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Azitra \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Azitra \/ Not Applicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"PL9643","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Palatin Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Hyundai Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Niclosamide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Hyundai Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Hyundai Bioscience \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Hyundai Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Alectinib Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Chugai Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Mepolizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Smallpox and Mpox Vaccine, Live","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Emergent BioSolutions \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Emergent BioSolutions \/ Not Applicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rheumatology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Colchicine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Scilex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Scilex Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"GT-02287","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Gain Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Gain Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Cladribine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Merck & Co \/ Not Applicable"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"OST31-164","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"OS Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"OS Therapies \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"OS Therapies \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"BAY2927088","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Nipocalimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Johnson & Johnson \/ Not Applicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"IO102","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"IO Biotech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"IO Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Mavacamten","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"VLA15","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"14","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Plozasiran","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Arrowhead Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Alintegimod","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"7 Hills Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"7 Hills Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Tividenofusp Alfa","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Denali Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Denali Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Bezuclastinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cogent Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cogent Biosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Cogent Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Sotagliflozin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Lexicon pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Descartes-15","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cartesian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Cartesian Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"JR-441","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"JCR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"JCR Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Merck & Co \/ Not Applicable"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"CBL-514","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Caliway Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Caliway Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Hanmi Pharmaceutical","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"alpha-galactosidase A","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"GC Biopharma \/ Hanmi Pharmaceutical","highestDevelopmentStatusID":"14","companyTruncated":"GC Biopharma \/ Hanmi Pharmaceutical"},{"orgOrder":0,"company":"Beijing Biostar Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Utidelone","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Beijing Biostar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Beijing Biostar Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Beijing Biostar Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Evommune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"EVO756","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Evommune \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Evommune \/ Not Applicable"},{"orgOrder":0,"company":"Remedy Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Glibenclamide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Remedy Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Remedy Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Remedy Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Nimodipine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Azurity Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Azurity Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Azurity Pharma \/ Not Applicable"},{"orgOrder":0,"company":"ProKidney","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Rilparencel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ProKidney","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ProKidney \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ProKidney \/ Not Applicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Bucillamine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Revive Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Istaroxime","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Windtree Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Windtree Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Allyx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"BMS-984923","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Allyx Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Allyx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Allyx Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Sanofi","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Evorpacept","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ALX Oncology \/ Sanofi","highestDevelopmentStatusID":"14","companyTruncated":"ALX Oncology \/ Sanofi"},{"orgOrder":0,"company":"OncoC4","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"ONC-841","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"OncoC4","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"OncoC4 \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"OncoC4 \/ Not Applicable"},{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"JNT-517","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Jnana Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Jnana Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Jnana Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Invivyd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"VYD2311","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Invivyd \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Invivyd \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Elinzanetant","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"MK-3000","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Merck & Co \/ Not Applicable"},{"orgOrder":0,"company":"Vesper Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"VES001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Vesper Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Vesper Bio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Vesper Bio \/ Not Applicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Vidofludimus calcium anhydrous","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Immunic Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ocuphire Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Immuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"IMM-529","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Immuron \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Immuron \/ Not Applicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"BI 771716","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Boehringer Ingelheim GmbH \/ Not Applicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Ivarmacitinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Arcutis Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Peptide","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Certepetide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Lisata Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Medigene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"MDG1015","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Medigene \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Medigene \/ Not Applicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Shilpa Medicare","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Bortezomib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Amneal Pharmaceuticals \/ Shilpa Medicare","highestDevelopmentStatusID":"14","companyTruncated":"Amneal Pharmaceuticals \/ Shilpa Medicare"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"MedinCell","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Olanzapine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Teva Pharmaceutical Industries \/ Medincell","highestDevelopmentStatusID":"14","companyTruncated":"Teva Pharmaceutical Industries \/ Medincell"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Aprepitant","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Hoth Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Aprepitant","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Hoth Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Olutasidenib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Rigel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Rigel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Insulin Efsitora Alfa","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Vivet Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"VTX-806","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Vivet Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Vivet Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Vivet Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Edaravone","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"VTX3232","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ventyx Biosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ventyx Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Sparsentan","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Travere Therapeutics \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"Travere Therapeutics \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"OmnImmune","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"TC BioPharm \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"TC BioPharm \/ Not Applicable"},{"orgOrder":0,"company":"Cytonics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"CYT-108","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cytonics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cytonics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Cytonics \/ Not Applicable"},{"orgOrder":0,"company":"Immunovant","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Batoclimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Immunovant \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Immunovant \/ Not Applicable"},{"orgOrder":0,"company":"PolTREG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"PTG-007","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"PolTREG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"PolTREG \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"PolTREG \/ Not Applicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Datopotamab Deruxtecan","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"AstraZeneca \/ Not Applicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Ivonescimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Akeso \/ Not Applicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Bexicaserin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Longboard Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Merck & Co","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Ifinatamab Deruxtecan","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ Merck & Co","highestDevelopmentStatusID":"14","companyTruncated":"Daiichi Sankyo \/ Merck & Co"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Vaccine","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Colecalciferol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Diamyd Medical AB \/ Not Applicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"OSE2101","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"OSE Immunotherapeutics SA \/ Not Applicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ARS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ARS Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Zongertinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Boehringer Ingelheim GmbH \/ Not Applicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Dapiglutide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Zealand Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"TARA-002","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Protara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Protara Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"EVX-01","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Evaxion Biotech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Evaxion Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Iadademstat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Oryzon Genomics \/ Not Applicable"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Brilaroxazine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Reviva Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Reviva Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Replimune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Replimune","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Replimune \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Replimune \/ Not Applicable"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"CX-801","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"CytomX Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"CytomX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"CytomX Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Actuate Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Elraglusib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Actuate Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Actuate Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Actuate Therapeutics, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"CK-586","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Cytokinetics \/ Not Applicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Ersodetug","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Rezolute \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Rezolute \/ Not Applicable"},{"orgOrder":0,"company":"Psyence","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Psyence \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Psyence \/ Not Applicable"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"TERN-601","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Terns Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Terns Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aurora Cannabis","sponsor":"Vectura Fertin Pharma","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aurora Cannabis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aurora Cannabis \/ Vectura Fertin Pharma","highestDevelopmentStatusID":"14","companyTruncated":"Aurora Cannabis \/ Vectura Fertin Pharma"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Descartes-08","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cartesian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Cartesian Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Akero Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"EVX-B2","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Evaxion Biotech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Evaxion Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"RLY-2608","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Relay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Relay Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Triptorelin Pamoate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Debiopharm \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Debiopharm \/ Not Applicable"},{"orgOrder":0,"company":"4M Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"4MT2001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"4M Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"4M Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"4M Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Xencor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Xencor \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Xencor \/ Not Applicable"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Oxaliplatin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Phanes Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Phanes Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Peptide","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Elamipretide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Stealth Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Stealth Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aisa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Cilnidipine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aisa Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aisa Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Aisa Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"WP1066","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"GRIN Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Radiprodil","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"GRIN Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"GRIN Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"GRIN Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sisram Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"DaxibotulinumtoxinA-lanm","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sisram Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sisram Medical \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Sisram Medical \/ Not Applicable"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"NVL-655","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Nuvalent \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Nuvalent \/ Not Applicable"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Immune Globulin Intravenous, Human","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"GC Biopharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"GC Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Depemokimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Dupilumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Sanofi \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"BBP-812","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"BBP-631","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Soquelitinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Corvus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Corvus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Tinlarebant","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Belite Bio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Belite Bio \/ Not Applicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Briquilimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Jasper Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Jasper Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"HA Antigen-based Vaccine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"TFF Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"SPC-15","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Silo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Silo Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Silo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Immunis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"IMM01-STEM","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Immunis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Immunis \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Immunis \/ Not Applicable"},{"orgOrder":0,"company":"Rion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Musculoskeletal","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Purified Exosome Product","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Rion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Rion \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Rion \/ Not Applicable"},{"orgOrder":0,"company":"Basking Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"BB-031","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Basking Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Basking Biosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Basking Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Elinzanetant","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Apitegromab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Scholar Rock \/ Not Applicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Plozasiran","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Arrowhead Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Radgocitabine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Delta-Fly Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Delta-Fly Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Delta-Fly Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"VRDN-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Viridian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Viridian Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Incendia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"IgG1 Monoclonal Antibody","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Incendia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Incendia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Incendia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"MAIA Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"5-fluorouracil","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cantargia AB \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Cantargia AB \/ Not Applicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Palopegteriparatide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ascendis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Tebapivat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Agios Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Sosei Group Corporation","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Sleep","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"ORX750","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Centessa Pharmaceuticals \/ Nxera Pharma","highestDevelopmentStatusID":"14","companyTruncated":"Centessa Pharmaceuticals \/ Nxera Pharma"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nephrology","country":"","productType":"Peptide","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"LSALT Peptide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Arch Biopartners \/ Not Applicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Dupilumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"14","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Human Papillomavirus 9-Valent Vaccine, Recombinant","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Merck & Co \/ Not Applicable"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eupraxia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Eupraxia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Kadmon Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Belumosudil","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kadmon Holdings","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kadmon Holdings \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Kadmon Holdings \/ Not Applicable"},{"orgOrder":0,"company":"Kadmon Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Belumosudil","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kadmon Holdings","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kadmon Holdings \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Kadmon Holdings \/ Not Applicable"},{"orgOrder":0,"company":"BioNova Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Belumosudil","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioNova Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioNova Pharma \/ Sanofi","highestDevelopmentStatusID":"14","companyTruncated":"BioNova Pharma \/ Sanofi"},{"orgOrder":0,"company":"BioNova Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Belumosudil","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioNova Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioNova Pharma \/ Sanofi","highestDevelopmentStatusID":"14","companyTruncated":"BioNova Pharma \/ Sanofi"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Belumosudil","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Meiji Seika Pharma \/ Sanofi","highestDevelopmentStatusID":"14","companyTruncated":"Meiji Seika Pharma \/ Sanofi"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Belumosudil","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Meiji Seika Pharma \/ Sanofi","highestDevelopmentStatusID":"14","companyTruncated":"Meiji Seika Pharma \/ Sanofi"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Belumosudil","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Meiji Seika Pharma \/ Sanofi","highestDevelopmentStatusID":"14","companyTruncated":"Meiji Seika Pharma \/ Sanofi"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Belumosudil","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Meiji Seika Pharma \/ Sanofi","highestDevelopmentStatusID":"14","companyTruncated":"Meiji Seika Pharma \/ Sanofi"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Immuneering Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Aquestive Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Dexmethylphenidate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cingulate Therapeutics, LLC \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Cingulate Therapeutics, LLC \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Nipocalimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Johnson & Johnson \/ Not Applicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Troculeucel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"NKGen Biotech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"NKGen Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Atacicept","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Vera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Vera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"MNPR-101-Zr","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Monopar Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"VYN202","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"VYNE Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"SER-155","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Seres Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Belzupacap Sarotalocan","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aura Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aura Biosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Aura Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"OmRx Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"OX-4224","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"OmRx Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"OmRx Oncology \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"OmRx Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Terbinafine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Moberg Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Moberg Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Silmitasertib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Senhwa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Senhwa Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Luvadaxistat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Neurocrine Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Stapokibart","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Connoya Biomedical Technology \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Connoya Biomedical Technology \/ Not Applicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"OmnImmune","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"TC BioPharm \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"TC BioPharm \/ Not Applicable"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"BMB-101","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bright Minds Biosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Bright Minds Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Biolexis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"BLX-7006","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Biolexis Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Biolexis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Biolexis Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Amivantamab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Johnson & Johnson \/ Not Applicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Brenetafusp","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Immunocore \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Immunocore \/ Not Applicable"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"GSK","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Belrestotug","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Iteos Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Iteos Therapeutics \/ GSK","highestDevelopmentStatusID":"14","companyTruncated":"Iteos Therapeutics \/ GSK"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Dupilumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Regeneron Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"PRT3789","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Prelude Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Prelude Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Prelude Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Masofaniten","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Essa Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Essa Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Lebrikizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Ocrelizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"CSL","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Self-amplifying mRNA Vaccine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arcturus Therapeutics \/ CSL","highestDevelopmentStatusID":"14","companyTruncated":"Arcturus Therapeutics \/ CSL"},{"orgOrder":0,"company":"AAVantgarde Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"AAVB-081","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AAVantgarde Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AAVantgarde Bio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"AAVantgarde Bio \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"ProfoundBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Rinatabart Sesutecan","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ProfoundBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ProfoundBio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ProfoundBio \/ Not Applicable"},{"orgOrder":0,"company":"23andMe","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"23ME-01473","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"23andMe \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"23andMe \/ Not Applicable"},{"orgOrder":0,"company":"23andMe","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"23ME-00610","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"23andMe \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"23andMe \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"AstraZeneca \/ Not Applicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Pyrrolobenzodiazepine ADC","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Daiichi Sankyo \/ Not Applicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Merck & Co \/ Not Applicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"14","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"GSK","sponsor":"CureVac","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"GSK4382276A","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"GSK \/ CureVac","highestDevelopmentStatusID":"14","companyTruncated":"GSK \/ CureVac"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Ketamine Analog","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Mira Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Mira Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Clindamycin Phosphate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bausch Health \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Bausch Health \/ Not Applicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"AstraZeneca \/ Not Applicable"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Ropidoxuridine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Shuttle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Shuttle Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Clene Nanomedicine \/ Not Applicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Eftilagimod Alfa","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Immutep \/ Not Applicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"CLN-978","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cullinan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Cullinan Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Namodenoson","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Can-Fite BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"Eisbach Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"EIS-12656","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eisbach Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eisbach Bio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Eisbach Bio \/ Not Applicable"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Azenosertib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Zentalis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Zentalis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"EVX-01","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Evaxion Biotech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Evaxion Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Nerandomilast","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Boehringer Ingelheim GmbH \/ Not Applicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"COYA 302","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Coya Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Coya Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"ABX-002","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Autobahn Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Autobahn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Autobahn Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"AstraZeneca \/ Not Applicable"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Tretinoin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"HighField Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"HighField Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Everolimus","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Upsher-Smith Laboratories \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Upsher-Smith Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"Imugene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Azercabtagene Zapreleucel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Imugene \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Imugene \/ Not Applicable"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Tegoprubart","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eledon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Eledon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"ONCT-534","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Oncternal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Oncternal Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kine Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Peptide","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"KINE-101","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kine Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kine Sciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Kine Sciences \/ Not Applicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"IO102","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"IO Biotech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"IO Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Vico Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"VO659","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Vico Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Vico Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Vico Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"INCB123667","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"CLN-978","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cullinan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Cullinan Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biophta","sponsor":"HTL Biotechnology","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","date":"June 2024","year":"2024","type":"Financing","leadProduct":"BO-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Biophta","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Biophta \/ HTL Biotechnology","highestDevelopmentStatusID":"14","companyTruncated":"Biophta \/ HTL Biotechnology"},{"orgOrder":0,"company":"Passage Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"PBFT02","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Passage Bio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Passage Bio \/ Not Applicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Rituximab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"AdHER2DC","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ImmunityBio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ImmunityBio \/ Not Applicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Exelixis \/ Not Applicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Ondansetron","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Adial Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Adial Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Tr1X Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"TRX103","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Tr1X Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Tr1X Bio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Tr1X Bio \/ Not Applicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Merck & Co","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Tedizolid","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Merck & Co","highestDevelopmentStatusID":"14","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tedizolid","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Merck & Co \/ Not Applicable"},{"orgOrder":0,"company":"Hetero Drugs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Tedizolid","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Hetero Drugs","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Hetero Drugs \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Hetero Drugs \/ Not Applicable"},{"orgOrder":0,"company":"CSPC Ouyi Pharmaceutical Co., Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Tedizolid","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"CSPC Ouyi Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"CSPC Ouyi Pharmaceutical Co., Ltd \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"CSPC Ouyi Pharmaceutical Co., Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Ironshore Pharmaceuticals","sponsor":"Collegium Pharmaceutical","pharmaFlowCategory":"D","upfrontCash":"$525.0 million","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Acquisition","leadProduct":"Methylphenidate Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ironshore Pharmaceuticals","amount2":0.53000000000000003,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ironshore Pharmaceuticals \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"14","companyTruncated":"Ironshore Pharmaceuticals \/ Collegium Pharmaceutical"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","upfrontCash":"$100.0 million","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Licensing Agreement","leadProduct":"NBI-1117568","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sosei Group Corporation","amount2":2.7000000000000002,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sosei Group Corporation \/ Neurocrine Biosciences","highestDevelopmentStatusID":"14","companyTruncated":"Sosei Group Corporation \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Imugene","pharmaFlowCategory":"D","upfrontCash":"$21.0 million","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Precision BioSciences","amount2":0.23000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Imugene","highestDevelopmentStatusID":"14","companyTruncated":"Precision BioSciences \/ Imugene"},{"orgOrder":0,"company":"Halda Therapeutics","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Series B Financing","leadProduct":"HLD-0915","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Halda Therapeutics","amount2":0.13,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Halda Therapeutics \/ Deep Track Capital","highestDevelopmentStatusID":"14","companyTruncated":"Halda Therapeutics \/ Deep Track Capital"},{"orgOrder":0,"company":"Kadmon Holdings","sponsor":"Sanofi","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","date":"November 2021","year":"2021","type":"Acquisition","leadProduct":"Belumosudil","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kadmon Holdings","amount2":1.8999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kadmon Holdings \/ Sanofi","highestDevelopmentStatusID":"14","companyTruncated":"Kadmon Holdings \/ Sanofi"},{"orgOrder":0,"company":"Kadmon Holdings","sponsor":"Meiji Seika Pharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Belumosudil","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kadmon Holdings","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kadmon Holdings \/ Meiji Seika Pharma","highestDevelopmentStatusID":"14","companyTruncated":"Kadmon Holdings \/ Meiji Seika Pharma"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"BofA Securities","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"September 2024","year":"2024","type":"Public Offering","leadProduct":"VAX-24","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Vaxcyte","amount2":1.3,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Vaxcyte \/ BofA Securities","highestDevelopmentStatusID":"14","companyTruncated":"Vaxcyte \/ BofA Securities"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"BofA Securities","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"September 2024","year":"2024","type":"Public Offering","leadProduct":"VAX-24","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Vaxcyte","amount2":1.5,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Vaxcyte \/ BofA Securities","highestDevelopmentStatusID":"14","companyTruncated":"Vaxcyte \/ BofA Securities"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"RNA-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Korro Bio","amount2":0.53000000000000003,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Korro Bio \/ Novo Nordisk","highestDevelopmentStatusID":"14","companyTruncated":"Korro Bio \/ Novo Nordisk"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","upfrontCash":"$175.0 million","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Voyager Therapeutics, Inc","amount2":1.6799999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ Neurocrine Biosciences","highestDevelopmentStatusID":"14","companyTruncated":"Voyager Therapeutics, Inc \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"ANI Pharmaceuticals Inc","pharmaFlowCategory":"D","upfrontCash":"$381.0 million","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Acquisition","leadProduct":"Fluocinolone Acetonide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alimera Sciences","amount2":0.38,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alimera Sciences \/ ANI Pharmaceuticals Inc","highestDevelopmentStatusID":"14","companyTruncated":"Alimera Sciences \/ ANI Pharmaceuticals Inc"},{"orgOrder":0,"company":"Nuvalent","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Public Offering","leadProduct":"Zidesamtinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Nuvalent","amount2":0.5,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Nuvalent \/ J.P. Morgan","highestDevelopmentStatusID":"14","companyTruncated":"Nuvalent \/ J.P. Morgan"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"D","upfrontCash":"$35.0 million","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Partnership","leadProduct":"Deramiocel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Capricor Therapeutics","amount2":0.73999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Capricor Therapeutics \/ Nippon Shinyaku","highestDevelopmentStatusID":"14","companyTruncated":"Capricor Therapeutics \/ Nippon Shinyaku"},{"orgOrder":0,"company":"AC Immune","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Vaccine","date":"September 2024","year":"2024","type":"Licensing Agreement","leadProduct":"JNJ-2056","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AC Immune","amount2":0.51000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AC Immune \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"14","companyTruncated":"AC Immune \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Organon","pharmaFlowCategory":"D","upfrontCash":"$175.0 million","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Acquisition","leadProduct":"Tapinarof","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Dermavant Sciences","amount2":1.2,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Dermavant Sciences \/ Organon","highestDevelopmentStatusID":"14","companyTruncated":"Dermavant Sciences \/ Organon"},{"orgOrder":0,"company":"NanoVation Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"NanoVation Therapeutics","amount2":0.59999999999999998,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"NanoVation Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"14","companyTruncated":"NanoVation Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","date":"September 2024","year":"2024","type":"Public Offering","leadProduct":"Palopegteriparatide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ascendis Pharma","amount2":0.28000000000000003,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ascendis Pharma \/ J.P. Morgan","highestDevelopmentStatusID":"14","companyTruncated":"Ascendis Pharma \/ J.P. Morgan"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Public Offering","leadProduct":"Obexelimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Zenas BioPharma","amount2":0.26000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Zenas BioPharma \/ Morgan Stanley","highestDevelopmentStatusID":"14","companyTruncated":"Zenas BioPharma \/ Morgan Stanley"},{"orgOrder":0,"company":"Generate Biomedicines","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","upfrontCash":"$65.0 million","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"Protein-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Generate Biomedicines","amount2":1.0700000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Generate Biomedicines \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"14","companyTruncated":"Generate Biomedicines \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Surrozen","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","upfrontCash":"$12.5 million","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"SZN-413","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Surrozen","amount2":0.59999999999999998,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Surrozen \/ Boehringer Ingelheim Gmbh","highestDevelopmentStatusID":"14","companyTruncated":"Surrozen \/ Boehringer Ingelheim Gmbh"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"C4 Therapeutics","amount2":0.41999999999999998,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"C4 Therapeutics \/ Biogen","highestDevelopmentStatusID":"14","companyTruncated":"C4 Therapeutics \/ Biogen"},{"orgOrder":0,"company":"HAYA Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"RNA-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"HAYA Therapeutics","amount2":1,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"HAYA Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"14","companyTruncated":"HAYA Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","upfrontCash":"$15.0 million","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Voyager Therapeutics, Inc","amount2":0.32000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"14","companyTruncated":"Voyager Therapeutics, Inc \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"DP Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"DPT0416","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"DP Technology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"DP Technology \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"DP Technology \/ Not Applicable"},{"orgOrder":0,"company":"Immorna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"JCXH-211","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Immorna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Immorna \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Immorna \/ Not Applicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"NeuroSense Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"R327","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Recce Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"NV-387","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"NanoViricides \/ Not Applicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Marijuana Analog","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Mira Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Mira Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Peptide","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Fexapotide triflutate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Nymox Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Nymox Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Nymox Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"De Motu Cordis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"De Motu Cordis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"De Motu Cordis \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"De Motu Cordis \/ Not Applicable"},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"ExoPTEN","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"NurExone Biologic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"NurExone Biologic \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"NurExone Biologic \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"PBA-0405","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Twist Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Dx&Vx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"GLP-1-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Dx&Vx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Dx&Vx \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Dx&Vx \/ Not Applicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Ifinatamab Deruxtecan","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Daiichi Sankyo \/ Not Applicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Prednisolone Acetate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Lupin Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Neurogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"NGN-401","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Neurogene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Neurogene \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Neurogene \/ Not Applicable"},{"orgOrder":0,"company":"Chengdu Weisijin Biomedical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"WGc-043","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Chengdu Weisijin Biomedical Technology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Chengdu Weisijin Biomedical Technology \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Chengdu Weisijin Biomedical Technology \/ Not Applicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"ONP-002","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Oragenics \/ Not Applicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Ziftomenib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Kura Oncology \/ Not Applicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Bezisterim","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioVie \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BioVie \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Bortezomib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Sanofi \/ Not Applicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Trazodone Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Granules India Limited \/ Not Applicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Lupin Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"CHIKV VLP","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Bavarian Nordic \/ Not Applicable"},{"orgOrder":0,"company":"Replimune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Replimune","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Replimune \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Replimune \/ Not Applicable"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"SP-1-303","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Shuttle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Shuttle Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"QRX003","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Quoin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Quoin Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Quoin Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Poxel","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Imeglimin Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sumitomo Pharma \/ Poxel","highestDevelopmentStatusID":"14","companyTruncated":"Sumitomo Pharma \/ Poxel"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Cibotercept","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Keros Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Keros Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Bezisterim","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioVie \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BioVie \/ Not Applicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"ARCT-032","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arcturus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Arcturus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"IBI363","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Innovent Biologics \/ Not Applicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"INB-100","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"IN8bio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"IN8bio \/ Not Applicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Outlook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Merakris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Human Amniotic Fluid","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Merakris Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Merakris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Merakris Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Abdera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Actinium-225","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Abdera Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Abdera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Abdera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"AUR200","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Aurinia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Crestone","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"CRS3123","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Crestone","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Crestone \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Crestone \/ Not Applicable"},{"orgOrder":0,"company":"Inflammasome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Kamuvudine-9","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Inflammasome Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Inflammasome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Inflammasome Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Amivantamab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"NS-050\/NCNP-03","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"NS Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"NS Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Oneness Biotech","sponsor":"Microbio","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"SNS812","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Oneness Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Oneness Biotech \/ Microbio","highestDevelopmentStatusID":"14","companyTruncated":"Oneness Biotech \/ Microbio"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"RAG-17","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ractigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ractigen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vaxxas","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"H7N9-targeted Vaccine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Vaxxas","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Vaxxas \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Vaxxas \/ Not Applicable"},{"orgOrder":0,"company":"Insignis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Insignis Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Insignis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Insignis Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Tecovirimat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"SIGA Technologies \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"SIGA Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Aflibercept","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Alvotech \/ Not Applicable"},{"orgOrder":0,"company":"Veralox Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"VLX-1005","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Veralox Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Veralox Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Veralox Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"AccutarBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"AC699","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AccutarBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AccutarBio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"AccutarBio \/ Not Applicable"},{"orgOrder":0,"company":"Metagenomi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"MGX-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Metagenomi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Metagenomi \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Metagenomi \/ Not Applicable"},{"orgOrder":0,"company":"Avalyn Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Pirfenidone","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Avalyn Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Avalyn Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Avalyn Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"RGX-121","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Regenxbio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Regenxbio \/ Not Applicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Fosgonimeton","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Athira Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Athira Pharma \/ Not Applicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Nusinersen Sodium","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Meloxicam","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Axsome Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"IGC Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Synthekine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"STK-009","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Synthekine \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Synthekine \/ Not Applicable"},{"orgOrder":0,"company":"Adaptin Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"APTN-101","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Adaptin Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Adaptin Bio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Adaptin Bio \/ Not Applicable"},{"orgOrder":0,"company":"Apotex Fermentation Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Dasatinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Apotex Fermentation Inc.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Apotex Fermentation Inc. \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Apotex Fermentation Inc. \/ Not Applicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"GPX-002","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Genprex \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"U.S. Renal Care","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Akebia Therapeutics \/ U.S. Renal Care","highestDevelopmentStatusID":"14","companyTruncated":"Akebia Therapeutics \/ U.S. Renal Care"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ultimovacs \/ Not Applicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Aim ImmunoTech \/ Not Applicable"},{"orgOrder":0,"company":"Actuate Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Elraglusib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Actuate Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Actuate Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Actuate Therapeutics, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"PAS-004","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Pasithea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Pasithea Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"RCT2100","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ReCode Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ReCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ReCode Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Darolutamide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"AstraZeneca \/ Not Applicable"},{"orgOrder":0,"company":"ArsenalBio","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Series C Financing","leadProduct":"AB-2100","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ArsenalBio","amount2":0.33000000000000002,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ArsenalBio \/ ARCH Venture Partners","highestDevelopmentStatusID":"14","companyTruncated":"ArsenalBio \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Genetic Leap","sponsor":"Eli Lilly","pharmaFlowCategory":"D","upfrontCash":"$409.0 million","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"RNA-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Genetic Leap","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Genetic Leap \/ Eli Lilly","highestDevelopmentStatusID":"14","companyTruncated":"Genetic Leap \/ Eli Lilly"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Public Offering","leadProduct":"RLY-4008","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Relay Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Relay Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"14","companyTruncated":"Relay Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Candid Therapeutics","sponsor":"Venrock Healthcare Capital Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Financing","leadProduct":"CND106","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Candid Therapeutics","amount2":0.37,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Candid Therapeutics \/ Venrock Healthcare Capital Partners","highestDevelopmentStatusID":"14","companyTruncated":"Candid Therapeutics \/ Venrock Healthcare Capital Partners"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Public Offering","leadProduct":"Zilganersen","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ionis Pharmaceuticals","amount2":0.55000000000000004,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ionis Pharmaceuticals \/ Morgan Stanley","highestDevelopmentStatusID":"14","companyTruncated":"Ionis Pharmaceuticals \/ Morgan Stanley"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Public Offering","leadProduct":"RLY-4008","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Relay Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Relay Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"14","companyTruncated":"Relay Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"ANI Pharmaceuticals Inc","pharmaFlowCategory":"D","upfrontCash":"$381.0 million","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Acquisition","leadProduct":"Fluocinolone Acetonide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alimera Sciences","amount2":0.38,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alimera Sciences \/ ANI Pharmaceuticals Inc","highestDevelopmentStatusID":"14","companyTruncated":"Alimera Sciences \/ ANI Pharmaceuticals Inc"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Public Offering","leadProduct":"Veligrotug","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Viridian Therapeutics","amount2":0.23000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Viridian Therapeutics \/ Jefferies","highestDevelopmentStatusID":"14","companyTruncated":"Viridian Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Public Offering","leadProduct":"Obexelimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Zenas BioPharma","amount2":0.23000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Zenas BioPharma \/ Morgan Stanley","highestDevelopmentStatusID":"14","companyTruncated":"Zenas BioPharma \/ Morgan Stanley"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Public Offering","leadProduct":"SerpinPC","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Centessa Pharmaceuticals","amount2":0.23000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Centessa Pharmaceuticals \/ Goldman Sachs & Co","highestDevelopmentStatusID":"14","companyTruncated":"Centessa Pharmaceuticals \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Braidwell LP","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Private Placement","leadProduct":"ORKA-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Oruka Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Oruka Therapeutics \/ Braidwell LP","highestDevelopmentStatusID":"14","companyTruncated":"Oruka Therapeutics \/ Braidwell LP"},{"orgOrder":0,"company":"Oranomed","sponsor":"Sanofi","pharmaFlowCategory":"D","upfrontCash":"$111.6 million","therapeuticArea":"Oncology","country":"","productType":"Peptide","date":"September 2024","year":"2024","type":"Licensing Agreement","leadProduct":"212Pb-DOTAMTATE","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Oranomed","amount2":0.35999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Oranomed \/ Sanofi","highestDevelopmentStatusID":"14","companyTruncated":"Oranomed \/ Sanofi"},{"orgOrder":0,"company":"Xencor","sponsor":"Leerink Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Public Offering","leadProduct":"Cabazitaxel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Xencor","amount2":0.20000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Xencor \/ Leerink Partners","highestDevelopmentStatusID":"14","companyTruncated":"Xencor \/ Leerink Partners"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Private Placement","leadProduct":"Carboplatin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Summit Therapeutics","amount2":0.23999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Summit Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"14","companyTruncated":"Summit Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Isotope Technologies Munich","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Peptide","date":"September 2024","year":"2024","type":"Licensing Agreement","leadProduct":"[177Lu]Lu-DPI-4452","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Debiopharm","amount2":0.33000000000000002,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Debiopharm \/ Isotope Technologies Munich","highestDevelopmentStatusID":"14","companyTruncated":"Debiopharm \/ Isotope Technologies Munich"},{"orgOrder":0,"company":"Bicara Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Public Offering","leadProduct":"Ficerafusp Alfa","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bicara Therapeutics","amount2":0.35999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bicara Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"14","companyTruncated":"Bicara Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"NanoVation Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","upfrontCash":"$600.0 million","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Partnership","leadProduct":"RNA-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"NanoVation Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"NanoVation Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"14","companyTruncated":"NanoVation Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","upfrontCash":"$1,525.0 million","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Termination","leadProduct":"SAGE-324","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sage Therapeutics","amount2":1.53,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"14","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Regor Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"D","upfrontCash":"$850.0 million","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Acquisition","leadProduct":"RGT-419B","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Regor Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Regor Therapeutics \/ Genentech","highestDevelopmentStatusID":"14","companyTruncated":"Regor Therapeutics \/ Genentech"},{"orgOrder":0,"company":"Bicara Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Public Offering","leadProduct":"Ficerafusp Alfa","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bicara Therapeutics","amount2":0.32000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bicara Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"14","companyTruncated":"Bicara Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Sonoma Biotherapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"$75.0 million","therapeuticArea":"Gastroenterology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"Treg Cell Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sonoma Biotherapeutics","amount2":0.12,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sonoma Biotherapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"Sonoma Biotherapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Ascenta Capital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Series B Financing","leadProduct":"TLC-6740","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"OrsoBio","amount2":0.070000000000000007,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"OrsoBio \/ Ascenta Capital","highestDevelopmentStatusID":"14","companyTruncated":"OrsoBio \/ Ascenta Capital"},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"CIRM","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Funding","leadProduct":"NRTX-1001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Neurona Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Neurona Therapeutics \/ CIRM","highestDevelopmentStatusID":"14","companyTruncated":"Neurona Therapeutics \/ CIRM"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Emory University","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Partnership","leadProduct":"mRNA-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"TFF Pharmaceuticals \/ Emory University","highestDevelopmentStatusID":"14","companyTruncated":"TFF Pharmaceuticals \/ Emory University"},{"orgOrder":0,"company":"Valneva","sponsor":"Undisclosed","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"September 2024","year":"2024","type":"Private Placement","leadProduct":"Chikungunya Vaccine, Live","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Valneva","amount2":0.070000000000000007,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Valneva \/ Undisclosed","highestDevelopmentStatusID":"14","companyTruncated":"Valneva \/ Undisclosed"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"BARDA","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Funding","leadProduct":"Ansuvimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Emergent BioSolutions","amount2":0.040000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Emergent BioSolutions \/ BARDA","highestDevelopmentStatusID":"14","companyTruncated":"Emergent BioSolutions \/ BARDA"},{"orgOrder":0,"company":"Alumis","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"ESK-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alumis","amount2":0.25,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alumis \/ Morgan Stanley","highestDevelopmentStatusID":"14","companyTruncated":"Alumis \/ Morgan Stanley"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"NXP800","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Nuvectis Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Nuvectis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Exenatide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Vivani Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Vivani Medical \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Vivani Medical \/ Not Applicable"},{"orgOrder":0,"company":"Aelis Farma","sponsor":"Indivior","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"AEF0117","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aelis Farma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aelis Farma \/ Indivior","highestDevelopmentStatusID":"14","companyTruncated":"Aelis Farma \/ Indivior"},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"ExoPTEN","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"NurExone Biologic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"NurExone Biologic \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"NurExone Biologic \/ Not Applicable"},{"orgOrder":0,"company":"Clear Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Etifoxine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Clear Scientific","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Clear Scientific \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Clear Scientific \/ Not Applicable"},{"orgOrder":0,"company":"GRI Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"GRI-0621","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"GRI Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"GRI Bio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"GRI Bio \/ Not Applicable"},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"ETD001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Enterprise Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Enterprise Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Enterprise Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"PTC518","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"PTC Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Paulson Investment Company, LLC","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Private Placement","leadProduct":"INDP020","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Indaptus Therapeutics \/ Paulson Investment Company, LLC","highestDevelopmentStatusID":"14","companyTruncated":"Indaptus Therapeutics \/ Paulson Investment Company, LLC"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Leerink Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Public Offering","leadProduct":"Furosemide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"scPharmaceuticals","amount2":0.050000000000000003,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"scPharmaceuticals \/ Leerink Partners","highestDevelopmentStatusID":"14","companyTruncated":"scPharmaceuticals \/ Leerink Partners"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"BVF Partners LP","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Private Placement","leadProduct":"Levosimendan","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Tenax Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Tenax Therapeutics \/ BVF Partners LP","highestDevelopmentStatusID":"14","companyTruncated":"Tenax Therapeutics \/ BVF Partners LP"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Undisclosed","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Public Offering","leadProduct":"Allogeneic Gamma Delta T Cell Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"TC BioPharm \/ Undisclosed","highestDevelopmentStatusID":"14","companyTruncated":"TC BioPharm \/ Undisclosed"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"TD Cowen","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Public Offering","leadProduct":"ANB032","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AnaptysBio","amount2":0.10000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AnaptysBio \/ TD Cowen","highestDevelopmentStatusID":"14","companyTruncated":"AnaptysBio \/ TD Cowen"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Undisclosed","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Public Offering","leadProduct":"Allogeneic Gamma Delta T Cell Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"TC BioPharm \/ Undisclosed","highestDevelopmentStatusID":"14","companyTruncated":"TC BioPharm \/ Undisclosed"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Public Offering","leadProduct":"Annamycin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Moleculin Biotech","amount2":0.02,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"14","companyTruncated":"Moleculin Biotech \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Evercore ISI","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Public Offering","leadProduct":"Vonoprazan Fumarate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Phathom Pharmaceuticals","amount2":0.13,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Phathom Pharmaceuticals \/ Evercore ISI","highestDevelopmentStatusID":"14","companyTruncated":"Phathom Pharmaceuticals \/ Evercore ISI"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Public Offering","leadProduct":"Annamycin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Moleculin Biotech","amount2":0.02,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"14","companyTruncated":"Moleculin Biotech \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Titan Partners Group","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Public Offering","leadProduct":"Brilaroxazine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Reviva Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Reviva Pharmaceuticals \/ Titan Partners Group","highestDevelopmentStatusID":"14","companyTruncated":"Reviva Pharmaceuticals \/ Titan Partners Group"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Oxprenolol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Actimed Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Actimed Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Rostaporfin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kintara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Kintara Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ois\u00edn Biotechnologies","sponsor":"AbbVie Ventures","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Musculoskeletal","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ois\u00edn Biotechnologies","amount2":0.02,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ois\u00edn Biotechnologies \/ AbbVie Ventures","highestDevelopmentStatusID":"14","companyTruncated":"Ois\u00edn Biotechnologies \/ AbbVie Ventures"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Funding","leadProduct":"Neldaleucel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Marker Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"14","companyTruncated":"Marker Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Financing","leadProduct":"Furosemide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"scPharmaceuticals","amount2":0.050000000000000003,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"scPharmaceuticals \/ Perceptive Advisors","highestDevelopmentStatusID":"14","companyTruncated":"scPharmaceuticals \/ Perceptive Advisors"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Mitem Pharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Pharmacology\/Toxicology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Acquisition","leadProduct":"Deferoxamine Mesylate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Mitem Pharma","highestDevelopmentStatusID":"14","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Mitem Pharma"},{"orgOrder":0,"company":"Aitia","sponsor":"Orion Corporation","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aitia","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aitia \/ Orion Corporation","highestDevelopmentStatusID":"14","companyTruncated":"Aitia \/ Orion Corporation"},{"orgOrder":0,"company":"nuBioAge","sponsor":"Marius Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"Testosterone Undecanoate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"nuBioAge","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"nuBioAge \/ Marius Pharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"nuBioAge \/ Marius Pharmaceuticals"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Oppenheimer & Co","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Public Offering","leadProduct":"CUE-401","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cue Biopharma","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cue Biopharma \/ Oppenheimer & Co","highestDevelopmentStatusID":"14","companyTruncated":"Cue Biopharma \/ Oppenheimer & Co"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Public Offering","leadProduct":"Gemcitabine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Theriva Biologics \/ Alliance Global Partners","highestDevelopmentStatusID":"14","companyTruncated":"Theriva Biologics \/ Alliance Global Partners"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Oppenheimer & Co","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Public Offering","leadProduct":"CUE-401","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cue Biopharma \/ Oppenheimer & Co","highestDevelopmentStatusID":"14","companyTruncated":"Cue Biopharma \/ Oppenheimer & Co"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Acumen Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"Sabirnetug","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lonza Group \/ Acumen Pharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"Lonza Group \/ Acumen Pharmaceuticals"},{"orgOrder":0,"company":"Genevant Sciences","sponsor":"Repair Biotechnologies","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Licensing Agreement","leadProduct":"mRNA-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Genevant Sciences","amount2":0.11,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Genevant Sciences \/ Repair Biotechnologies","highestDevelopmentStatusID":"14","companyTruncated":"Genevant Sciences \/ Repair Biotechnologies"},{"orgOrder":0,"company":"Tempus","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Tempus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Tempus \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"14","companyTruncated":"Tempus \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"858 Therapeutics","sponsor":"Avidity Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Series B Financing","leadProduct":"ETX-19477","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"858 Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"858 Therapeutics \/ Avidity Partners","highestDevelopmentStatusID":"14","companyTruncated":"858 Therapeutics \/ Avidity Partners"},{"orgOrder":0,"company":"Phare Bio","sponsor":"ARPA-H","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Funding","leadProduct":"Antibiotic-based Thearpy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Phare Bio","amount2":0.029999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Phare Bio \/ ARPA-H","highestDevelopmentStatusID":"14","companyTruncated":"Phare Bio \/ ARPA-H"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Precision BioSciences","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Azercabtagene Zapreleucel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"TG Therapeutics \/ Precision BioSciences","highestDevelopmentStatusID":"14","companyTruncated":"TG Therapeutics \/ Precision BioSciences"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Peptide","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"GP2 Peptide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Greenwich LifeSciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Greenwich LifeSciences \/ Not Applicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Linvoseltamab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Regeneron Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Mirdametinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"SpringWorks Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"SpringWorks Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"NorthStar Medical Radioisotopes","sponsor":"Convergent Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Expanded Collaboration","leadProduct":"Rosopatamab Tetraxetan-225Ac","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"NorthStar Medical Radioisotopes","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"NorthStar Medical Radioisotopes \/ Convergent Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"NorthStar Medical Radioisotopes \/ Convergent Therapeutics"},{"orgOrder":0,"company":"EnPlusOne Biosciences","sponsor":"Wyss Institute","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","date":"August 2024","year":"2024","type":"Collaboration","leadProduct":"RNA-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"EnPlusOne Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"EnPlusOne Biosciences \/ Wyss Institute","highestDevelopmentStatusID":"14","companyTruncated":"EnPlusOne Biosciences \/ Wyss Institute"},{"orgOrder":0,"company":"Nuntius Therapeutics","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Collaboration","leadProduct":"mRNA-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Nuntius Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Nuntius Therapeutics \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"14","companyTruncated":"Nuntius Therapeutics \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Aarvik Therapeutics","sponsor":"Arrivent","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Collaboration","leadProduct":"ADC-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aarvik Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aarvik Therapeutics \/ ArriVent","highestDevelopmentStatusID":"14","companyTruncated":"Aarvik Therapeutics \/ ArriVent"},{"orgOrder":0,"company":"AbSci","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Collaboration","leadProduct":"Antibody-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AbSci","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AbSci \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"14","companyTruncated":"AbSci \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Crown Laboratories","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Acquisition","leadProduct":"Daxibotulinumtoxin A","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Revance Therapeutics","amount2":0.92000000000000004,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Revance Therapeutics \/ Crown Laboratories","highestDevelopmentStatusID":"14","companyTruncated":"Revance Therapeutics \/ Crown Laboratories"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Boudicca Dx","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Collaboration","leadProduct":"Ondansetron","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Adial Pharmaceuticals \/ Boudicca Dx","highestDevelopmentStatusID":"14","companyTruncated":"Adial Pharmaceuticals \/ Boudicca Dx"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"NRC IRAP","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Podiatry","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Funding","leadProduct":"Edetate Calcium Disodium","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kane Biotech \/ NRC IRAP","highestDevelopmentStatusID":"14","companyTruncated":"Kane Biotech \/ NRC IRAP"},{"orgOrder":0,"company":"Sable Therapeutics","sponsor":"Columbia University","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Licensing Agreement","leadProduct":"SBL-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sable Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sable Therapeutics \/ Columbia University","highestDevelopmentStatusID":"14","companyTruncated":"Sable Therapeutics \/ Columbia University"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Anson Funds","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Financing","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"NRx Pharmaceuticals \/ Anson Funds","highestDevelopmentStatusID":"14","companyTruncated":"NRx Pharmaceuticals \/ Anson Funds"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Sever Pharma Solutions","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Silo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Silo Pharma \/ Sever Pharma Solutions","highestDevelopmentStatusID":"14","companyTruncated":"Silo Pharma \/ Sever Pharma Solutions"},{"orgOrder":0,"company":"Citius Oncology","sponsor":"TenX Keane Acquisition","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Merger","leadProduct":"Denileukin Diftitox","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Citius Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Citius Oncology \/ TenX Keane Acquisition","highestDevelopmentStatusID":"14","companyTruncated":"Citius Oncology \/ TenX Keane Acquisition"},{"orgOrder":0,"company":"Immuron","sponsor":"NMRC","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Agreement","leadProduct":"Bovine Colostrum","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Immuron \/ NMRC","highestDevelopmentStatusID":"14","companyTruncated":"Immuron \/ NMRC"},{"orgOrder":0,"company":"Merus","sponsor":"Foundation Medicine","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Collaboration","leadProduct":"Zenocutuzumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Merus \/ Foundation Medicine","highestDevelopmentStatusID":"14","companyTruncated":"Merus \/ Foundation Medicine"},{"orgOrder":0,"company":"Quotient Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","date":"August 2024","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Quotient Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Quotient Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"14","companyTruncated":"Quotient Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"EydisBio","sponsor":"National Institute of Health","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Funding","leadProduct":"EYD-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"EydisBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"EydisBio \/ National Institute of Health","highestDevelopmentStatusID":"14","companyTruncated":"EydisBio \/ National Institute of Health"},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Oruka Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Merger","leadProduct":"ORKA-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ARCA Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ARCA Biopharma \/ Oruka Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"ARCA Biopharma \/ Oruka Therapeutics"},{"orgOrder":0,"company":"CSPC Pharmaceutical Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"SYS6016","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"CSPC Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"CSPC Pharmaceutical Group \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"CSPC Pharmaceutical Group \/ Not Applicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"AMT-191","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Uniqure \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Uniqure \/ Not Applicable"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"BDTX-1535","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Black Diamond Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Black Diamond Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Sleep","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Daridorexant Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sosei Group Corporation \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Sosei Group Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Takeda Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Peptide","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"LTI-03","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aileron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Aileron Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Enliven Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"ELVN-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Enliven Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Enliven Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Enliven Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Rivus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"HU6","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Rivus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Rivus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Rivus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Cereno Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Divalproex Sodium","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cereno Scientific","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cereno Scientific \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Cereno Scientific \/ Not Applicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"mRNA-1403","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Moderna Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Pirepemat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"IRLAB \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"IRLAB \/ Not Applicable"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Oxyntomodulin Analog","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"NeuroBo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"NeuroBo Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Zhejiang Doer Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"DR10624","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Zhejiang Doer Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Zhejiang Doer Biologics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Zhejiang Doer Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Fresenius SE & Co. KGaA","sponsor":"Formycon","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Fresenius SE & Co. KGaA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Fresenius SE & Co. KGaA \/ Formycon","highestDevelopmentStatusID":"14","companyTruncated":"Fresenius SE & Co. KGaA \/ Formycon"},{"orgOrder":0,"company":"PANTHERx Rare Pharmacy","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Partnership","leadProduct":"Seladelpar Lysine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"PANTHERx Rare Pharmacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"PANTHERx Rare Pharmacy \/ Gilead Sciences","highestDevelopmentStatusID":"14","companyTruncated":"PANTHERx Rare Pharmacy \/ Gilead Sciences"},{"orgOrder":0,"company":"Oblique Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Collaboration","leadProduct":"Antibody-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Oblique Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Oblique Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"14","companyTruncated":"Oblique Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Borealis Biosciences","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Series A Financing","leadProduct":"xRNA-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Borealis Biosciences","amount2":0.14999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Borealis Biosciences \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"14","companyTruncated":"Borealis Biosciences \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Peptide","date":"August 2024","year":"2024","type":"Financing","leadProduct":"Sovateltide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Pharmazz","amount2":0.02,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Pharmazz \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"14","companyTruncated":"Pharmazz \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Peptide","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Estradiol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Aurobindo Pharma Limited \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Iptacopan Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Mediar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"MTX-474","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Mediar Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Mediar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Mediar Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Denileukin Diftitox","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Citius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Furosemide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"scPharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"ONP-002","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Oragenics \/ Not Applicable"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Aceclidine Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"LENZ Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"LENZ Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"LENZ Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vimgreen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"VG081821AC","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Vimgreen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Vimgreen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Vimgreen Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"ONP-002","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Oragenics \/ Not Applicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"TNX-801","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"SciSparc \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"SciSparc \/ Not Applicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"PAS-Nomacopan","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Akari Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Peptide","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Pegtarazimod","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ReAlta Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ReAlta Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"RNA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"BLA-761423","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"RNA Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"RNA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"RNA Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Apogee Biotechnology Corporation","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Opaganib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"RedHill Biopharma \/ Apogee Biotechnology Corporation","highestDevelopmentStatusID":"14","companyTruncated":"RedHill Biopharma \/ Apogee Biotechnology Corporation"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Pathos","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Licensing Agreement","leadProduct":"PRT811","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Prelude Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Prelude Therapeutics \/ Pathos","highestDevelopmentStatusID":"14","companyTruncated":"Prelude Therapeutics \/ Pathos"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Tempus","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Collaboration","leadProduct":"Bemcentinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BerGenBio ASA \/ Tempus","highestDevelopmentStatusID":"14","companyTruncated":"BerGenBio ASA \/ Tempus"},{"orgOrder":0,"company":"Visiox Pharma","sponsor":"Ocuvex Therpeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Merger","leadProduct":"Omidenepag Isopropyl","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Visiox Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Visiox Pharma \/ Ocuvex Therpeutics","highestDevelopmentStatusID":"14","companyTruncated":"Visiox Pharma \/ Ocuvex Therpeutics"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Public Offering","leadProduct":"Clobetasol Propionate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eyenovia \/ Dawson James Securities","highestDevelopmentStatusID":"14","companyTruncated":"Eyenovia \/ Dawson James Securities"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Organon","pharmaFlowCategory":"D","upfrontCash":"$22.5 million","therapeuticArea":"Neurology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Agreement","leadProduct":"Galcanezumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eli Lilly \/ Organon","highestDevelopmentStatusID":"14","companyTruncated":"Eli Lilly \/ Organon"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Public Offering","leadProduct":"Clobetasol Propionate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eyenovia","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eyenovia \/ Dawson James Securities","highestDevelopmentStatusID":"14","companyTruncated":"Eyenovia \/ Dawson James Securities"},{"orgOrder":0,"company":"PhotonPharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"August 2024","year":"2024","type":"Financing","leadProduct":"Autologous Cellular-based Vaccine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"PhotonPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"PhotonPharma \/ Undisclosed","highestDevelopmentStatusID":"14","companyTruncated":"PhotonPharma \/ Undisclosed"},{"orgOrder":0,"company":"HitGen","sponsor":"Bridge Biotherapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"HitGen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"HitGen \/ Bridge Biotherapeutics","highestDevelopmentStatusID":"14","companyTruncated":"HitGen \/ Bridge Biotherapeutics"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Public Offering","leadProduct":"Clobetasol Propionate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eyenovia","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eyenovia \/ Dawson James Securities","highestDevelopmentStatusID":"14","companyTruncated":"Eyenovia \/ Dawson James Securities"},{"orgOrder":0,"company":"Cessatech","sponsor":"Proveca","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cessatech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cessatech \/ Proveca","highestDevelopmentStatusID":"14","companyTruncated":"Cessatech \/ Proveca"},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"Insud Pharma","pharmaFlowCategory":"D","upfrontCash":"$45.0 million","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Acquisition","leadProduct":"Levonorgestrel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Agile Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Agile Therapeutics \/ Insud Pharma","highestDevelopmentStatusID":"14","companyTruncated":"Agile Therapeutics \/ Insud Pharma"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Bilthoven Biologicals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"August 2024","year":"2024","type":"Collaboration","leadProduct":"TNX-801","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Bilthoven Biologicals","highestDevelopmentStatusID":"14","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Bilthoven Biologicals"},{"orgOrder":0,"company":"Diakonos Oncology","sponsor":"Restem Group Inc","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"August 2024","year":"2024","type":"Financing","leadProduct":"DOC1021","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Diakonos Oncology","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Diakonos Oncology \/ Restem Group Inc","highestDevelopmentStatusID":"14","companyTruncated":"Diakonos Oncology \/ Restem Group Inc"},{"orgOrder":0,"company":"Circle Pharma","sponsor":"The Column Group","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Peptide","date":"September 2024","year":"2024","type":"Series D Financing","leadProduct":"CID-078","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Circle Pharma","amount2":0.089999999999999997,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Circle Pharma \/ The Column Group","highestDevelopmentStatusID":"14","companyTruncated":"Circle Pharma \/ The Column Group"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Private Placement","leadProduct":"Tafenoquine Succinate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"60 Degrees Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"14","companyTruncated":"60 Degrees Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"NRG Therapeutics","sponsor":"ALS Foundation","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"NRG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"NRG Therapeutics \/ ALS Foundation","highestDevelopmentStatusID":"14","companyTruncated":"NRG Therapeutics \/ ALS Foundation"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Private Placement","leadProduct":"Tafenoquine Succinate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"60 Degrees Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"14","companyTruncated":"60 Degrees Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Public Offering","leadProduct":"Clobetasol Propionate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eyenovia \/ Alliance Global Partners","highestDevelopmentStatusID":"14","companyTruncated":"Eyenovia \/ Alliance Global Partners"},{"orgOrder":0,"company":"Semnur Pharmaceuticals","sponsor":"Denali Capital Acquisition Corp","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Merger","leadProduct":"Dexamethasone Sodium Phosphate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Semnur Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Semnur Pharmaceuticals \/ Denali Capital Acquisition Corp","highestDevelopmentStatusID":"14","companyTruncated":"Semnur Pharmaceuticals \/ Denali Capital Acquisition Corp"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"March 2022","year":"2022","type":"Private Placement","leadProduct":"Rotigotine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"14","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Rotigotine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bionxt Solutions \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Bionxt Solutions \/ Not Applicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Rotigotine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Luye Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Luye Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Rotigotine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Luye Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Luye Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Edaravone","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ferrer Internacional \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ferrer Internacional \/ Not Applicable"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Edaravone","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ferrer Internacional \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ferrer Internacional \/ Not Applicable"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"FNP-223","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ferrer Internacional \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ferrer Internacional \/ Not Applicable"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Ferrer Internacional","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Agreement","leadProduct":"Treprostinil Sodium","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"United Therapeutics \/ Ferrer Internacional","highestDevelopmentStatusID":"14","companyTruncated":"United Therapeutics \/ Ferrer Internacional"},{"orgOrder":0,"company":"Seibersdorf Labor","sponsor":"Blue Earth Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Large molecule","date":"August 2024","year":"2024","type":"Partnership","leadProduct":"225Ac-rhPSMA-10.1","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Seibersdorf Labor","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Seibersdorf Labor \/ Blue Earth Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"Seibersdorf Labor \/ Blue Earth Therapeutics"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Acquisition","leadProduct":"HYDROXYPROPYLMETHYLCELLULOSE","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alcon Inc \/ Ocumension Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"Alcon Inc \/ Ocumension Therapeutics"},{"orgOrder":0,"company":"Nanoform","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Collaboration","leadProduct":"Plasma-derived Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Nanoform","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Nanoform \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"14","companyTruncated":"Nanoform \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Aronnax","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"CANADA","productType":"Large molecule","date":"August 2024","year":"2024","type":"Agreement","leadProduct":"HT-KIT","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aronnax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aronnax \/ Hoth Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"Aronnax \/ Hoth Therapeutics"},{"orgOrder":0,"company":"Biomotion Sciences","sponsor":"Silexion Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","date":"August 2024","year":"2024","type":"Merger","leadProduct":"SIL-204","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Biomotion Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Biomotion Sciences \/ Silexion Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"Biomotion Sciences \/ Silexion Therapeutics"},{"orgOrder":0,"company":"BITT","sponsor":"MSRD","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Agreement","leadProduct":"BITD401412","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BITT","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BITT \/ MSRD","highestDevelopmentStatusID":"14","companyTruncated":"BITT \/ MSRD"},{"orgOrder":0,"company":"Abata Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Financing","leadProduct":"ABA-101","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Abata Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Abata Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"14","companyTruncated":"Abata Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"DeepCure","sponsor":"LIRMM","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Collaboration","leadProduct":"DC-9476","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"DeepCure","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"DeepCure \/ LIRMM","highestDevelopmentStatusID":"14","companyTruncated":"DeepCure \/ LIRMM"},{"orgOrder":0,"company":"Pathalys Pharma","sponsor":"TCGX","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Series B Financing","leadProduct":"Upacicalcet Sodium","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Pathalys Pharma","amount2":0.11,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Pathalys Pharma \/ TCGX","highestDevelopmentStatusID":"14","companyTruncated":"Pathalys Pharma \/ TCGX"},{"orgOrder":0,"company":"Talus Bioscience","sponsor":"Two Bear Capital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Financing","leadProduct":"Transcription Factor Modulator-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Talus Bioscience","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Talus Bioscience \/ Two Bear Capital","highestDevelopmentStatusID":"14","companyTruncated":"Talus Bioscience \/ Two Bear Capital"},{"orgOrder":0,"company":"Sichuan Kelun Pharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Licensing Agreement","leadProduct":"SKB571","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sichuan Kelun Pharmaceutical","amount2":0.040000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sichuan Kelun Pharmaceutical \/ Merck & Co","highestDevelopmentStatusID":"14","companyTruncated":"Sichuan Kelun Pharmaceutical \/ Merck & Co"},{"orgOrder":0,"company":"SciSparc","sponsor":"Polyrizon","pharmaFlowCategory":"D","upfrontCash":"$3.0 million","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Cannabinoid-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"SciSparc","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"SciSparc \/ Polyrizon","highestDevelopmentStatusID":"14","companyTruncated":"SciSparc \/ Polyrizon"},{"orgOrder":0,"company":"Aurigene Pharmaceutical Services","sponsor":"Kainomyx","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","date":"August 2024","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aurigene Pharmaceutical Services","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aurigene Pharmaceutical Services \/ Kainomyx","highestDevelopmentStatusID":"14","companyTruncated":"Aurigene Pharmaceutical Services \/ Kainomyx"},{"orgOrder":0,"company":"Touchlight","sponsor":"University of Nottingham","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"August 2024","year":"2024","type":"Agreement","leadProduct":"DNA-based Vaccine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Touchlight","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Touchlight \/ University of Nottingham","highestDevelopmentStatusID":"14","companyTruncated":"Touchlight \/ University of Nottingham"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Agreement","leadProduct":"Tecovirimat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"SIGA Technologies \/ U.S. Department of Defense","highestDevelopmentStatusID":"14","companyTruncated":"SIGA Technologies \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Retension Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Series A Financing","leadProduct":"RTN-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Retension Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Retension Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"14","companyTruncated":"Retension Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"University of California","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Funding","leadProduct":"CNDR-51997","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"University of California","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"University of California \/ National Institute on Aging","highestDevelopmentStatusID":"14","companyTruncated":"University of California \/ National Institute on Aging"},{"orgOrder":0,"company":"Rafael Holdings","sponsor":"Cyclo Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Merger","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Rafael Holdings","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Rafael Holdings \/ Cyclo Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"Rafael Holdings \/ Cyclo Therapeutics"},{"orgOrder":0,"company":"Pharma Nordic","sponsor":"Altamira Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Agreement","leadProduct":"Bentonite","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Pharma Nordic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Pharma Nordic \/ Altamira Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"Pharma Nordic \/ Altamira Therapeutics"},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"Target ALS Foundation","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Funding","leadProduct":"C-mods-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Dewpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Dewpoint Therapeutics \/ Target ALS Foundation","highestDevelopmentStatusID":"14","companyTruncated":"Dewpoint Therapeutics \/ Target ALS Foundation"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","date":"August 2024","year":"2024","type":"Public Offering","leadProduct":"MBX 2109","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"MBX Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"14","companyTruncated":"MBX Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"Mangalam Drugs & Organics Ltd","sponsor":"Medicines for Malaria Venture","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Funding","leadProduct":"Pyronaridine Tetraphosphate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Mangalam Drugs & Organics Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Mangalam Drugs & Organics Ltd \/ Medicines for Malaria Venture","highestDevelopmentStatusID":"14","companyTruncated":"Mangalam Drugs & Organics Ltd \/ Medicines for Malaria Venture"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Xiamen Amoytop Biotech","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"ALG-000184","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aligos Therapeutics \/ Xiamen Amoytop Biotech","highestDevelopmentStatusID":"14","companyTruncated":"Aligos Therapeutics \/ Xiamen Amoytop Biotech"},{"orgOrder":0,"company":"Huons CO., LTD","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Cyclosporine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Huons CO., LTD","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Huons CO., LTD \/ Lupin Ltd","highestDevelopmentStatusID":"14","companyTruncated":"Huons CO., LTD \/ Lupin Ltd"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"CIRM","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"July 2024","year":"2024","type":"Funding","leadProduct":"NXC-201","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Immix Biopharma","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Immix Biopharma \/ CIRM","highestDevelopmentStatusID":"14","companyTruncated":"Immix Biopharma \/ CIRM"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Newpath Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Series C Financing","leadProduct":"ABX-002","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Autobahn Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Autobahn Therapeutics \/ Newpath Partners","highestDevelopmentStatusID":"14","companyTruncated":"Autobahn Therapeutics \/ Newpath Partners"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Partnership","leadProduct":"Lithium Salicylate Proline","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alzamend Neuro \/ Massachusetts General Hospital","highestDevelopmentStatusID":"14","companyTruncated":"Alzamend Neuro \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"Emory University","sponsor":"MAPS","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","date":"August 2024","year":"2024","type":"Funding","leadProduct":"3,4-Methylenedioxymethamphetamine HCl","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Emory University","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Emory University \/ MAPS","highestDevelopmentStatusID":"14","companyTruncated":"Emory University \/ MAPS"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Hercules Capital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Financing","leadProduct":"Casdatifan","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arcus Biosciences \/ Hercules Capital","highestDevelopmentStatusID":"14","companyTruncated":"Arcus Biosciences \/ Hercules Capital"},{"orgOrder":0,"company":"YolTech Therapeutics","sponsor":"SHENZHEN SALUBRIS PHARMACEUTICALS","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Licensing Agreement","leadProduct":"YOLT-101","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"YolTech Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"YolTech Therapeutics \/ SHENZHEN SALUBRIS PHARMACEUTICALS CO.LTD","highestDevelopmentStatusID":"14","companyTruncated":"YolTech Therapeutics \/ SHENZHEN SALUBRIS PHARMACEUTICALS CO.LTD"},{"orgOrder":0,"company":"SciSparc","sponsor":"Polyrizon","pharmaFlowCategory":"D","upfrontCash":"$3.0 million","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Cannabinoid-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"SciSparc","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"SciSparc \/ Polyrizon","highestDevelopmentStatusID":"14","companyTruncated":"SciSparc \/ Polyrizon"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Qatar Datamation Systems","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Podiatry","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Agreement","leadProduct":"Polyhexanide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kane Biotech \/ Qatar Datamation Systems","highestDevelopmentStatusID":"14","companyTruncated":"Kane Biotech \/ Qatar Datamation Systems"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Private Placement","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BetterLife Pharma \/ Undisclosed","highestDevelopmentStatusID":"14","companyTruncated":"BetterLife Pharma \/ Undisclosed"},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Bpifrance","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Funding","leadProduct":"ICT01","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ImCheck Therapeutics","amount2":0.02,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ImCheck Therapeutics \/ Bpifrance","highestDevelopmentStatusID":"14","companyTruncated":"ImCheck Therapeutics \/ Bpifrance"},{"orgOrder":0,"company":"RevolKa","sponsor":"DEEPCORE","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Series A Financing","leadProduct":"RKD001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"RevolKa","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"RevolKa \/ DEEPCORE","highestDevelopmentStatusID":"14","companyTruncated":"RevolKa \/ DEEPCORE"},{"orgOrder":0,"company":"Evoq Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","date":"August 2024","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Evoq Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Evoq Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"14","companyTruncated":"Evoq Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Hanmi Pharmaceutical","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Financing","leadProduct":"Tuspetinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aptose Biosciences \/ Hanmi Pharmaceutical","highestDevelopmentStatusID":"14","companyTruncated":"Aptose Biosciences \/ Hanmi Pharmaceutical"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Shanghai Allist Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"$28.1 million","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Glecirasib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Jacobio Pharma","amount2":0.13,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Jacobio Pharma \/ Shanghai Allist Pharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"Jacobio Pharma \/ Shanghai Allist Pharmaceuticals"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Ustekinumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Biocon Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Biocon Biologics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"14","companyTruncated":"Biocon Biologics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Mestag Therapeutics","sponsor":"Innovate UK","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Funding","leadProduct":"MST-0300","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Mestag Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Mestag Therapeutics \/ Innovate UK","highestDevelopmentStatusID":"14","companyTruncated":"Mestag Therapeutics \/ Innovate UK"},{"orgOrder":0,"company":"CancerVAX","sponsor":"Flashpoint Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"August 2024","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"CancerVAX","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"CancerVAX \/ Flashpoint Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"CancerVAX \/ Flashpoint Therapeutics"},{"orgOrder":0,"company":"Theolytics","sponsor":"Innovate UK","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Funding","leadProduct":"THEO-260","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Theolytics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Theolytics \/ Innovate UK","highestDevelopmentStatusID":"14","companyTruncated":"Theolytics \/ Innovate UK"},{"orgOrder":0,"company":"Syntekabio","sponsor":"Enamine Ltd","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Syntekabio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Syntekabio \/ Enamine Ltd","highestDevelopmentStatusID":"14","companyTruncated":"Syntekabio \/ Enamine Ltd"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"AVZO-021","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Avenzo Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Avenzo Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"14","companyTruncated":"Avenzo Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Alkem Laboratories","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Vonoprazan Fumarate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Takeda Pharmaceutical \/ Alkem Laboratories","highestDevelopmentStatusID":"14","companyTruncated":"Takeda Pharmaceutical \/ Alkem Laboratories"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","date":"September 2024","year":"2024","type":"Financing","leadProduct":"Palopegteriparatide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ascendis Pharma","amount2":0.14999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ascendis Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"14","companyTruncated":"Ascendis Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Oragenics","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Oragenics \/ Dawson James Securities","highestDevelopmentStatusID":"14","companyTruncated":"Oragenics \/ Dawson James Securities"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Veld Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Peptide","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"Melphalan Flufenamide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Oncopeptides \/ Veld Pharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"Oncopeptides \/ Veld Pharmaceuticals"},{"orgOrder":0,"company":"PsyLabs","sponsor":"Psyence Biomed","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","date":"September 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Psilocybine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"PsyLabs","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"PsyLabs \/ Psyence Biomed","highestDevelopmentStatusID":"14","companyTruncated":"PsyLabs \/ Psyence Biomed"},{"orgOrder":0,"company":"Tempus","sponsor":"BioNTech","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Tempus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Tempus \/ BioNTech","highestDevelopmentStatusID":"14","companyTruncated":"Tempus \/ BioNTech"},{"orgOrder":0,"company":"Eva Pharma","sponsor":"Eli Lilly","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"Baricitinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eva Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eva Pharma \/ Eli Lilly","highestDevelopmentStatusID":"14","companyTruncated":"Eva Pharma \/ Eli Lilly"},{"orgOrder":0,"company":"Oragenics","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Oragenics \/ Dawson James Securities","highestDevelopmentStatusID":"14","companyTruncated":"Oragenics \/ Dawson James Securities"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Funding","leadProduct":"TTX-MC138","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"14","companyTruncated":"TransCode Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Biotherapeutics","sponsor":"NImmune Biopharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"LANCL-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Biotherapeutics \/ NImmune Biopharma","highestDevelopmentStatusID":"14","companyTruncated":"Biotherapeutics \/ NImmune Biopharma"},{"orgOrder":0,"company":"Atamyo Therapeutics","sponsor":"The Dion Foundation","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Partnership","leadProduct":"ATA-200","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Atamyo Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Atamyo Therapeutics \/ The Dion Foundation","highestDevelopmentStatusID":"14","companyTruncated":"Atamyo Therapeutics \/ The Dion Foundation"},{"orgOrder":0,"company":"X-Chem","sponsor":"Evotec","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"X-Chem","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"X-Chem \/ Evotec","highestDevelopmentStatusID":"14","companyTruncated":"X-Chem \/ Evotec"},{"orgOrder":0,"company":"Alopexx Oncology","sponsor":"Biotech Consortia","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"September 2024","year":"2024","type":"Financing","leadProduct":"AV0328","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alopexx Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alopexx Oncology \/ Biotech Consortia","highestDevelopmentStatusID":"14","companyTruncated":"Alopexx Oncology \/ Biotech Consortia"},{"orgOrder":0,"company":"Epsilogen","sponsor":"British Patient Capital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Series B Financing","leadProduct":"MOv18 IgE","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Epsilogen","amount2":0.050000000000000003,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Epsilogen \/ British Patient Capital","highestDevelopmentStatusID":"14","companyTruncated":"Epsilogen \/ British Patient Capital"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"GENESIS Pharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Agreement","leadProduct":"Vamorolone","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Santhera Pharmaceuticals \/ GENESIS Pharma","highestDevelopmentStatusID":"14","companyTruncated":"Santhera Pharmaceuticals \/ GENESIS Pharma"},{"orgOrder":0,"company":"Superluminal Medicines","sponsor":"RA Capital Management","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Superluminal Medicines","amount2":0.12,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Superluminal Medicines \/ RA Capital Management","highestDevelopmentStatusID":"14","companyTruncated":"Superluminal Medicines \/ RA Capital Management"},{"orgOrder":0,"company":"Osivax","sponsor":"KM Biologics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"September 2024","year":"2024","type":"Licensing Agreement","leadProduct":"OVX836","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Osivax \/ KM Biologics","highestDevelopmentStatusID":"14","companyTruncated":"Osivax \/ KM Biologics"},{"orgOrder":0,"company":"Sanofi","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Licensing Agreement","leadProduct":"AMX-818","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sanofi \/ Vir Biotechnology","highestDevelopmentStatusID":"14","companyTruncated":"Sanofi \/ Vir Biotechnology"},{"orgOrder":0,"company":"OmniaBio","sponsor":"Somite Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"SMT-M01","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"OmniaBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"OmniaBio \/ Somite Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"OmniaBio \/ Somite Therapeutics"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","date":"September 2024","year":"2024","type":"Public Offering","leadProduct":"MBX 2109","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"MBX Biosciences","amount2":0.16,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"MBX Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"14","companyTruncated":"MBX Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Public Offering","leadProduct":"TERN-701","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Terns Pharmaceuticals","amount2":0.14999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Terns Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"14","companyTruncated":"Terns Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Alopexx Oncology","sponsor":"Bharat Biotech","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"AV0328","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alopexx Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alopexx Oncology \/ Bharat Biotech","highestDevelopmentStatusID":"14","companyTruncated":"Alopexx Oncology \/ Bharat Biotech"},{"orgOrder":0,"company":"Abvance Therapeutics","sponsor":"Helmsley Charitable Trust","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","date":"September 2024","year":"2024","type":"Financing","leadProduct":"Insulin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Abvance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Abvance Therapeutics \/ Helmsley Charitable Trust","highestDevelopmentStatusID":"14","companyTruncated":"Abvance Therapeutics \/ Helmsley Charitable Trust"},{"orgOrder":0,"company":"Xencor","sponsor":"Leerink Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Public Offering","leadProduct":"Cabazitaxel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Xencor \/ Leerink Partners","highestDevelopmentStatusID":"14","companyTruncated":"Xencor \/ Leerink Partners"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Public Offering","leadProduct":"Veligrotug","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Viridian Therapeutics","amount2":0.17000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Viridian Therapeutics \/ Jefferies","highestDevelopmentStatusID":"14","companyTruncated":"Viridian Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Kallyope","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","date":"September 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Peptide-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kallyope","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kallyope \/ Novo Nordisk","highestDevelopmentStatusID":"14","companyTruncated":"Kallyope \/ Novo Nordisk"},{"orgOrder":0,"company":"Genesis Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Genesis Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Genesis Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"14","companyTruncated":"Genesis Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Expanded Collaboration","leadProduct":"CAR-M-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Carisma Therapeutics \/ Moderna Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"Carisma Therapeutics \/ Moderna Therapeutics"},{"orgOrder":0,"company":"GC Cell","sponsor":"PT Bifarma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Licensing Agreement","leadProduct":"CIK-based Cell Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"GC Cell","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"GC Cell \/ PT Bifarma","highestDevelopmentStatusID":"14","companyTruncated":"GC Cell \/ PT Bifarma"},{"orgOrder":0,"company":"Quantum BioPharma","sponsor":"Ingenu CRO","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Agreement","leadProduct":"Lucid-21-302","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Quantum BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Quantum BioPharma \/ Ingenu CRO","highestDevelopmentStatusID":"14","companyTruncated":"Quantum BioPharma \/ Ingenu CRO"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Abacus Medicine","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Agreement","leadProduct":"Maralixibat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Mirum Pharmaceuticals \/ Abacus Medicine","highestDevelopmentStatusID":"14","companyTruncated":"Mirum Pharmaceuticals \/ Abacus Medicine"},{"orgOrder":0,"company":"Radiant Biotherapeutics","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Series A Financing","leadProduct":"Antibody-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Radiant Biotherapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Radiant Biotherapeutics \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"14","companyTruncated":"Radiant Biotherapeutics \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Xencor","sponsor":"Leerink Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Public Offering","leadProduct":"Cabazitaxel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Xencor","amount2":0.17999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Xencor \/ Leerink Partners","highestDevelopmentStatusID":"14","companyTruncated":"Xencor \/ Leerink Partners"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Undisclosed","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"September 2024","year":"2024","type":"Private Placement","leadProduct":"BVX-0918","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Biovaxys \/ Undisclosed","highestDevelopmentStatusID":"14","companyTruncated":"Biovaxys \/ Undisclosed"},{"orgOrder":0,"company":"Integrated Nanotherapeutics","sponsor":"Breakthrough T1D","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Endocrinology","country":"","productType":"Undisclosed","date":"September 2024","year":"2024","type":"Funding","leadProduct":"LNP-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Integrated Nanotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Integrated Nanotherapeutics \/ Breakthrough T1D","highestDevelopmentStatusID":"14","companyTruncated":"Integrated Nanotherapeutics \/ Breakthrough T1D"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"GIBF2","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Financing","leadProduct":"Rifabutin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioVersys AG","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioVersys AG \/ GIBF2","highestDevelopmentStatusID":"14","companyTruncated":"BioVersys AG \/ GIBF2"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","date":"September 2024","year":"2024","type":"Public Offering","leadProduct":"MBX 2109","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"MBX Biosciences","amount2":0.16,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"MBX Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"14","companyTruncated":"MBX Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Public Offering","leadProduct":"TERN-701","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Terns Pharmaceuticals","amount2":0.17000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Terns Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"14","companyTruncated":"Terns Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Enable Injections","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","date":"September 2024","year":"2024","type":"Agreement","leadProduct":"Pegcetacoplan","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Enable Injections","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Enable Injections \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"14","companyTruncated":"Enable Injections \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Biosplice","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"Cirtuvivint","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Biosplice","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Biosplice \/ National Cancer Institute","highestDevelopmentStatusID":"14","companyTruncated":"Biosplice \/ National Cancer Institute"},{"orgOrder":0,"company":"F2G Limited","sponsor":"AMR Action Fund","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Financing","leadProduct":"Olorofim","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"F2G Limited","amount2":0.10000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"F2G Limited \/ AMR Action Fund","highestDevelopmentStatusID":"14","companyTruncated":"F2G Limited \/ AMR Action Fund"},{"orgOrder":0,"company":"Epitopea","sponsor":"Innovate UK","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Funding","leadProduct":"Cryptigen-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Epitopea","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Epitopea \/ Innovate UK","highestDevelopmentStatusID":"14","companyTruncated":"Epitopea \/ Innovate UK"},{"orgOrder":0,"company":"Sinopia Biosciences","sponsor":"NIDCR","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sinopia Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sinopia Biosciences \/ NIDCR","highestDevelopmentStatusID":"14","companyTruncated":"Sinopia Biosciences \/ NIDCR"},{"orgOrder":0,"company":"Turbine","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Turbine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Turbine \/ Ono Pharmaceutical","highestDevelopmentStatusID":"14","companyTruncated":"Turbine \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Umoja Biopharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"CAR-T Cell-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Umoja Biopharma","highestDevelopmentStatusID":"14","companyTruncated":"Nona Biosciences \/ Umoja Biopharma"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"QIMR Berghofer Medical Research Institute","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Paxalisib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kazia Therapeutics \/ QIMR Berghofer Medical Research Institute","highestDevelopmentStatusID":"14","companyTruncated":"Kazia Therapeutics \/ QIMR Berghofer Medical Research Institute"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Series D Financing","leadProduct":"ONL1204","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ONL Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ONL Therapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":"14","companyTruncated":"ONL Therapeutics \/ Johnson & Johnson"},{"orgOrder":0,"company":"GI Innovation","sponsor":"Merck & Co","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Collaboration","leadProduct":"GI-102","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"GI Innovation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"GI Innovation \/ Merck & Co","highestDevelopmentStatusID":"14","companyTruncated":"GI Innovation \/ Merck & Co"},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Private Placement","leadProduct":"Cannabidiol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Avicanna \/ Undisclosed","highestDevelopmentStatusID":"14","companyTruncated":"Avicanna \/ Undisclosed"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Undisclosed","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Public Offering","leadProduct":"Allogeneic Gamma Delta T Cell Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"TC BioPharm \/ Undisclosed","highestDevelopmentStatusID":"14","companyTruncated":"TC BioPharm \/ Undisclosed"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","date":"September 2024","year":"2024","type":"Public Offering","leadProduct":"MBX 2109","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"MBX Biosciences","amount2":0.19,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"MBX Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"14","companyTruncated":"MBX Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"Kairos Pharma","sponsor":"Boustead Securities, LLC","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Public Offering","leadProduct":"Apalutamide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kairos Pharma","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kairos Pharma \/ Boustead Securities, LLC","highestDevelopmentStatusID":"14","companyTruncated":"Kairos Pharma \/ Boustead Securities, LLC"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Nuance Pharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Bentonite","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Altamira Therapeutics \/ Nuance Pharma","highestDevelopmentStatusID":"14","companyTruncated":"Altamira Therapeutics \/ Nuance Pharma"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"CPRIT","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Funding","leadProduct":"Sirolimus","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Biodexa Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Biodexa Pharmaceuticals \/ CPRIT","highestDevelopmentStatusID":"14","companyTruncated":"Biodexa Pharmaceuticals \/ CPRIT"},{"orgOrder":0,"company":"BioVie","sponsor":"OHRO","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Funding","leadProduct":"Bezisterim","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioVie","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioVie \/ OHRO","highestDevelopmentStatusID":"14","companyTruncated":"BioVie \/ OHRO"},{"orgOrder":0,"company":"Debiopharm","sponsor":"WhiteLab Genomics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","date":"September 2024","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Debiopharm \/ WhiteLab Genomics","highestDevelopmentStatusID":"14","companyTruncated":"Debiopharm \/ WhiteLab Genomics"},{"orgOrder":0,"company":"Wacker Chemie AG","sponsor":"MinervaX ApS","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"GBS-NN\/NN2","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Wacker Chemie AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Wacker Chemie AG \/ MinervaX ApS","highestDevelopmentStatusID":"14","companyTruncated":"Wacker Chemie AG \/ MinervaX ApS"},{"orgOrder":0,"company":"Nuvalent","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Public Offering","leadProduct":"Zidesamtinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Nuvalent \/ J.P. Morgan","highestDevelopmentStatusID":"14","companyTruncated":"Nuvalent \/ J.P. Morgan"},{"orgOrder":0,"company":"Kairos Pharma","sponsor":"Boustead Securities, LLC","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Public Offering","leadProduct":"Apalutamide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kairos Pharma","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kairos Pharma \/ Boustead Securities, LLC","highestDevelopmentStatusID":"14","companyTruncated":"Kairos Pharma \/ Boustead Securities, LLC"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Variational AI","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Rakovina Therapeutics \/ Variational AI","highestDevelopmentStatusID":"14","companyTruncated":"Rakovina Therapeutics \/ Variational AI"},{"orgOrder":0,"company":"Brenus Pharma","sponsor":"Angelor","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"September 2024","year":"2024","type":"Series A Financing","leadProduct":"STC-1010","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Brenus Pharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Brenus Pharma \/ Angelor","highestDevelopmentStatusID":"14","companyTruncated":"Brenus Pharma \/ Angelor"},{"orgOrder":0,"company":"Nexilico","sponsor":"Siolta Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"Microbial-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Nexilico","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Nexilico \/ Siolta Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"Nexilico \/ Siolta Therapeutics"},{"orgOrder":0,"company":"Vivtex","sponsor":"Orbis Medicines","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"Macrocycle-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Vivtex","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Vivtex \/ Orbis Medicines","highestDevelopmentStatusID":"14","companyTruncated":"Vivtex \/ Orbis Medicines"},{"orgOrder":0,"company":"Nura Bio","sponsor":"The Column Group","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Series A Financing","leadProduct":"Caffeine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Nura Bio","amount2":0.14000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Nura Bio \/ The Column Group","highestDevelopmentStatusID":"14","companyTruncated":"Nura Bio \/ The Column Group"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Private Placement","leadProduct":"DMT310","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Dermata Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"14","companyTruncated":"Dermata Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"OpenBench","sponsor":"ORIC Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"OpenBench","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"OpenBench \/ ORIC Pharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"OpenBench \/ ORIC Pharmaceuticals"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Cebina","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Charles River Laboratories, Inc \/ CEBINA","highestDevelopmentStatusID":"14","companyTruncated":"Charles River Laboratories, Inc \/ CEBINA"},{"orgOrder":0,"company":"Unravel Biosciences","sponsor":"Jackson Laboratory","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Undisclosed","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Unravel Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Unravel Biosciences \/ Jackson Laboratory","highestDevelopmentStatusID":"14","companyTruncated":"Unravel Biosciences \/ Jackson Laboratory"},{"orgOrder":0,"company":"The Ritedose Corporation","sponsor":"Verona Pharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Partnership","leadProduct":"Ensifentrine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"The Ritedose Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"The Ritedose Corporation \/ Verona Pharma","highestDevelopmentStatusID":"14","companyTruncated":"The Ritedose Corporation \/ Verona Pharma"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"BARDA","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Funding","leadProduct":"Fosmanogepix","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Basilea Pharmaceutica","amount2":0.029999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Basilea Pharmaceutica \/ BARDA","highestDevelopmentStatusID":"14","companyTruncated":"Basilea Pharmaceutica \/ BARDA"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Numan","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Partnership","leadProduct":"Testosterone Undecanoate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Marius Pharmaceuticals \/ Numan","highestDevelopmentStatusID":"14","companyTruncated":"Marius Pharmaceuticals \/ Numan"},{"orgOrder":0,"company":"Ichnos Glenmark Innovation","sponsor":"Certara","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"ISB 2001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ichnos Glenmark Innovation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ichnos Glenmark Innovation \/ Certara","highestDevelopmentStatusID":"14","companyTruncated":"Ichnos Glenmark Innovation \/ Certara"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Gavi","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"September 2024","year":"2024","type":"Agreement","leadProduct":"Modified Vaccinia Ankara","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bavarian Nordic \/ Gavi","highestDevelopmentStatusID":"14","companyTruncated":"Bavarian Nordic \/ Gavi"},{"orgOrder":0,"company":"Axcelead","sponsor":"Eli Lilly","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Undisclosed","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Axcelead","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Axcelead \/ Eli Lilly","highestDevelopmentStatusID":"14","companyTruncated":"Axcelead \/ Eli Lilly"},{"orgOrder":0,"company":"Glytherix","sponsor":"SHINE Technologies","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Agreement","leadProduct":"177Lu-DOTA-Miltuximab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Glytherix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Glytherix \/ SHINE Technologies","highestDevelopmentStatusID":"14","companyTruncated":"Glytherix \/ SHINE Technologies"},{"orgOrder":0,"company":"Expert Systems","sponsor":"Polku Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Expert Systems","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Expert Systems \/ Polku Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"Expert Systems \/ Polku Therapeutics"},{"orgOrder":0,"company":"Adare Pharma Solutions","sponsor":"Laxxon Medical","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Undisclosed","date":"September 2024","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Adare Pharma Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Adare Pharma Solutions \/ Laxxon Medical","highestDevelopmentStatusID":"14","companyTruncated":"Adare Pharma Solutions \/ Laxxon Medical"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Vonoprazan Fumarate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Takeda Pharmaceutical \/ Lupin Ltd","highestDevelopmentStatusID":"14","companyTruncated":"Takeda Pharmaceutical \/ Lupin Ltd"},{"orgOrder":0,"company":"Biolexis Therapeutics","sponsor":"Halia Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Biolexis Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Biolexis Therapeutics \/ Halia Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"Biolexis Therapeutics \/ Halia Therapeutics"},{"orgOrder":0,"company":"Axcelead","sponsor":"Acadia Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Undisclosed","date":"September 2024","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Axcelead","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Axcelead \/ Acadia Pharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"Axcelead \/ Acadia Pharmaceuticals"},{"orgOrder":0,"company":"CorMedix","sponsor":"Undisclosed","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Agreement","leadProduct":"Taurolidine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"CorMedix \/ Undisclosed","highestDevelopmentStatusID":"14","companyTruncated":"CorMedix \/ Undisclosed"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Funding","leadProduct":"Foralumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Tiziana Life Sciences \/ National Institutes of Health","highestDevelopmentStatusID":"14","companyTruncated":"Tiziana Life Sciences \/ National Institutes of Health"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Public Offering","leadProduct":"Mipletamig","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aptevo Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"14","companyTruncated":"Aptevo Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Asamedic","sponsor":"Bormioli Pharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Partnership","leadProduct":"Aspirin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Asamedic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Asamedic \/ Bormioli Pharma","highestDevelopmentStatusID":"14","companyTruncated":"Asamedic \/ Bormioli Pharma"},{"orgOrder":0,"company":"ME Therapeutics","sponsor":"Nanovation Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"mRNA-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ME Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ME Therapeutics \/ Nanovation Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"ME Therapeutics \/ Nanovation Therapeutics"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"BIOSYENT PHARMA INC","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Acquisition","leadProduct":"Tibolone","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Mithra Pharmaceuticals \/ BioSyent Pharma Inc","highestDevelopmentStatusID":"14","companyTruncated":"Mithra Pharmaceuticals \/ BioSyent Pharma Inc"},{"orgOrder":0,"company":"Fortress Biotech","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Public Offering","leadProduct":"Carboplatin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Fortress Biotech","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Fortress Biotech \/ Alliance Global Partners","highestDevelopmentStatusID":"14","companyTruncated":"Fortress Biotech \/ Alliance Global Partners"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Glaukos","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Licensing Agreement","leadProduct":"NCX 1728","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Nicox SA \/ Glaukos","highestDevelopmentStatusID":"14","companyTruncated":"Nicox SA \/ Glaukos"},{"orgOrder":0,"company":"Vicebio","sponsor":"TCGX","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"September 2024","year":"2024","type":"Series B Financing","leadProduct":"VXB-241","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Vicebio","amount2":0.10000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Vicebio \/ TCGX","highestDevelopmentStatusID":"14","companyTruncated":"Vicebio \/ TCGX"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"SWK Funding LLC","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Financing","leadProduct":"Hypochlorous Acid","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Relief Therapeutics","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Relief Therapeutics \/ SWK Funding LLC","highestDevelopmentStatusID":"14","companyTruncated":"Relief Therapeutics \/ SWK Funding LLC"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Private Placement","leadProduct":"DMT310","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Dermata Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"14","companyTruncated":"Dermata Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Public Offering","leadProduct":"Mipletamig","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aptevo Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"14","companyTruncated":"Aptevo Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Sanofi","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Agreement","leadProduct":"VTX3232","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ventyx Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ventyx Biosciences \/ Sanofi","highestDevelopmentStatusID":"14","companyTruncated":"Ventyx Biosciences \/ Sanofi"},{"orgOrder":0,"company":"BioAtla","sponsor":"Context Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Licensing Agreement","leadProduct":"BA3362","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioAtla","amount2":0.13,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioAtla \/ Context Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"BioAtla \/ Context Therapeutics"},{"orgOrder":0,"company":"LIfT Biosciences","sponsor":"Sijbrandij Foundation","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Series A Financing","leadProduct":"Immunomodulatory Alpha Neutrophils","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"LIfT Biosciences","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"LIfT Biosciences \/ Sijbrandij Foundation","highestDevelopmentStatusID":"14","companyTruncated":"LIfT Biosciences \/ Sijbrandij Foundation"},{"orgOrder":0,"company":"Genespire","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Series B Financing","leadProduct":"GENE202","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Genespire","amount2":0.050000000000000003,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Genespire \/ Sofinnova Partners","highestDevelopmentStatusID":"14","companyTruncated":"Genespire \/ Sofinnova Partners"},{"orgOrder":0,"company":"Kairos Pharma","sponsor":"PreCheck Health Services","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"Apalutamide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kairos Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kairos Pharma \/ PreCheck Health Services","highestDevelopmentStatusID":"14","companyTruncated":"Kairos Pharma \/ PreCheck Health Services"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"BARDA","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"September 2024","year":"2024","type":"Funding","leadProduct":"Smallpox and Monkeypox Vaccine, Live, Nonreplicating","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bavarian Nordic","amount2":0.059999999999999998,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bavarian Nordic \/ BARDA","highestDevelopmentStatusID":"14","companyTruncated":"Bavarian Nordic \/ BARDA"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Araris Biotech","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Acquisition","leadProduct":"ADC-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Innate Pharma \/ Araris Biotech","highestDevelopmentStatusID":"14","companyTruncated":"Innate Pharma \/ Araris Biotech"},{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"eXmoor pharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Partnership","leadProduct":"QEL-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Quell Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Quell Therapeutics \/ eXmoor pharma","highestDevelopmentStatusID":"14","companyTruncated":"Quell Therapeutics \/ eXmoor pharma"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"The Benchmark Company, LLC","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Financing","leadProduct":"Galantamine Benzoate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alpha Cognition","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alpha Cognition \/ The Benchmark Company, LLC","highestDevelopmentStatusID":"14","companyTruncated":"Alpha Cognition \/ The Benchmark Company, LLC"},{"orgOrder":0,"company":"Belief BioMed","sponsor":"AskBio","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Technology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"Gene-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Belief BioMed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Belief BioMed \/ AskBio","highestDevelopmentStatusID":"14","companyTruncated":"Belief BioMed \/ AskBio"},{"orgOrder":0,"company":"pharma&","sponsor":"Tolmar","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Agreement","leadProduct":"Rucaparib Camsylate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"pharma&","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"pharma& \/ Tolmar","highestDevelopmentStatusID":"14","companyTruncated":"pharma& \/ Tolmar"},{"orgOrder":0,"company":"Longbio Pharma","sponsor":"Qiming Venture Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Series B Financing","leadProduct":"LP-003","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Longbio Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Longbio Pharma \/ Qiming Venture Partners","highestDevelopmentStatusID":"14","companyTruncated":"Longbio Pharma \/ Qiming Venture Partners"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Alkyon Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"Antibody-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Alkyon Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"Nona Biosciences \/ Alkyon Therapeutics"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Leiden University Medical Center","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"Ibezapolstat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Acurx Pharmaceuticals \/ Leiden University Medical Center","highestDevelopmentStatusID":"14","companyTruncated":"Acurx Pharmaceuticals \/ Leiden University Medical Center"},{"orgOrder":0,"company":"OncoC4","sponsor":"AcroImmune","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Merger","leadProduct":"AI-071","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"OncoC4","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"OncoC4 \/ AcroImmune","highestDevelopmentStatusID":"14","companyTruncated":"OncoC4 \/ AcroImmune"},{"orgOrder":0,"company":"Aurigene Oncology","sponsor":"ICMR","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aurigene Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aurigene Oncology \/ ICMR","highestDevelopmentStatusID":"14","companyTruncated":"Aurigene Oncology \/ ICMR"},{"orgOrder":0,"company":"Epitopea","sponsor":"Universit\u00e9 de Montr\u00e9al","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"RNA-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Epitopea","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Epitopea \/ Universit\u00e9 de Montr\u00e9al","highestDevelopmentStatusID":"14","companyTruncated":"Epitopea \/ Universit\u00e9 de Montr\u00e9al"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Merck & Co","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"September 2024","year":"2024","type":"Expanded Collaboration","leadProduct":"EVX-B2","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Evaxion Biotech \/ Merck & Co","highestDevelopmentStatusID":"14","companyTruncated":"Evaxion Biotech \/ Merck & Co"},{"orgOrder":0,"company":"Tabuk Pharmaceuticals","sponsor":"Biocon","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Endocrinology","country":"","productType":"Undisclosed","date":"September 2024","year":"2024","type":"Licensing Agreement","leadProduct":"GLP-1-based Drug","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Tabuk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Tabuk Pharmaceuticals \/ Biocon","highestDevelopmentStatusID":"14","companyTruncated":"Tabuk Pharmaceuticals \/ Biocon"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Gregory George","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Financing","leadProduct":"Remestemcel-L","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Mesoblast","amount2":0.050000000000000003,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Mesoblast \/ Gregory George","highestDevelopmentStatusID":"14","companyTruncated":"Mesoblast \/ Gregory George"},{"orgOrder":0,"company":"Poxel","sponsor":"OrbiMed","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Financing","leadProduct":"Imeglimin Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Poxel","amount2":0.050000000000000003,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Poxel \/ OrbiMed","highestDevelopmentStatusID":"14","companyTruncated":"Poxel \/ OrbiMed"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Indivior","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Addex Therapeutics","amount2":0.34000000000000002,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Addex Therapeutics \/ Indivior","highestDevelopmentStatusID":"14","companyTruncated":"Addex Therapeutics \/ Indivior"},{"orgOrder":0,"company":"Ypsomed","sponsor":"Astria Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Partnership","leadProduct":"Navenibart","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ypsomed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ypsomed \/ Astria Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"Ypsomed \/ Astria Therapeutics"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Cenra Healthcare","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"September 2024","year":"2024","type":"Agreement","leadProduct":"Covid-19 Vaccine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Cenra Healthcare","highestDevelopmentStatusID":"14","companyTruncated":"Moderna Therapeutics \/ Cenra Healthcare"},{"orgOrder":0,"company":"Cartherics","sponsor":"Undisclosed","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Private Placement","leadProduct":"CTH-401","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cartherics","amount2":0.02,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cartherics \/ Undisclosed","highestDevelopmentStatusID":"14","companyTruncated":"Cartherics \/ Undisclosed"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Shionogi","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Sleep","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Partnership","leadProduct":"Daridorexant Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sosei Group Corporation \/ Shionogi","highestDevelopmentStatusID":"14","companyTruncated":"Sosei Group Corporation \/ Shionogi"},{"orgOrder":0,"company":"LeaderMed Group","sponsor":"Combiphar","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"LM-008","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"LeaderMed Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"LeaderMed Group \/ Combiphar","highestDevelopmentStatusID":"14","companyTruncated":"LeaderMed Group \/ Combiphar"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"T-Cell Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Prime Medicine","amount2":3.6099999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Prime Medicine \/ Bristol Myers Squibb","highestDevelopmentStatusID":"14","companyTruncated":"Prime Medicine \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"U.S. Department of Health and Human Services","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Funding","leadProduct":"Peramivir","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioCryst Pharmaceuticals","amount2":0.070000000000000007,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioCryst Pharmaceuticals \/ U.S. Department of Health and Human Services","highestDevelopmentStatusID":"14","companyTruncated":"BioCryst Pharmaceuticals \/ U.S. Department of Health and Human Services"},{"orgOrder":0,"company":"Tessellate BIO","sponsor":"Omico","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Tessellate BIO","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Tessellate BIO \/ Omico","highestDevelopmentStatusID":"14","companyTruncated":"Tessellate BIO \/ Omico"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Prevail Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"October 2024","year":"2024","type":"Financing","leadProduct":"HEMO-CAR-T Cell Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Hemogenyx Pharmaceuticals \/ Prevail Partners","highestDevelopmentStatusID":"14","companyTruncated":"Hemogenyx Pharmaceuticals \/ Prevail Partners"},{"orgOrder":0,"company":"Aytu BioPharma","sponsor":"Lupin Pharma Canada","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Agreement","leadProduct":"Amphetamine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aytu BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aytu BioPharma \/ Lupin Pharma Canada","highestDevelopmentStatusID":"14","companyTruncated":"Aytu BioPharma \/ Lupin Pharma Canada"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"AstraZeneca","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Collaboration","leadProduct":"Casdatifan","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arcus Biosciences \/ AstraZeneca","highestDevelopmentStatusID":"14","companyTruncated":"Arcus Biosciences \/ AstraZeneca"},{"orgOrder":0,"company":"TNF Pharmaceuticals","sponsor":"Prevail Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Financing","leadProduct":"Isomyosamine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"TNF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"TNF Pharmaceuticals \/ Prevail Partners","highestDevelopmentStatusID":"14","companyTruncated":"TNF Pharmaceuticals \/ Prevail Partners"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Viatris","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Lenacapavir","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Gilead Sciences \/ Viatris","highestDevelopmentStatusID":"14","companyTruncated":"Gilead Sciences \/ Viatris"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Charles River Laboratories, Inc \/ H. Lundbeck AS","highestDevelopmentStatusID":"14","companyTruncated":"Charles River Laboratories, Inc \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Xcell Biosciences","sponsor":"AmplifyBio","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"October 2024","year":"2024","type":"Expanded Collaboration","leadProduct":"TCR-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Xcell Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Xcell Biosciences \/ AmplifyBio","highestDevelopmentStatusID":"14","companyTruncated":"Xcell Biosciences \/ AmplifyBio"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Biotheus","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Agreement","leadProduct":"TATX-20","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ImmunoPrecise","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ImmunoPrecise \/ Biotheus","highestDevelopmentStatusID":"14","companyTruncated":"ImmunoPrecise \/ Biotheus"},{"orgOrder":0,"company":"Resolution Therapeutics","sponsor":"Syncona","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Cell and Gene therapy","date":"October 2024","year":"2024","type":"Series B Financing","leadProduct":"RTX001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Resolution Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Resolution Therapeutics \/ Syncona","highestDevelopmentStatusID":"14","companyTruncated":"Resolution Therapeutics \/ Syncona"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Hetero","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Lenacapavir","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Gilead Sciences \/ Hetero","highestDevelopmentStatusID":"14","companyTruncated":"Gilead Sciences \/ Hetero"},{"orgOrder":0,"company":"Triveni Bio","sponsor":"Goldman Sachs Alternatives","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Series B Financing","leadProduct":"TRIV-509","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Triveni Bio","amount2":0.12,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Triveni Bio \/ Goldman Sachs Alternatives","highestDevelopmentStatusID":"14","companyTruncated":"Triveni Bio \/ Goldman Sachs Alternatives"},{"orgOrder":0,"company":"LoQus23 Therapeutics","sponsor":"Forbion","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"LoQus23 Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"LoQus23 Therapeutics \/ Forbion","highestDevelopmentStatusID":"14","companyTruncated":"LoQus23 Therapeutics \/ Forbion"},{"orgOrder":0,"company":"Enara Bio","sponsor":"Pfizer Ventures","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"October 2024","year":"2024","type":"Series B Financing","leadProduct":"TCR-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Enara Bio","amount2":0.029999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Enara Bio \/ Pfizer Ventures","highestDevelopmentStatusID":"14","companyTruncated":"Enara Bio \/ Pfizer Ventures"},{"orgOrder":0,"company":"Citryll","sponsor":"ReumaNederland","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Funding","leadProduct":"CIT-013","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Citryll","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Citryll \/ ReumaNederland","highestDevelopmentStatusID":"14","companyTruncated":"Citryll \/ ReumaNederland"},{"orgOrder":0,"company":"Kineta","sponsor":"TuHURA Biosciences","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Agreement","leadProduct":"KVA12123","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kineta","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kineta \/ TuHURA Biosciences","highestDevelopmentStatusID":"14","companyTruncated":"Kineta \/ TuHURA Biosciences"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"SymBiosis","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Public Offering","leadProduct":"CNM-Au8","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Clene Nanomedicine","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Clene Nanomedicine \/ SymBiosis","highestDevelopmentStatusID":"14","companyTruncated":"Clene Nanomedicine \/ SymBiosis"},{"orgOrder":0,"company":"IN8bio","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"October 2024","year":"2024","type":"Private Placement","leadProduct":"INB-100","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"IN8bio","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"IN8bio \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"14","companyTruncated":"IN8bio \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"PDRadiopharma","sponsor":"CURIUM US LLC","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Partnership","leadProduct":"177Lu-PSMA-I&T","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"PDRadiopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"PDRadiopharma \/ CURIUM US LLC","highestDevelopmentStatusID":"14","companyTruncated":"PDRadiopharma \/ CURIUM US LLC"},{"orgOrder":0,"company":"Kailera Therapeutics","sponsor":"Atlas Venture","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","date":"October 2024","year":"2024","type":"Series A Financing","leadProduct":"KAI-9531","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kailera Therapeutics","amount2":0.40000000000000002,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kailera Therapeutics \/ Atlas Venture","highestDevelopmentStatusID":"14","companyTruncated":"Kailera Therapeutics \/ Atlas Venture"},{"orgOrder":0,"company":"CAMP4 Therapeutics","sponsor":"BioMarin Pharmaceutical","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Collaboration","leadProduct":"regRNA-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"CAMP4 Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"CAMP4 Therapeutics \/ BioMarin Pharmaceutical","highestDevelopmentStatusID":"14","companyTruncated":"CAMP4 Therapeutics \/ BioMarin Pharmaceutical"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"DRI Healthcare Trust","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","date":"October 2024","year":"2024","type":"Financing","leadProduct":"Renizgamglogene Autogedtemcel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Editas Medicine","amount2":0.059999999999999998,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Editas Medicine \/ DRI Healthcare Trust","highestDevelopmentStatusID":"14","companyTruncated":"Editas Medicine \/ DRI Healthcare Trust"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Mabxience","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Partnership","leadProduct":"Anti PD-1-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Teva Pharmaceutical Industries \/ mAbxience","highestDevelopmentStatusID":"14","companyTruncated":"Teva Pharmaceutical Industries \/ mAbxience"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"NRC IRAP","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Funding","leadProduct":"DispersinB","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kane Biotech \/ NRC IRAP","highestDevelopmentStatusID":"14","companyTruncated":"Kane Biotech \/ NRC IRAP"},{"orgOrder":0,"company":"GigaGen","sponsor":"BARDA","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Funding","leadProduct":"Recombinant Polyclonal Antibody Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"GigaGen","amount2":0.14000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"GigaGen \/ BARDA","highestDevelopmentStatusID":"14","companyTruncated":"GigaGen \/ BARDA"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"FDA","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Funding","leadProduct":"Sirolimus","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Palvella Therapeutics \/ FDA","highestDevelopmentStatusID":"14","companyTruncated":"Palvella Therapeutics \/ FDA"},{"orgOrder":0,"company":"Ipsen","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Acquisition","leadProduct":"Mecasermin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ipsen \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"Ipsen \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Enara Bio","sponsor":"Pfizer Ventures","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"October 2024","year":"2024","type":"Series B Financing","leadProduct":"TCR-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Enara Bio","amount2":0.029999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Enara Bio \/ Pfizer Ventures","highestDevelopmentStatusID":"14","companyTruncated":"Enara Bio \/ Pfizer Ventures"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Lenacapavir","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Gilead Sciences \/ Dr. Reddy\u2019s Laboratories","highestDevelopmentStatusID":"14","companyTruncated":"Gilead Sciences \/ Dr. Reddy\u2019s Laboratories"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Emcure Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Lenacapavir","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Gilead Sciences \/ Emcure Pharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"Gilead Sciences \/ Emcure Pharmaceuticals"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Eva Pharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Lenacapavir","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Gilead Sciences \/ Eva Pharma","highestDevelopmentStatusID":"14","companyTruncated":"Gilead Sciences \/ Eva Pharma"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Ferozsons Laboratories","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Lenacapavir","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Gilead Sciences \/ Ferozsons Laboratories","highestDevelopmentStatusID":"14","companyTruncated":"Gilead Sciences \/ Ferozsons Laboratories"},{"orgOrder":0,"company":"Modular Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"GUB014295","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Modular Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Modular Medical \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Modular Medical \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Peptide","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Liraglutide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"Eyenovia","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Clobetasol Propionate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Formosa Pharmaceuticals \/ Eyenovia","highestDevelopmentStatusID":"14","companyTruncated":"Formosa Pharmaceuticals \/ Eyenovia"},{"orgOrder":0,"company":"IN8bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"INB-100","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"IN8bio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"IN8bio \/ Not Applicable"},{"orgOrder":0,"company":"Talphera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Nafamostat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Talphera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Talphera \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Talphera \/ Not Applicable"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"LSD","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"MindBio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"MindBio Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Opus Genetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"OPGx-LCA5","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Opus Genetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Opus Genetics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Opus Genetics \/ Not Applicable"},{"orgOrder":0,"company":"Innovo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"INV-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Innovo Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Innovo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Innovo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ImmPACT Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"IMPT-514","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ImmPACT Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ImmPACT Bio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ImmPACT Bio \/ Not Applicable"},{"orgOrder":0,"company":"Actinogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Xanamem","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Actinogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Actinogen \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Actinogen \/ Not Applicable"},{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Lenvatinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AiViva Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AiViva Biopharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"AiViva Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"CAMP4 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"CMP-CPS-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"CAMP4 Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"CAMP4 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"CAMP4 Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Diazoxide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Soleno Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Axalbion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"AX-8","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Axalbion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Axalbion \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Axalbion \/ Not Applicable"},{"orgOrder":0,"company":"Turn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"GX-03","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Turn Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Turn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Turn Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"IGC-1A","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"IGC Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Arcutis Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Relutrigine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Praxis Precision Medicines \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Praxis Precision Medicines \/ Not Applicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Sebetralstat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"KalVista Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"KalVista Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"HF50","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"HighField Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"HighField Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Allergen Aesthetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"OnabotulinumtoxinA","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Allergen Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Allergen Aesthetics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Allergen Aesthetics \/ Not Applicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"TNX-801","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"P-BCMA-ALLO1","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Poseida Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Poseida Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Poseida Therapeutics, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"PALI-2108","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Merck & Co","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Patritumab Deruxtecan","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ Merck & Co","highestDevelopmentStatusID":"14","companyTruncated":"Daiichi Sankyo \/ Merck & Co"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Peptide","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Navepegritide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ascendis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"ATH-1105","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Athira Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Athira Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Alkeus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Gildeuretinol Acetate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alkeus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alkeus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Alkeus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Peptide","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Certepetide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Lisata Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"ATSN-201","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Atsena Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Atsena Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Atsena Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"TTX-MC138","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"TransCode Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"ATI-2138","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aclaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Aclaris Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Papillon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"PPL-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Papillon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Papillon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Papillon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"RP-A501","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Rocket Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Rocket Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Sapropterin Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Relief Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Pidnarulex","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Senhwa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Senhwa Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"iView Therapeutics Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"IVW-1001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"iView Therapeutics Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"iView Therapeutics Inc \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"iView Therapeutics Inc \/ Not Applicable"},{"orgOrder":0,"company":"Revalesio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"RNS60","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Revalesio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Revalesio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Revalesio \/ Not Applicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"HT-ALZ","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Hoth Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biolexis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"BLX-7006","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Biolexis Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Biolexis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Biolexis Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Baloxavir Marboxil","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"ALG-055009","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Aligos Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"SciSparc \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"SciSparc \/ Not Applicable"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Peptide","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"IRL201104","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Revolo Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Revolo Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sonnet BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Sonnet BioTherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Eftilagimod Alfa","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"14","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Mannkind","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Clofazimine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Mannkind \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Mannkind \/ Not Applicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"ANK-700","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Anokion SA \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Anokion SA \/ Not Applicable"},{"orgOrder":0,"company":"Glycomine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"GLM101","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Glycomine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Glycomine \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Glycomine \/ Not Applicable"},{"orgOrder":0,"company":"Azitra","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"ATR-04","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Azitra","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Azitra \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Azitra \/ Not Applicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"IGC-AD1","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"IGC Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"SAT-3247","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Satellos Bioscience \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Satellos Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Baloxavir Marboxil","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Genentech \/ Not Applicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"InnoCare Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Alzprotect","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Ezeprogind","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alzprotect","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alzprotect \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Alzprotect \/ Not Applicable"},{"orgOrder":0,"company":"Xspray Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Dasatinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Xspray Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Xspray Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Xspray Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Bexicaserin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Longboard Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Ondansetron","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Adial Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Adial Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aim ImmunoTech \/ AstraZeneca","highestDevelopmentStatusID":"14","companyTruncated":"Aim ImmunoTech \/ AstraZeneca"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"ALG-055009","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Aligos Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Beacon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Laruparetigene Zovaparvovec","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Beacon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Beacon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Beacon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"RVU120","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ryvu Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ryvu Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Sleep","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Oxybutynin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Apnimed \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Apnimed \/ Not Applicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"EDG-7500","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Edgewise Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Edgewise Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Olanzapine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Teva Pharmaceutical Industries \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Monlunabant","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"TC BioPharm \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"TC BioPharm \/ Not Applicable"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Zevra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Zevra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Kangpu Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"KPG-818","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kangpu Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kangpu Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Kangpu Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Mirvetuximab Soravtansine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"AbbVie Inc \/ Not Applicable"},{"orgOrder":0,"company":"CD (Suzhou) Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"CD-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"CD (Suzhou) Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"CD (Suzhou) Biopharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"CD (Suzhou) Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Datopotamab Deruxtecan","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"AstraZeneca \/ Not Applicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"IPH4502","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Innate Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Innate Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Ketamine Analog","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Mira Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Mira Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Alligator Bioscience","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"ALG.APV-527","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aptevo Therapeutics \/ Alligator Bioscience","highestDevelopmentStatusID":"14","companyTruncated":"Aptevo Therapeutics \/ Alligator Bioscience"},{"orgOrder":0,"company":"SciSparc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"SciSparc \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"SciSparc \/ Not Applicable"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"CD388","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cidara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Cidara Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"CT7439","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Carrick Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Carrick Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Theriva Biologics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Theriva Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Rivoceranib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Elevar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Elevar Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Odevixibat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"AlgoTherapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Amitriptyline Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AlgoTherapeutix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AlgoTherapeutix \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"AlgoTherapeutix \/ Not Applicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Fosmanogepix","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Basilea Pharmaceutica \/ Not Applicable"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Viaskin Peanut","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"DBV Technologies \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"DBV Technologies \/ Not Applicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Fasedienol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"VistaGen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"LP-184","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Peptide","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"RLS-0071","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ReAlta Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ReAlta Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"ARO-INHBE","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Arrowhead Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Delgocitinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Leo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Enfortumab Vedotin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Astellas Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"14","companyTruncated":"Astellas Pharma \/ Pfizer Inc"},{"orgOrder":0,"company":"Priovant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Brepocitinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Priovant Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Priovant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Priovant Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"EO-3021","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Elevation Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Elevation Oncology \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Elevation Oncology \/ Not Applicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Biogen","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Dapirolizumab Pegol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"UCB Pharma S.A \/ Biogen","highestDevelopmentStatusID":"14","companyTruncated":"UCB Pharma S.A \/ Biogen"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"UCB Pharma S.A \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Selinexor","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Donanemab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Arcutis Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Georgiamune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"GIM-407","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Georgiamune","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Georgiamune \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Georgiamune \/ Not Applicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Musculoskeletal","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Enlivex Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Simufilam","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Cassava Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Deramiocel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Capricor Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Arcutis Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Liposomal Tacrolimus","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lipella Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Lipella Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Vaccine","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"VTP-1000","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Barinthus Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Barinthus Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Hesperos","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"DNTH103","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Dianthus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Dianthus Therapeutics \/ Hesperos","highestDevelopmentStatusID":"14","companyTruncated":"Dianthus Therapeutics \/ Hesperos"},{"orgOrder":0,"company":"Spine BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Peptide","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"SB-01","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Spine BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Spine BioPharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Spine BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"Aviceda Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"AVD-104","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aviceda Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aviceda Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Aviceda Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Alpha-lactalbumin-based Vaccine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Anixa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Anixa Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Convergent Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Ac-225 Rosopatamab Tetraxetan","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Convergent Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Convergent Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Convergent Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"2Seventy Bio","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Fludarabine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ 2seventy Bio","highestDevelopmentStatusID":"14","companyTruncated":"Bristol Myers Squibb \/ 2seventy Bio"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Favezelimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Merck & Co \/ Not Applicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"SPG302","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Spinogenix \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Spinogenix \/ Not Applicable"},{"orgOrder":0,"company":"Cyclacel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Fadraciclib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cyclacel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cyclacel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Cyclacel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Elixirgen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"EXG-34217","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Elixirgen Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Elixirgen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Elixirgen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"PALI-2108","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Acasti Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Nimodipine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Acasti Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Acasti Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Acasti Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Vedolizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Alvotech \/ Not Applicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Obinutuzumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Genentech \/ Not Applicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Picankibart","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Innovent Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Orismilast","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Union Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Union Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"EydisBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"EYD-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"EydisBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"EydisBio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"EydisBio \/ Not Applicable"},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Larsucosterol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Durect Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Durect Corporation \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Durect Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Rocatinlimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kyowa Kirin \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Kyowa Kirin \/ Not Applicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Paltusotine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Crinetics Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Crinetics Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Pegtibatinase","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Travere Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Travere Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"BMF-219","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Biomea Fusion \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Biomea Fusion \/ Not Applicable"},{"orgOrder":0,"company":"Minovia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"MNV-201","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Minovia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Minovia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Minovia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Musculoskeletal","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Enlivex Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"CDI-988","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Cocrystal Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Musculoskeletal","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Enekinragene Inzadenovec","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Pacira BioSciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Pacira BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"OMEICOS Therapeutics GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"OMT-28","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"OMEICOS Therapeutics GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"OMEICOS Therapeutics GmbH \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"OMEICOS Therapeutics GmbH \/ Not Applicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Bexicaserin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Longboard Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"EDP-323","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Enanta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Enanta Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Tavapadon","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"AbbVie Inc \/ Not Applicable"},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Padeliporfin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ImPact Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ImPact Biotech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ImPact Biotech \/ Not Applicable"},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Bemdaneprocel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BlueRock Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BlueRock Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BlueRock Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Paliperidone Palmitate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Alembic Pharmaceuticals Limited \/ Not Applicable"},{"orgOrder":0,"company":"Modalis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"MDL-101","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Modalis Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Modalis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Modalis Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Daratumumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Etilevodopa","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Mitsubishi Tanabe Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Trastuzumab Deruxtecan","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"14","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"InCarda Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Flecainide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"InCarda Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"InCarda Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"InCarda Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Kezar Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Navenibart","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Astria Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Astria Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"ADI-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Adicet Bio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Adicet Bio \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Pertuzumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Shanghai Henlius Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Gritstone bio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Gritstone bio \/ Not Applicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"SciSparc \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"SciSparc \/ Not Applicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Istaroxime","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Windtree Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Windtree Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Pegipanermin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"INmune Bio \/ Not Applicable"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"CLD-101","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Calidi Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Calidi Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"AriBio","sponsor":"Adaptive Research","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Methylbenzylamine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AriBio \/ Adaptive Research","highestDevelopmentStatusID":"14","companyTruncated":"AriBio \/ Adaptive Research"},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Peptide","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"CNP-104","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cour Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cour Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Cour Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Merus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Merus \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Merus \/ Not Applicable"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Ratutrelvir","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Traws Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Traws Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Peptide","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Pemvidutide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Altimmune \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Ribitol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Walden Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"WAL0921","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Walden Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Walden Biosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Walden Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Macitentan","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Dupilumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"14","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Daratumumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"IRL757","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"IRLAB \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"IRLAB \/ Not Applicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Crofelemer","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Jaguar Health \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Jaguar Health \/ Not Applicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Mitomycin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"UroGen Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Volastra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"VLS-1488","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Volastra Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Volastra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Volastra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"ALE.P02","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alentis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Alentis Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"NXC-201","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Immix Biopharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Immix Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"REC-1245","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Recursion Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Recursion Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Recursion Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"BCX17725","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BioCryst Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Genenta Science \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Genenta Science \/ Not Applicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Atacicept","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Vera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Vera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Octreotide Acetate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Teva Pharmaceutical Industries \/ Not Applicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Doxycycline Hyclate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"PolyPid \/ Not Applicable"},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Denifanstat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sagimet Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sagimet Biosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Sagimet Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Vafidemstat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Oryzon Genomics \/ Not Applicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"UX701","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ultragenyx Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ultragenyx Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Obefazimod","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Abivax \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Abivax \/ Not Applicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Immutep \/ Not Applicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Obefazimod","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Abivax \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Abivax \/ Not Applicable"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Eniluracil","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Processa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Processa Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Reproxalap","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Aldeyra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"AstraZeneca \/ Not Applicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Delpacibart Etedesiran","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Avidity Biosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Avidity Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Paliperidone","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ANI Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ANI Pharmaceuticals Inc \/ Not Applicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Paliperidone","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Alembic Pharmaceuticals Limited \/ Not Applicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Paliperidone Palmitate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Luye Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Luye Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Paliperidone Palmitate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Luye Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Luye Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Paliperidone Palmitate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Qilu Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Qilu Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Camber Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Paliperidone","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Camber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Camber Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Camber Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Paliperidone Palmitate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Luye Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Luye Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Lamotrigine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Alembic Pharmaceuticals Limited \/ Not Applicable"},{"orgOrder":0,"company":"Indoco Remedies Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Cetirizine Dihydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Indoco Remedies Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Indoco Remedies Limited \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Indoco Remedies Limited \/ Not Applicable"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Panobinostat lactate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Biodexa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Biodexa Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Beijing Avistone Pharmaceuticals Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"ANS014004","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Beijing Avistone Pharmaceuticals Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Beijing Avistone Pharmaceuticals Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Beijing Avistone Pharmaceuticals Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Tiumbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Tiumbio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Tiumbio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Tiumbio \/ Not Applicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Sapropterin Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Relief Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Papillon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"PPL-002","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Papillon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Papillon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Papillon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Trastuzumab Deruxtecan","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"14","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"MZE782","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Maze Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Maze Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Maze Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Kezar Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"VIP943","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Vincerx Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Vincerx Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"KB-7898","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kronos Bio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Kronos Bio \/ Not Applicable"},{"orgOrder":0,"company":"Insignis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Insignis Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Insignis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Insignis Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Setrusumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ultragenyx Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ultragenyx Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Neuvivo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Chlorite","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Neuvivo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Neuvivo \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Neuvivo \/ Not Applicable"},{"orgOrder":0,"company":"MicuRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Oxaborole Prodrug","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"MicuRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"MicuRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"MicuRx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Halia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"HT-4253","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Halia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Halia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Halia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BerGenBio ASA \/ Not Applicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Albuterol Sulfate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"AstraZeneca \/ Not Applicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Arcutis Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Arcutis Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Arcutis Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Arcutis Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Arcutis Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Arcutis Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Arcutis Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Arcutis Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Arcutis Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Arcutis Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Arcutis Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Arcutis Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Arcutis Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"Simcere Zaiming","pharmaFlowCategory":"D","upfrontCash":"$20.0 million","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Collaboration","leadProduct":"Deulorlatinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Shenzhen TargetRx","amount2":0.02,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Shenzhen TargetRx \/ Simcere Zaiming","highestDevelopmentStatusID":"14","companyTruncated":"Shenzhen TargetRx \/ Simcere Zaiming"},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"OnKure Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Merger","leadProduct":"Fulvestrant","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Reneo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Reneo Pharmaceuticals \/ OnKure Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"Reneo Pharmaceuticals \/ OnKure Therapeutics"},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Private Placement","leadProduct":"Fulvestrant","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"OnKure Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"OnKure Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"14","companyTruncated":"OnKure Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Humacyte","sponsor":"EF Hutton LLC","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Cell and Gene therapy","date":"October 2024","year":"2024","type":"Public Offering","leadProduct":"Human Acellular Vessel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Humacyte","amount2":0.029999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Humacyte \/ EF Hutton LLC","highestDevelopmentStatusID":"14","companyTruncated":"Humacyte \/ EF Hutton LLC"},{"orgOrder":0,"company":"ABL Bio","sponsor":"Merck & Co","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Collaboration","leadProduct":"ABL103","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ABL Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ABL Bio \/ Merck & Co","highestDevelopmentStatusID":"14","companyTruncated":"ABL Bio \/ Merck & Co"},{"orgOrder":0,"company":"Dogwood Therapeutics","sponsor":"WEX Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Merger","leadProduct":"Tetrodotoxin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Dogwood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Dogwood Therapeutics \/ Wex Pharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"Dogwood Therapeutics \/ Wex Pharmaceuticals"},{"orgOrder":0,"company":"GBI","sponsor":"Allterum Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Collaboration","leadProduct":"4A10","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"GBI","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"GBI \/ Allterum Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"GBI \/ Allterum Therapeutics"},{"orgOrder":0,"company":"Rege Nephro","sponsor":"DCI Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Series B Financing","leadProduct":"Tamibarotene","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Rege Nephro","amount2":0.02,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Rege Nephro \/ DCI Partners","highestDevelopmentStatusID":"14","companyTruncated":"Rege Nephro \/ DCI Partners"},{"orgOrder":0,"company":"Bridge Medicines","sponsor":"Galecto","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Acquisition","leadProduct":"BRM-1420","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bridge Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bridge Medicines \/ Galecto","highestDevelopmentStatusID":"14","companyTruncated":"Bridge Medicines \/ Galecto"},{"orgOrder":0,"company":"ModeX Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Funding","leadProduct":"MDX2202","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ModeX Therapeutics","amount2":0.11,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ModeX Therapeutics \/ BARDA","highestDevelopmentStatusID":"14","companyTruncated":"ModeX Therapeutics \/ BARDA"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Er-Kim","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"October 2024","year":"2024","type":"Partnership","leadProduct":"Atidarsagene Autotemcel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Orchard Therapeutics \/ Er-Kim","highestDevelopmentStatusID":"14","companyTruncated":"Orchard Therapeutics \/ Er-Kim"},{"orgOrder":0,"company":"Aosaikang Pharmaceutical","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Collaboration","leadProduct":"Limertinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aosaikang Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aosaikang Pharmaceutical \/ Innovent Biologics","highestDevelopmentStatusID":"14","companyTruncated":"Aosaikang Pharmaceutical \/ Innovent Biologics"},{"orgOrder":0,"company":"MediLink Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Collaboration","leadProduct":"Tarlatamab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"MediLink Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"MediLink Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"14","companyTruncated":"MediLink Therapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"U.S. Renal Care","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Agreement","leadProduct":"Vadadustat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Akebia Therapeutics \/ U.S. Renal Care","highestDevelopmentStatusID":"14","companyTruncated":"Akebia Therapeutics \/ U.S. Renal Care"},{"orgOrder":0,"company":"Orasis Pharmaceuticals","sponsor":"Arboretum Ventures","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Series D Financing","leadProduct":"Pilocarpine Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Orasis Pharmaceuticals","amount2":0.080000000000000002,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Orasis Pharmaceuticals \/ Arboretum Ventures","highestDevelopmentStatusID":"14","companyTruncated":"Orasis Pharmaceuticals \/ Arboretum Ventures"},{"orgOrder":0,"company":"Lipocine","sponsor":"Pharmalink, S.L.","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Agreement","leadProduct":"Testosterone Undecanoate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lipocine \/ Pharmalink, S.L.","highestDevelopmentStatusID":"14","companyTruncated":"Lipocine \/ Pharmalink, S.L."},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Leerink Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Public Offering","leadProduct":"Paltusotine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Crinetics Pharmaceuticals","amount2":0.5,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Crinetics Pharmaceuticals \/ Leerink Partners","highestDevelopmentStatusID":"14","companyTruncated":"Crinetics Pharmaceuticals \/ Leerink Partners"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Leerink Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Public Offering","leadProduct":"Paltusotine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Crinetics Pharmaceuticals","amount2":0.46000000000000002,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Crinetics Pharmaceuticals \/ Leerink Partners","highestDevelopmentStatusID":"14","companyTruncated":"Crinetics Pharmaceuticals \/ Leerink Partners"},{"orgOrder":0,"company":"Cerevance","sponsor":"Merck & Co","pharmaFlowCategory":"D","upfrontCash":"$25.0 million","therapeuticArea":"Neurology","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cerevance","amount2":1.1299999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cerevance \/ Merck & Co","highestDevelopmentStatusID":"14","companyTruncated":"Cerevance \/ Merck & Co"},{"orgOrder":0,"company":"X-Chem","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Collaboration","leadProduct":"TNX-4200","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"X-Chem","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"X-Chem \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"14","companyTruncated":"X-Chem \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"Mestag Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Mestag Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Mestag Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"14","companyTruncated":"Mestag Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Somagenetix","sponsor":"Vi Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"October 2024","year":"2024","type":"Series A Financing","leadProduct":"SGX-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Somagenetix","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Somagenetix \/ Vi Partners","highestDevelopmentStatusID":"14","companyTruncated":"Somagenetix \/ Vi Partners"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Basilea Pharmaceutica \/ Pfizer Inc","highestDevelopmentStatusID":"14","companyTruncated":"Basilea Pharmaceutica \/ Pfizer Inc"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Soleus Capital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Private Placement","leadProduct":"Imatinib Mesylate Prodrug","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Inhibikase Therapeutics","amount2":0.11,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Inhibikase Therapeutics \/ Soleus Capital","highestDevelopmentStatusID":"14","companyTruncated":"Inhibikase Therapeutics \/ Soleus Capital"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Alkem Laboratories","pharmaFlowCategory":"D","upfrontCash":"$1.0 million","therapeuticArea":"Neurology","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Atexakin Alfa","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sonnet BioTherapeutics \/ Alkem Laboratories","highestDevelopmentStatusID":"14","companyTruncated":"Sonnet BioTherapeutics \/ Alkem Laboratories"},{"orgOrder":0,"company":"Reunion Neuroscience","sponsor":"Seleni Institute","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Partnership","leadProduct":"RE104","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Reunion Neuroscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Reunion Neuroscience \/ Seleni Institute","highestDevelopmentStatusID":"14","companyTruncated":"Reunion Neuroscience \/ Seleni Institute"},{"orgOrder":0,"company":"Purespring Therapeutics","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","date":"October 2024","year":"2024","type":"Series B Financing","leadProduct":"PS-002","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Purespring Therapeutics","amount2":0.11,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Purespring Therapeutics \/ Sofinnova Partners","highestDevelopmentStatusID":"14","companyTruncated":"Purespring Therapeutics \/ Sofinnova Partners"},{"orgOrder":0,"company":"Autonomous Therapeutics","sponsor":"MiNK Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"October 2024","year":"2024","type":"Collaboration","leadProduct":"MiNK-215","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Autonomous Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Autonomous Therapeutics \/ MiNK Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"Autonomous Therapeutics \/ MiNK Therapeutics"},{"orgOrder":0,"company":"Immatics","sponsor":"Jefferies","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"October 2024","year":"2024","type":"Public Offering","leadProduct":"IMA203","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Immatics","amount2":0.14999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Immatics \/ Jefferies","highestDevelopmentStatusID":"14","companyTruncated":"Immatics \/ Jefferies"},{"orgOrder":0,"company":"Upstream Bio","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Public Offering","leadProduct":"Verekitug","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Upstream Bio","amount2":0.26000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Upstream Bio \/ J.P. Morgan","highestDevelopmentStatusID":"14","companyTruncated":"Upstream Bio \/ J.P. Morgan"},{"orgOrder":0,"company":"CAMP4 Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Public Offering","leadProduct":"CMP-CPS-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"CAMP4 Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"CAMP4 Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"14","companyTruncated":"CAMP4 Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Immatics","sponsor":"Jefferies","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"October 2024","year":"2024","type":"Public Offering","leadProduct":"IMA203","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Immatics","amount2":0.14999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Immatics \/ Jefferies","highestDevelopmentStatusID":"14","companyTruncated":"Immatics \/ Jefferies"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"MD Anderson Cancer Center","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Imiquimod","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"UroGen Pharma \/ MD Anderson Cancer Center","highestDevelopmentStatusID":"14","companyTruncated":"UroGen Pharma \/ MD Anderson Cancer Center"},{"orgOrder":0,"company":"Humacyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Cell and Gene therapy","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Human Acellular Vessel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Humacyte \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Humacyte \/ Not Applicable"},{"orgOrder":0,"company":"Awakn Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Awakn Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Awakn Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Awakn Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Cocaine Esterase","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Propofol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Amneal Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TNF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Isomyosamine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"TNF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"TNF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"TNF Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Isotretinoin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Timber Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Timber Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Merck & Co \/ Not Applicable"},{"orgOrder":0,"company":"Biocon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Sacubitril Sodium","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Biocon \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Biocon \/ Not Applicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Promethazine Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ANI Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ANI Pharmaceuticals Inc \/ Not Applicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Cetirizine Dihydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Nicox SA \/ Not Applicable"},{"orgOrder":0,"company":"CAMP4 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"CMP-CPS-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"CAMP4 Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"CAMP4 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"CAMP4 Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BeiGene \/ Not Applicable"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"FNP-223","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ferrer Internacional \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ferrer Internacional \/ Not Applicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Govorestat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Applied Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Applied Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Engrail Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"ENX-104","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Engrail Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Engrail Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Engrail Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Accord BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Trastuzumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Accord BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Accord BioPharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Accord BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"TX000045","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Tectonic Therapeutic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Tectonic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Tectonic Therapeutic \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Elafibranor","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Deutetrabenazine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Teva Pharmaceutical Industries \/ Not Applicable"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"ABI-5366","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Assembly Biosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Assembly Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Carbidopa","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Amneal Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Delgocitinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Leo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Pharmacology\/Toxicology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Patiromer Sorbitex Calcium","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Zeria Pharmaceutical \/ CSL Vifor","highestDevelopmentStatusID":"14","companyTruncated":"Zeria Pharmaceutical \/ CSL Vifor"},{"orgOrder":0,"company":"Immusoft Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Iduronicrin Genleukocel-T","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Immusoft Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Immusoft Corporation \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Immusoft Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"SMC Laboratories","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Leronlimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"CytoDyn \/ SMC Laboratories","highestDevelopmentStatusID":"14","companyTruncated":"CytoDyn \/ SMC Laboratories"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Eflornithine Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Panbela Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Panbela Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"WVE-N531","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Wave Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Wave Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"KSQ-004EX","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"KSQ Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"KSQ Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"KSQ Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Dydo Pharma","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Amifampridine Phosphate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Dydo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Dydo Pharma \/ Catalyst Pharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"Dydo Pharma \/ Catalyst Pharmaceuticals"},{"orgOrder":0,"company":"YourChoice Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"YCT529","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"YourChoice Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"YourChoice Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"YourChoice Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Voclosporin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Aurinia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Infigratinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Mineralys Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Lorundrostat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Mineralys Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Mineralys Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Mineralys Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"SC0062","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioCity Biopharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BioCity Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"OV329","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ovid Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ovid Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ovid Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Ibezapolstat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Acurx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Acurx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Talquetamab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Estrella Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"EB103","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Estrella Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Estrella Biopharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Estrella Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Deucravacitinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Septerna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"SEP-786","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Septerna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Septerna \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Septerna \/ Not Applicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Calcipotriol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Leo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"P-BCMA-ALLO1","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Poseida Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"14","companyTruncated":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Daratumumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Johnson & Johnson \/ Not Applicable"},{"orgOrder":0,"company":"Amplifica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"AMP-303","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Amplifica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Amplifica \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Amplifica \/ Not Applicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"BHV-2100","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Biohaven Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Cadonilimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Akeso \/ Not Applicable"},{"orgOrder":0,"company":"Purdue Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Nalmefene Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Purdue Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Purdue Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Purdue Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Cell and Gene therapy","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"PBGENE-HBV","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Precision BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Sebetralstat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"KalVista Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"KalVista Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Peptide","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Afamelanotide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Clinuvel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Clinuvel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Clinuvel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Ibudilast","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Medicinova \/ Not Applicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Prabotulinumtoxin A","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AEON Biopharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"AEON Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"177Lu-SN201","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Spago Nanomedical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Spago Nanomedical \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Spago Nanomedical \/ Not Applicable"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"ChAdOx1-HBV","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Barinthus Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Barinthus Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Tafenoquine Succinate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"60 Degrees Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"60 Degrees Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Lamotrigine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Alembic Pharmaceuticals Limited \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Darolutamide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bayer AG \/ Orion Corporation","highestDevelopmentStatusID":"14","companyTruncated":"Bayer AG \/ Orion Corporation"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"SAT-3247","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Satellos Bioscience \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Satellos Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Silexion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"SIL-204","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Silexion Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Silexion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Silexion Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"MNPR-101-Lu","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Monopar Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cybrexa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Peptide","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"CBX-12","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cybrexa Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cybrexa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Cybrexa Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Hypochlorous Acid","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Relief Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"TLD-1433","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Theralase Technologies \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Theralase Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Verismo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"SynKIR-310","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Verismo Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Verismo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Verismo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Rgenta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"RGT-61159","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Rgenta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Rgenta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Rgenta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"RGLS8429","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Regulus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Regulus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"GRIN Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Radiprodil","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"GRIN Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"GRIN Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"GRIN Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Vatiquinone","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"PTC Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"KaliVir Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"KaliVir Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"KaliVir Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"KaliVir Immunotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"KB-GDT-01","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kiromic BioPharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Kiromic BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Scorpion Therapeutics","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"STX-241","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Pierre Fabre \/ Scorpion Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"Pierre Fabre \/ Scorpion Therapeutics"},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"KVA12123","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Kineta \/ Not Applicable"},{"orgOrder":0,"company":"E-Star Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Peptide","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Modified Atrial Natriuretic Peptide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"E-Star Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"E-Star Biotech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"E-Star Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"ONP-002","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Oragenics \/ Not Applicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Diazoxide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Soleno Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"AVTX-009","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Avalo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Avalo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Denosumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Teva Pharmaceutical Industries \/ Not Applicable"},{"orgOrder":0,"company":"Aurigene Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Ribrecabtagene Autoleucel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aurigene Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aurigene Oncology \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Aurigene Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Felzartamab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Vanqua Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"VQ-101","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Vanqua Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Vanqua Bio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Vanqua Bio \/ Not Applicable"},{"orgOrder":0,"company":"Panavance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Misetionamide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Panavance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Panavance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Panavance Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Namodenoson","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Can-Fite BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"KT-621","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kymera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Kymera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"OCU200","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ocugen \/ Not Applicable"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Axitinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Clearside Biomedical \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Clearside Biomedical \/ Not Applicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Dasiglucagon","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Zealand Pharma \/ Not Applicable"},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Rinvecalinase Alfa","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"DiaMedica Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"DiaMedica Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"DiaMedica Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Elinzanetant","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"ICP-488","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"InnoCare Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Vutrisiran","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Alnylam Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Liafensine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Denovo Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Denovo Biopharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Denovo Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Revalesio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"RNS60","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Revalesio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Revalesio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Revalesio \/ Not Applicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"NeuroSense Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"NVX-CoV2601","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Novavax \/ Not Applicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"VK0214","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Viking Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Viking Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Venlafaxine Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Viatris \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Viatris \/ Not Applicable"},{"orgOrder":0,"company":"Antag Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"AT-7687","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Antag Therapeutic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Antag Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Antag Therapeutic \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Nusinersen Sodium","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Elafibranor","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Leads Biolabs \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Leads Biolabs \/ Not Applicable"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Burning Rock Dx","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Sunvozertinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Dizal Pharmaceutical \/ Burning Rock Dx","highestDevelopmentStatusID":"14","companyTruncated":"Dizal Pharmaceutical \/ Burning Rock Dx"},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"AK006","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Allakos \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Allakos \/ Not Applicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"PALI-2108","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Clearmind Medicine \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Clearmind Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Cytisine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Achieve Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"R327","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Recce Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"TTX-MC138","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"TransCode Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"FHD-909","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Foghorn Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"14","companyTruncated":"Foghorn Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"IMA203","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Immatics \/ Not Applicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Denosumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Alvotech \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Daratumumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Johnson & Johnson \/ Not Applicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Volixibat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Mirum Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Myrtelle","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Levetiracetam","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Myrtelle","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Myrtelle \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Myrtelle \/ Not Applicable"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Alpha-emitting Radionuclide Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Oncoinvent \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Oncoinvent \/ Not Applicable"},{"orgOrder":0,"company":"Arrivo BioVentures","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"SP-624","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arrivo BioVentures","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arrivo BioVentures \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Arrivo BioVentures \/ Not Applicable"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Midazolam","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Melt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Melt Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Paliperidone","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Deramiocel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Capricor Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Sandoz B2B \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Marstacimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Dong-A ST Co., Ltd. \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Dong-A ST Co., Ltd. \/ Not Applicable"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Inavolisib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Foundation Medicine \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Foundation Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Inavolisib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Genentech \/ Not Applicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"CAN10","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cantargia AB \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Cantargia AB \/ Not Applicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Peptide","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Elamipretide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Stealth Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Stealth Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Savara","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Molgramostim","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Savara \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Savara \/ Not Applicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Telisotuzumab Vedotin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"AbbVie Inc \/ Not Applicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Lonapegsomatropin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ascendis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Pharmanovia","sponsor":"Lindus Health","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Sleep","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Chloral Hydrate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Pharmanovia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Pharmanovia \/ Lindus Health","highestDevelopmentStatusID":"14","companyTruncated":"Pharmanovia \/ Lindus Health"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Deramiocel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Capricor Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Brexanolone","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Lipocine \/ Not Applicable"},{"orgOrder":0,"company":"USV Private Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Sacubitril Sodium","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"USV Private Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"USV Private Limited \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"USV Private Limited \/ Not Applicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Jazz Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"WVE-006","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Wave Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Wave Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"SYS6002","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Corbus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Corbus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Peptide","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"OK-101","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"OKYO Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"OKYO Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"CLN-978","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cullinan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Cullinan Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Genetic Disease","country":"","productType":"Peptide","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Trofinetide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Acadia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Lithium Salicylate Proline","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alzamend Neuro \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Alzamend Neuro \/ Not Applicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Musculoskeletal","country":"","productType":"Cell and Gene therapy","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"ADI-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Adicet Bio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Adicet Bio \/ Not Applicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Picankibart","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Innovent Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"SPN-820","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Supernus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Supernus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Sleep","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Avadel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Avadel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Intercept Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Noema Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Gemlapodect","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Noema Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Noema Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Noema Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"BPT567","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bright Peak Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bright Peak Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Bright Peak Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"AF710B","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Anavex Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Selinexor","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Sparsentan","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Travere Therapeutics \/ CSL Vifor","highestDevelopmentStatusID":"14","companyTruncated":"Travere Therapeutics \/ CSL Vifor"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Picankibart","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Innovent Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Clesrovimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Merck & Co \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Kezar Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Clarametyx Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"CMTX-101","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Clarametyx Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Clarametyx Biosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Clarametyx Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Foslevodopa","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"AbbVie Inc \/ Not Applicable"},{"orgOrder":0,"company":"Exemed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"October 2024","year":"2024","type":"Not Applicable","leadProduct":"Sacubitril Sodium","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Exemed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Exemed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Exemed Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Olopatadine Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Glenmark Pharmaceuticals \/ Not Applicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Belief BioMed

                            China arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Belief BioMed

                            China arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gene-based Therapy

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : AskBio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Belief BioMed to Collaborate with AskBio to Explore the Potential of New Gene Therapies

                            Details : Through the collaboration, the companies will combine efforts & experience in gene therapy technology to explore potential therapies in diseases that may be treatable using a liver-targeted approach.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 25, 2024

                            Lead Product(s) : Gene-based Therapy

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : AskBio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Generate Biomedicines

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Generate Biomedicines

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Protein-based Therapy

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $1,065.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Novartis Inks $1B-plus Biobucks Deal with Flagship's Generate

                            Details : The collaboration leverages Generate’s proprietary generative AI platform to create potentially first- and best-in-class molecules through AI-based optimization and de novo generation.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : $65.0 million

                            September 24, 2024

                            Lead Product(s) : Protein-based Therapy

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $1,065.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Innate Pharma

                            France arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Innate Pharma

                            France arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADC-based Therapy

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : Araris Biotech

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Araris Biotech Acquires Innate Pharma Patents For Antibody-Drug Conjugates

                            Details : Araris biotech expands its ip portfolio with the acquisition of innate pharma’s portfolio of transglutaminase patents for the generation of antibody-drug conjugates.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 24, 2024

                            Lead Product(s) : ADC-based Therapy

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : Araris Biotech

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Axcelead

                            Japan arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Axcelead

                            Japan arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : Acadia Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Axcelead Partners with Acadia Pharmaceuticals For Drug Discovery Projects

                            Details : Axcelead will provide drug discovery support to Acadia by leveraging its drug discovery platform, deep knowledge, and experience in discovery research to potentially generate high-quality candidate.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 19, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : Acadia Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Axcelead

                            Japan arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Axcelead

                            Japan arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery

                            Sponsor : Eli Lilly

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Axcelead DDP and Lilly Enter into Research and Collaboration Agreement

                            Details : The collaboration with Eli Lilly will support Axcelead DDP in generating drug candidates through its innovative advancements in drug discovery programs.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 18, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery

                            Sponsor : Eli Lilly

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Adare Pharma Solutions

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Adare Pharma Solutions

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery

                            Sponsor : Laxxon Medical

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Adare Pharma, Laxxon Partner to Advance 3D Printed Oral Dosage Forms

                            Details : The partnership aims to leverage Adare's state-of-the-art cGMP facilities and Laxxon's innovative 3D printing technology to bring innovative new oral dosage forms to market.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 18, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery

                            Sponsor : Laxxon Medical

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Unravel Biosciences

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Unravel Biosciences

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Undisclosed

                            Sponsor : Jackson Laboratory

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Unravel Biosciences and Jackson Laboratory Partner On High Unmet Need Drugs

                            Details : Through collaboration, Unravel will utilize the BioNAV drug discovery platform & JAX's extensive expertise in pre-clinical disease modeling to identify potential drugs across multiple diseases.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 17, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Undisclosed

                            Sponsor : Jackson Laboratory

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Genesis Therapeutics

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Genesis Therapeutics

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery

                            Sponsor : Gilead Sciences

                            Deal Size : $35.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Gilead and Genesis Partner To Develop Novel Therapies

                            Details : Gilead Sciences and Genesis Therapeutics entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 10, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery

                            Sponsor : Gilead Sciences

                            Deal Size : $35.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            X-Chem

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed

                            X-Chem

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : Evotec

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Evotec and X-Chem Collaborate to Accelerate Early-Stage Drug Discovery

                            Details : The collaboration aims to accelerate early-stage drug discovery by using X-Chem’s DEL technology which streamlines hit finding by simultaneously screening up to billions of DNA-tagged compounds.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 05, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : Evotec

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Syntekabio

                            South Korea arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Syntekabio

                            South Korea arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : Enamine Ltd

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Syntekabio and Enamine partner for AI-based drug development

                            Details : The alliance will leverage an extensive synthetic compound library provided by Enamine to support drug candidate discovery services through Syntekabio’s AI platform, DeepMatcher.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 03, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : Enamine Ltd

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth